View Filing Data

Print Document View Excel Document

Document And Entity Information	9 Months Ended
Document And Entity Information	Sep. 30, 2018 shares
Document Information [Line Items]
Entity Registrant Name	Precision Therapeutics Inc.
Entity Central Index Key	0001446159
Trading Symbol	aipt
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)	13,398,339
Document Type	S-4/A
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Amendment Flag	true
Amendment Description	This Registration Statement shall hereafter become effective in accordance with the provisions of Section 8(a) of the Securities Act of 1933.
Entity Ex Transition Period	false

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current Assets:
Cash & cash equivalents	$ 209,891	$ 766,189
Certificates of deposit		244,971
Accounts Receivable	238,598	137,499
Loan Receivable – Bridge Loan	1,815,000
Notes Receivable	163,468	667,512
Inventories	278,155	265,045
Prepaid Expense and other assets	404,428	289,966
Total Current Assets	3,109,540	2,371,182
Notes Receivable	1,134,774	1,070,000
Fixed Assets, net	198,258	87,716
Intangibles, net	973,127	95,356
Total Assets	5,415,699	3,624,254
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	409,099	140,462
Note Payable – Bridge Loan Net of Discount of $1,293,047	1,004,680
Accrued Expenses	315,039	785,215
Derivative Liability	645,008
Deferred Revenue	15,306	6,663
Total Liabilities	2,389,132	932,340
Commitments and Contingencies
Stockholders’ Equity:
Common Stock, $.01 par value, 50,000,000 authorized, 6,943,283 and 4,564,428 outstanding	133,983	69,432
Additional paid-in capital	(64,297,137)	(57,380,256)
Accumulated deficit	61,405,345	54,765,045
Total Stockholders' Equity	3,026,567	2,691,914
Total Liabilities and Stockholders' Equity	5,415,699	3,624,254
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock	792	792
Series C Convertible Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock		$ 6,479

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Discount of note payable	$ 1,293,047	$ 0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares outstanding (in shares)	13,398,339	6,943,283
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	79,246	79,246
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	0	647,819

Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Revenue			$ 1,100,108	$ 434,523	$ 654,836	$ 456,495
Cost of goods sold			309,320	87,709	148,045	181,620
Gross margin			790,788	346,814	506,791	274,875
General and administrative expense			2,708,274	3,968,493	6,041,485	5,174,799
Operations expense			1,390,434	575,467	1,207,724	1,158,117
Sales and marketing expense			1,726,087	680,396	1,004,175	467,970
Total Expense			5,824,795	5,224,356	8,253,384	6,800,889
Loss on equity method investment			(1,606,294)
Net loss available to common shareholders	$ (2,506,869)	$ (992,095)	(6,640,301)	(4,877,542)	(7,746,593)	(6,526,014)
Comprehensive loss	$ (2,506,869)	$ (992,095)	$ (6,640,301)	$ (4,877,542)	$ (7,746,593)	$ (6,524,513)
Loss per common share - basic and diluted (in dollars per share)	$ (0.19)	$ (0.16)	$ (0.55)	$ (0.78)	$ (1.22)	$ (2.31)
Weighted average shares used in computation - basic and diluted (in shares)			12,178,285	6,283,567	6,362,989	2,823,345

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Over-Allotment Option [Member] Common Stock [Member]	Over-Allotment Option [Member] Additional Paid-in Capital [Member]	Over-Allotment Option [Member] Retained Earnings [Member]	Over-Allotment Option [Member]	Helomics Holding Corp. [Member] Common Stock [Member]	Helomics Holding Corp. [Member] Additional Paid-in Capital [Member]	Helomics Holding Corp. [Member]	Consulting Agreement One [Member] Common Stock [Member]	Consulting Agreement One [Member] Additional Paid-in Capital [Member]	Consulting Agreement One [Member]	Consulting Agreement Two [Member] Common Stock [Member]	Consulting Agreement Two [Member] Additional Paid-in Capital [Member]	Consulting Agreement Two [Member]	Consultant Contract One [Member] Common Stock [Member]	Consultant Contract One [Member] Additional Paid-in Capital [Member]	Consultant Contract One [Member]	Consultant Contract Two [Member] Common Stock [Member]	Consultant Contract Two [Member] Additional Paid-in Capital [Member]	Consultant Contract Two [Member]	Contract with TumorGenesis [Member] Common Stock [Member]	Contract with TumorGenesis [Member] Additional Paid-in Capital [Member]	Contract with TumorGenesis [Member]	Series E Warrants [Member] Common Stock [Member]	Series E Warrants [Member] Additional Paid-in Capital [Member]	Series E Warrants [Member]	Re-priced Warrants [Member] Common Stock [Member]	Re-priced Warrants [Member] Additional Paid-in Capital [Member]	Re-priced Warrants [Member]	Preferred Stock [Member] Series C Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2015																															$ 18,950	$ 2,080	$ 44,584,118	$ (40,492,437)		$ 4,112,711
Balance (in shares) at Dec. 31, 2015																																208,259
Vesting Expense																																	165,271			165,271
Unrealized (loss) from marketable securities																																			$ 1,501	1,501
Net loss																																		(6,526,014)		(6,526,014)
Balance at Dec. 31, 2016																															792	$ 45,644	47,894,196	(47,018,451)	1,501	923,682
Balance (in shares) at Dec. 31, 2016																														79,246		4,564,428
Shares issued pursuant to the public offering	$ 1,750	$ 392,000		$ 393,750																												$ 17,500	3,403,688			3,421,188
Shares issued pursuant to the public offering (in shares)	175,000																															1,750,000
Vesting Expense																																	2,142,189			2,142,189
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement																																$ (4,000)				(4,000)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares)																																(400,000)
Shares issued for services								$ 1,000	$ 219,000	$ 220,000	$ 433	$ 63,699	$ 64,132
Shares issued for services (in shares)								100,000			43,333
Unrealized (loss) from marketable securities																																			(1,501)	(1,501)
Net loss																																		(4,877,542)		(4,877,542)
Balance at Sep. 30, 2017																															792	$ 62,327	54,114,771	(51,895,993)		2,281,897
Balance (in shares) at Sep. 30, 2017																														79,246		6,232,761
Balance at Dec. 31, 2016																															792	$ 45,644	47,894,196	(47,018,451)	1,501	923,682
Balance (in shares) at Dec. 31, 2016																														79,246		4,564,428
Shares issued pursuant to the public offering	$ 1,750	392,000		393,750																												$ 17,500	3,403,688			3,421,188
Shares issued pursuant to the public offering (in shares)	175,000																															1,750,000
Vesting Expense																																	4,042,256			4,042,256
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement																																$ (4,000)				(4,000)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares)																																(400,000)
Unrealized (loss) from marketable securities																																		(1)	(1,501)
Net loss																																		(7,746,593)		(7,746,593)
Balance at Dec. 31, 2017																															7,271	$ 69,432	57,380,256	(54,765,045)		2,691,914
Balance (in shares) at Dec. 31, 2017																													647,819	79,246		6,943,283
Preferred conversion to common shares pursuant to private placement agreement																															(5,659)	$ 6,604	85,236			86,182
Preferred conversion to common shares pursuant to private placement agreement (in shares)																																660,522
Shares issued pursuant to the public offering	$ 2,153	$ 202,268	$ 1	$ 204,422																												$ 29,000	2,726,087			2,755,087
Shares issued pursuant to the public offering (in shares)	215,247																															2,900,000
Vesting Expense																																	800,322			800,322
Shares issued for services														$ 1,500	$ 175,500	$ 177,000	$ 1,000	$ 117,000	$ 118,000
Shares issued for services (in shares)														150,000			100,000
Net loss																																		(6,640,301)		(6,640,301)
Balance at Sep. 30, 2018																															792	$ 133,983	64,297,137	(61,405,345)		3,026,567
Balance (in shares) at Sep. 30, 2018																														79,246		13,398,339
Preferred conversion to common shares pursuant to private placement agreement																															(6,479)	$ 5,897	582			0
Preferred conversion to common shares pursuant to private placement agreement (in shares)																													(647,819)			589,747
Investment pursuant to Helomics 20% acquisition					$ 11,000	$ 1,031,250	$ 1,042,250
Investment pursuant to Helomics 20% acquisition (in shares)					1,100,000
Warrant exercises																							$ 1,454	$ 143,942	$ 145,396	$ 5,046	$ 499,619	$ 504,665
Warrant exercises (in shares)																							145,396			504,666
Shares issued in escrow pursuant to a contract with TumorGenesis @ $1.17 per share																				$ 7,500	$ 870,000	$ 877,500
Shares issued in escrow pursuant to a contract with TumorGenesis @ $1.17 per share (in shares)																				750,000
Stock issuable for bridge loan																																	206,605			206,605
Warrants issued per bridge loan																																	$ 143,707			$ 143,707

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parentheticals)	Sep. 30, 2018 $ / shares
Series E Warrants [Member] \| Common Stock [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1
Common Stock [Member] \| Over-Allotment Option [Member]
Price of shares issued (in dollars per share)	0.9497
Common Stock [Member] \| Consultant Contract One [Member]
Price of shares issued (in dollars per share)	1.18
Common Stock [Member] \| Consultant Contract Two [Member]
Price of shares issued (in dollars per share)	1.18
Common Stock [Member] \| Contract with TumorGenesis [Member]
Price of shares issued (in dollars per share)	$ 1.17

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flow from operating activities:
Net loss	$ (6,640,301)	$ (4,877,542)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on equity method investment	1,606,294
Depreciation and amortization	105,569	53,831
Vested stock options and warrants	800,322	2,142,189
Equity instruments issued for management and consulting	295,000	280,133
Gain (loss) from sale of marketable securities		(1,837)
Changes in assets and liabilities:
Accounts receivable	(101,099)	(52,789)
Inventories	(13,110)	33,319
Prepaid expense and other assets	70,536	(48,188)
Accounts payable	268,637	(145,470)
Accrued expenses	(470,176)	(523,142)
Deferred revenue	8,643	2,187
Net cash used in operating activities	(4,069,685)	(3,137,309)
Cash flow from investing activities:
Proceeds from sale of marketable securities		284,665
Purchase of certificates of deposit		(2,594,728)
Redemption of certificates of deposit	244,971	1,470,000
Advance on notes receivable	(124,774)	(785,000)
Purchase of fixed assets	(169,983)	(43,251)
Purchase of intangibles	(46,398)	(7,701)
Net cash used in investing activities:	(96,184)	(1,676,015)
Cash flow from financing activities:
Proceeds from exercise of warrants into common stock	650,062
Issuance of common stock	2,959,509	3,814,938
Net cash provided by financing activities	3,609,571	3,814,938
Net increase (decrease) in cash and cash equivalents	(556,298)	(998,386)
Cash at beginning of period	766,189	1,764,090
Cash at end of period	209,891	765,704
Non-cash transactions:
Shares issued into escrow for TumorGenesis	877,500
Bridge loan receivable	1,815,000
Conversion of Preferred Stock to Common Stock	6,479
Equity method investment - Helomics	$ 1,542,250

Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Current Assets:
Cash & cash equivalents	$ 209,891	$ 766,189	$ 1,764,090
Certificates of deposit		244,971	100,000
Marketable securities			284,329
Accounts Receivable	238,598	137,499	38,919
Notes Receivable	163,468	667,512
Inventories	278,155	265,045	272,208
Prepaid Expense and other assets	404,428	289,966	148,637
Total Current Assets	3,109,540	2,371,182	2,608,183
Notes Receivable	1,134,774	1,070,000
Fixed Assets, net	198,258	87,716	101,496
Intangibles, net	973,127	95,356	97,867
Total Assets	5,415,699	3,624,254	2,807,546
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	409,099	140,462	220,112
Accrued Expenses	315,039	785,215	1,346,105
Deferred Revenue	15,306	6,663	7,998
Total Current Liabilities		932,340	1,574,215
Accrued Expenses			309,649
Total Liabilities	2,389,132	932,340	1,883,864
Commitments and Contingencies
Stockholders’ Equity:
Common Stock, $.01 par value, 50,000,000 authorized, 6,943,283 and 4,564,428 outstanding	133,983	69,432	45,644
Additional paid-in capital	(64,297,137)	(57,380,256)	(47,894,196)
Accumulated deficit	61,405,345	54,765,045	47,018,451
Accumulated Other Comprehensive Income			1,501
Total Stockholders' Equity	3,026,567	2,691,914	923,682
Total Liabilities and Stockholders' Equity	5,415,699	3,624,254	2,807,546
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock	792	792	792
Series C Convertible Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock		$ 6,479

Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	50,000,000	50,000,000	50,000,000
Common stock, shares outstanding (in shares)	13,398,339	6,943,283	4,564,428
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	79,246	79,246	79,246
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	0	647,819	0

Consolidated Statements of Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenue	$ 654,836	$ 456,495
Cost of goods sold	148,045	181,620
Gross margin	506,791	274,875
General and administrative expense	6,041,485	5,174,799
Operations expense	1,207,724	1,158,117
Sales and marketing expense	1,004,175	467,970
Interest expense		3
Total Expense	8,253,384	6,800,889
Net loss available to common shareholders	(7,746,593)	(6,526,014)
Other comprehensive income
Unrealized (loss) from marketable securities		1,501
Comprehensive loss	$ (7,746,593)	$ (6,524,513)
Loss per common share - basic and diluted (in dollars per share)	$ (1.22)	$ (2.31)
Weighted average shares used in computation - basic and diluted (in shares)	6,362,989	2,823,345

Consolidated Statements of Stockholders' Equity - USD ($)	Series A Warrants [Member] Common Stock [Member]	Series A Warrants [Member] Additional Paid-in Capital [Member]	Series A Warrants [Member]	Series B Warrants [Member] Common Stock [Member]	Series B Warrants [Member] Additional Paid-in Capital [Member]	Series B Warrants [Member]	Investment Banker [Member] Common Stock [Member]	Investment Banker [Member] Additional Paid-in Capital [Member]	Investment Banker [Member]	Investor Relations Consultant [Member] Common Stock [Member]	Investor Relations Consultant [Member] Additional Paid-in Capital [Member]	Investor Relations Consultant [Member]	GLG Pharma, LLC. [Member] Common Stock [Member]	GLG Pharma, LLC. [Member]	Former CEO [Member] Common Stock [Member]	Former CEO [Member] Additional Paid-in Capital [Member]	Former CEO [Member]	The 2016 Registered Direct Offering [Member] Common Stock [Member]	The 2016 Registered Direct Offering [Member] Additional Paid-in Capital [Member]	The 2016 Registered Direct Offering [Member]	Over-Allotment Option [Member] Common Stock [Member]	Over-Allotment Option [Member] Additional Paid-in Capital [Member]	Over-Allotment Option [Member] Retained Earnings [Member]	Over-Allotment Option [Member]	Consulting Agreement One [Member] Common Stock [Member]	Consulting Agreement One [Member] Additional Paid-in Capital [Member]	Consulting Agreement One [Member]	Consulting Agreement Two [Member] Common Stock [Member]	Consulting Agreement Two [Member] Additional Paid-in Capital [Member]	Consulting Agreement Two [Member]	Investor Relations Consultant [Member] Common Stock [Member]	Investor Relations Consultant [Member] Additional Paid-in Capital [Member]	Investor Relations Consultant [Member]	Private Placement [Member] Preferred Stock [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2015																																					$ 18,950	$ 2,080	$ 44,584,118	$ (40,492,437)		$ 4,112,711
Balance (in shares) at Dec. 31, 2015																																						208,259
Shares issued for two options exercised at $65.75 per share (in shares)																																						1,312
Shares issued for two options exercised at $65.75 per share																																						$ 13	86,240			86,253
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering																																					(18,158)	$ 664	17,494			0
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering (in shares)																																						66,396
Warrant exercises (in shares)	2,318,663			628,237
Warrant exercises	$ 23,187	$ 556,479	$ 579,666	$ 6,282	$ 150,777	$ 157,059
Shares issued for services (in shares)							135,995
Shares issued for services							$ 1,360	$ 508,620	$ 509,980
Shares issued pursuant to the public offering (in shares)										26,000			400,000		20,000			756,999
Shares issued pursuant to the public offering										$ 260	$ 116,740	$ 117,000	$ 4,000	$ 4,000	$ 200	$ 90,151	$ 90,351	$ 7,570	$ 1,618,335	$ 1,625,905
Vesting Expense																																							165,271			165,271
Unrealized (loss) from marketable securities																																									$ 1,501	1,501
Corrections due to rounding for reverse split and DTCC increase (in shares)																																						2,567
Corrections due to rounding for reverse split and DTCC increase																																						$ 28	(29)			(1)
Net loss																																								(6,526,014)		(6,526,014)
Balance at Dec. 31, 2016																																					792	$ 45,644	47,894,196	(47,018,451)	1,501	923,682
Balance (in shares) at Dec. 31, 2016																																						4,564,428
Shares issued for services (in shares)
Shares issued pursuant to the public offering (in shares)																					175,000																	1,750,000
Shares issued pursuant to the public offering																					$ 1,750	$ 392,000		$ 393,750														$ 17,500	3,403,688			3,421,188
Vesting Expense																																							2,142,189			2,142,189
Unrealized (loss) from marketable securities																																									(1,501)	(1,501)
Net loss																																								(4,877,542)		(4,877,542)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares)																																						(400,000)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement																																						$ (4,000)				(4,000)
Balance at Sep. 30, 2017																																					792	$ 62,327	54,114,771	(51,895,993)		2,281,897
Balance (in shares) at Sep. 30, 2017																																						6,232,761
Balance at Dec. 31, 2016																																					792	$ 45,644	47,894,196	(47,018,451)	1,501	923,682
Balance (in shares) at Dec. 31, 2016																																						4,564,428
Shares issued for services (in shares)																									100,000			43,333			50,000
Shares issued for services																									$ 1,000	$ 219,000	$ 220,000	$ 433	$ 63,699	$ 64,132	$ 500	$ 78,500	$ 79,000
Shares issued pursuant to the public offering (in shares)																					175,000																	1,750,000
Shares issued pursuant to the public offering																					$ 1,750	392,000		393,750										$ 12,138	$ 1,201,681	$ 1,213,819		$ 17,500	3,403,688			3,421,188
Vesting Expense																																							4,042,256			4,042,256
Unrealized (loss) from marketable securities																																								(1)	(1,501)
Net loss																																								(7,746,593)		(7,746,593)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares)																																						(400,000)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement																																						$ (4,000)				(4,000)
Preferred conversion to common shares pursuant to private placement agreement																																					(5,659)	$ 6,604	85,236			86,182
Preferred conversion to common shares pursuant to private placement agreement (in shares)																																						660,522
Balance at Dec. 31, 2017																																					7,271	$ 69,432	57,380,256	(54,765,045)		2,691,914
Balance (in shares) at Dec. 31, 2017																																						6,943,283
Shares issued pursuant to the public offering (in shares)																					215,247																	2,900,000
Shares issued pursuant to the public offering																					$ 2,153	$ 202,268	$ 1	$ 204,422														$ 29,000	2,726,087			2,755,087
Vesting Expense																																							800,322			800,322
Net loss																																								(6,640,301)		(6,640,301)
Preferred conversion to common shares pursuant to private placement agreement																																					(6,479)	$ 5,897	582			0
Preferred conversion to common shares pursuant to private placement agreement (in shares)																																						589,747
Balance at Sep. 30, 2018																																					$ 792	$ 133,983	$ 64,297,137	$ (61,405,345)		$ 3,026,567
Balance (in shares) at Sep. 30, 2018																																						13,398,339

Consolidated Statements of Stockholders' Equity (Parentheticals)	Dec. 31, 2017 $ / shares
Investor Relations Consultant [Member]
Price of shares issued (in dollars per share)	$ 1.58

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Cash flow from operating activities:
Net loss	$ (7,746,593)	$ (6,526,014)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	71,562	82,356
Vested stock options and warrants	4,042,256	165,271
Equity instruments issued for management and consulting	359,133	721,330
Issuance of common stock in cashless warrant exchange		736,725
(Gain) loss on Sales of Equipment		(2,387)
Gain (loss) from sale of marketable securities	(1,837)	(4,716)
Changes in assets and liabilities:
Accounts receivable	(98,580)	(636)
Inventories	7,163	(40,468)
Prepaid expense and other assets	(141,329)	122,943
Accounts payable	(79,650)	(430,301)
Accrued expenses	(870,540)	791,459
Deferred revenue	(1,335)	2,998
Net cash used in operating activities	(4,459,750)	(4,381,440)
Cash flow from investing activities:
Purchase of marketable securities		(850,000)
Proceeds from sale of marketable securities	284,665	571,887
Purchase of certificates of deposit	(3,084,971)	(1,100,000)
Redemption of certificates of deposit	2,940,000	1,000,000
Advance on notes receivable	(1,737,512)
Purchase of fixed assets	(45,093)	(32,760)
Purchase of intangibles	(10,179)	(11,987)
Net cash used in investing activities:	(1,653,090)	(422,860)
Cash flow from financing activities:
Net proceeds from issuance of preferred stock	1,300,001
Net proceeds from issuance of common stock	3,814,938	1,712,158
Net cash provided by financing activities	5,114,939	1,712,158
Net increase (decrease) in cash and cash equivalents	(997,901)	(3,092,142)
Cash at beginning of period	1,764,090	4,856,232
Cash at end of period	$ 766,189	$ 1,764,090

Note 1 - Summary of Significant Accounting Policies

9 Months Ended

12 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Notes to Financial Statements

Significant Accounting Policies [Text Block]

NOTE

— SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations and Continuance of Operations

Precision Therapeutics Inc., (the “Company”) was originally incorporated on

April 23, 2002

in Minnesota as BioDrain Medical, Inc. Effective

August 6, 2013,

the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective

December 16, 2013,

the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware corporation as the surviving corporation of the merger. On

August 31, 2015,

the Company completed a successful offering and concurrent uplisting to the NASDAQ Capital Market. On

February 1, 2018,

the Company filed with the Secretary of State of Delaware a Certificate of Amendment to its Certificate of Incorporation to change the corporate name from Skyline Medical Inc. to Precision Therapeutics Inc., effective

February 1, 2018.

Because of this change, the Company’s common stock trades under the new ticker symbol “AIPT,” effective

February 2, 2018.

Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.

As of

September 30, 2018,

the Company had

13,398,339

shares of common stock outstanding, par value

$.01

per share. The Company is a healthcare company that provides personalized medicine solution and medical devices in

two

main areas: (

) precision medicine, which aims to apply artificial intelligence to personalized medicine and drug discovery; and (

) the Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of proprietary cleaning fluid and filters to users of its systems. In

April 2009,

the Company received

510

(k) clearance from the Food & Drug Administration (the “FDA”) to authorize the Company to market and sell its STREAMWAY System products.

The Company acquired

25%

of the capital stock of Helomics Holding Corporation (“Helomics”), in transactions in the

first

quarter of

2018,

and in

April 2018

the Company entered into a letter of intent for a proposed merger transaction to acquire the remaining ownership of Helomics. In

June 2018,

the Company and Helomics entered into a definitive merger agreement – see Note

The Company’s precision medicine services – designed to use artificial intelligence and a comprehensive disease database to improve the effectiveness of cancer therapy – were launched with the Company’s investment in Helomics. Helomics’ precision oncology services are based on its D-CHIP™ diagnostic platform, which combines a database of genomic and drug response profiles from over

149,000

tumors with an artificial intelligence based searchable bioinformatics platform. Once a patient’s tumor is excised and analyzed, the D-CHIP platform compares the tumor profile with its database, and using its extensive drug response data, provides a specific therapeutic roadmap. In addition, the Company has formed a wholly-owned subsidiary, TumorGenesis Inc., to develop the next generation, patient derived tumor models for precision cancer therapy and drug development. TumorGenesis Inc., formed during the

first

quarter of

2018,

is presented as part of the condensed consolidated financial statements (“financial statements”).

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of

$61,405,345.

The Company does

not

expect to generate sufficient operating revenue to sustain its operations in the near-term. The Company had cash and cash equivalents of

$209,891

as of

September 30, 2018

and needs to raise significant additional capital to meet its operating needs, and therefore there is substantial doubt about the Company’s ability to continue as a going concern for

one

year after the date that the financial statements are issued. The financial statements do

not

include any adjustments that might result from the outcome of this uncertainty. The Company raised

$1,815,000,

net, from a bridge loan executed on

September 28, 2018.

Neither the cash nor the stock transferred until the

first

week in

October 2018

and is reported in the balance sheet as a loan receivable and note payable. Warrants accompanied the agreement with a grant date of

September 28, 2018

and are included in the outstanding stock option and warrant lists.

Since inception to

September 30, 2018,

the Company has raised approximately

$36,490,000

in equity offerings, inclusive of (

)

$2,055,000

from a private placement of Series A Convertible Preferred Stock, (

)

$13,555,003

from the public offering of Units, (

)

$1,739,770

from a registered direct offering, (

)

$3,937,500

plus an overallotment of

$358,312

from a firm commitment underwritten public offering, and (

)

$1,300,000

from a private placement of Series C Convertible Preferred Stock. Also included in the

$36,490,000

aggregate is a total of

$3,405,052

from

2018

including

$2,755,000

from a firm commitment underwritten public offering and

$650,062

from exercising warrants into common stock. In addition, historically there was

$5,685,000

in debt financing.

Interim Financial Statements

The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form

-K filed with the SEC on

April 2, 2018.

The nature of the Company’s business is such that the results of any interim period

may

not

be indicative of the results to be expected for the entire year.

Recent Accounting Developments

May 2014,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

No.

2014

09,

Revenue from Contracts with Customers (Topic

606

which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard’s core principle is that an entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the standard on

January 1, 2018

using the modified retrospective method applied to those contracts which were

not

completed as of

December 31, 2017.

Results for reporting periods beginning after

January

2018

are presented under Topic

606,

while prior-period amounts have

not

been retrospectively adjusted and continue to be reported in accordance with Topic

605,

Revenue Recognition

. Based upon the Company’s contracts which were

not

completed as of

December 31, 2017,

the Company was

not

required to make an adjustment to the opening balance of retained earnings as of

January 1, 2018,

and there was

material impact. See Note

for further discussion.

January 2016,

the FASB issued ASU

No.

2016

01,

Financial Instruments-Overall (Subtopic

825

): Recognition and Measurement of Financial Assets and Financial Liabilities

(“ASU

2016

01”

). The standard changes how entities measure certain equity investments and present changes in the fair value of financial liabilities measured under the fair value option that are attributable to their own credit. Under the new guidance, entities will be required to measure equity investments that do

not

result in consolidation and are

not

accounted for under the equity method at fair value and recognize any changes in fair value in net income unless the investments qualify for the new practicability exception. The Company adopted the standard as of

January 1, 2018.

As of

June 30, 2018,

there is

material impact on the Company’s financial statements and disclosures.

February 2016,

the FASB issued ASU

No.

2016

02,

“

Leases (Topic

842

)

” (“ASU

2016

02”

), which requires lessees to put most leases on their balance sheets but recognize the expenses on their income statements in a manner similar to current practice. The standard states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The standard is effective for fiscal years and interim periods within those fiscal years beginning after

December 15, 2018.

Early adoption is permitted. The Company believes that upon adoption, ASU

2016

will

not

have a material impact on the Company’s balance sheet, results of operations, equity or cash flows. Further, the Company is continuing to assess any incremental disclosures that will be required in our consolidated financial statements.

Valuation of Intangible Assets

The Company reviews identifiable intangible assets for impairment annually, or whenever events or changes in circumstances indicate the carrying amount

may

not

be recoverable. The Company’s intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount

may

not

be recoverable include, but are

not

limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management’s best estimate of the related risks and return at the time the impairment assessment is made.

Accounting Policies and Estimates

The presentation of financial statements is in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of

three

months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximates fair value.

Certificates of Deposit

Short-term interest-bearing investments are those with maturities of less than

one

year but greater than

three

months when purchased. Certificates with maturity dates beyond

one

year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value.

Fair Value Measurements

Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC)

820,

fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standards ASC

820

establishes a

three

-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level

– Observable inputs such as quoted prices in active markets;

Level

– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level

– Unobservable inputs where there is little or

market data, which requires the reporting entity to develop its own assumptions.

The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation.

The fair value of the Company’s investment securities was determined based on Level

inputs.

Inventories

Inventories are stated at the lower of cost and net realizable value, with cost determined on a

first

-in,

first

-out basis. Inventory balances are as follows:

	September 30, 2018		December 31, 2017

Finished goods	$	61,587	$	62,932
Raw materials		157,610		141,028
Work-In-Process		58,958		61,085
Total	$	278,155	$	265,045

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows:

	Years
Computers and office equipment	3	-	7
Leasehold improvements		3
Manufacturing tooling	3	-	7
Demo equipment		3

The Company’s fixed assets consist of the following:

	September 30, 2018		December 31, 2017
Computers and office equipment	$	204,904	$	183,528
Leasehold improvements		140,114		25,635
Manufacturing tooling		108,955		108,955
Demo equipment		77,496		43,368
Total		531,469		361,486
Less: Accumulated depreciation		333,211		273,770
Total Fixed Assets, Net	$	198,258	$	87,716

Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.

Depreciation expense was

$26,120

and

$59,442

in the

three

and

nine

months ended

September 30, 2018

and was

$14,561

and

$44,764

for the

three

and

nine

months ended

September 30, 2017.

Intangible Assets

Intangible assets consist of trademarks, patent costs and license fees. Amortization expense was

$38,387

and

$46,127

in the

three

and

nine

months ended

September 30, 2018

and was

$3,276

and

$9,067

in the

three

and

nine

months ended

September 30, 2017.

The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.

Income Taxes

The Company accounts for income taxes in accordance with ASC

740

Income Taxes

(“ASC

740”

). Under ASC

740,

deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

There is

income tax provision in the accompanying statements of operations due to the cumulative operating losses that indicate a

100%

valuation allowance for the deferred tax assets and state income taxes is appropriate.

The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than

not

that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified

income tax uncertainties.

Tax years subsequent to

2014

remain open to examination by federal and state tax authorities.

Offering Costs

Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.

Patents and Intellectual Property

January 25, 2014,

the Company filed a non-provisional Patent Cooperation Treaty (“PCT”) Application

No.

PCT/US2014/013081

claiming priority from the U.S. Provisional Patent Application, number

61756763

which was filed

one

year earlier on

January 25, 2013.

The “PCT” allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the

148

countries of the PCT, including the United States. Filing this single “international” patent application through the PCT is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired.

The Company’s PCT patent application is for the new model of the surgical fluid waste management system. The Company obtained a favorable International Search Report from the PCT searching authority indicating that the claims in its PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facility’s sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is

not

interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid.

The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models:

US7469727,

US8123731

and U.S. Publication

No.

US20090216205

(collectively, the “Patents”). These Patents will begin to expire on

August 8, 2023.

July 2015,

the Company filed an international PCT patent application for its fluid waste collection system and received a favorable determination by the International Searching Authority finding that all of the claims satisfy the requirements for novelty, inventive step and industrial applicability. The Company anticipates that the favorable International Search Report will result in allowance of its various national applications.

The United States Patent Office has assigned application

#14/763,459

to the Company’s previously filed PCT application.

As of

November 22, 2017,

the Company was informed that the European Patent Office has allowed all claims for application

#14743665.3

1651

and has sent a Notice of Intent to Grant.

As of

July 11, 2018,

the Company was informed that the European Patent

#EP2948200

was granted and published validating in the following countries: Belgium, Germany, Spain, France, United Kingdom, Ireland, Italy, Netherlands, Norway, Poland and Sweden.

Credit Risk

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any

one

financial institution. The Company has

credit risk concentration because there are

funds in excess of insurance limits in a single bank.

Segments

The Company operates in

two

segments for the sale of its medical device and consumable products. Substantially all the Company’s assets, revenues, and expenses for the

three

and

nine

months ended

September 30, 2018

and

2017

were located at or derived from operations in the United States. There was

$4,195

and

$288

in revenues from sales outside the United States during the

three

-month period of

September 2018

and

2017,

respectively; and

$10,061

and

$25,188

in revenues from sales outside of the United States during the

first

nine

months of

2018

and

2017,

respectively.

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device industry, including, but

not

limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.

NOTE

— SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations and Continuance of Operations

The Company was originally incorporated on

April 23, 2002

in Minnesota as BioDrain Medical, Inc. Effective

August 6, 2013,

the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective

December 16, 2013,

the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. On

August 31, 2015,

the Company completed a successful offering and concurrent uplisting to The NASDAQ Capital Market. On

February 1, 2018,

we filed with the Secretary of State of Delaware a Certificate of Amendment to our Certificate of Incorporation to change our corporate name from Skyline Medical Inc. to Precision Therapeutics Inc., effective

February 1, 2018.

Because of this change, our common stock trades under the new ticker symbol “AIPT,” effective

February 2, 2018.

Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.

As of

December 31, 2017,

the registrant had

6,943,283

shares of common stock, par value

$.01

per share, outstanding, adjusted for a

-for-

reverse stock split effective

October 27, 2016.

In this Report, all numbers of shares and per share amounts, as appropriate, have been stated to reflect the reverse stock split. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of our proprietary cleaning fluid and filters to users of our systems. In

April 2009,

the Company received

510

(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY System products.

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until

August 31, 2015

whereupon the Company closed its public offering of units of common stock, Series B Convertible Preferred Stock and Series A Warrants (the “Units”). There remains though, substantial doubt about its ability to continue as a going concern. The financial statements do

not

include any adjustments that might result from the outcome of this uncertainty.

Since inception to

December 31, 2017,

the Company raised approximately

$29,065,934

in equity, inclusive of

$2,055,000

from a private placement of Series A Convertible Preferred Stock,

$13,555,003

from the public offering of Units,

$1,739,770

from a registered direct offering,

$3,937,500

plus an overallotment of

$358,312

from a firm commitment underwritten public offering,

$1,300,000

from a private placement of Series C Convertible Preferred Stock, and

$5,685,000

in debt financing. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources.”

Recent Accounting Developments

May 2014,

the Financial Accounting Standards Board (“FASB”) issued ASU

2014

09,

Revenue from Contracts with Customers

and created a new topic in the FASB Accounting Standards Codification ("ASC"), Topic

606,

and has since amended the standard with ASU

2015

14,

“Revenue from Contracts with Customers: Deferral of the Effective Date,”

ASU

2016

08,

“Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net),”

ASU

2016

10,

“Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing,”

ASU

2016

12,

“Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients.”

ASU

2017

13.

These new standards provide a single comprehensive revenue recognition framework for all entities and supersedes nearly all existing U.S. GAAP revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue in a manner that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and also requires enhanced disclosures. The amendments are effective for annual reporting periods beginning after

December 15, 2017,

including interim periods within that reporting period. Early application is

not

permitted. The FASB allows

two

adoption methods under ASC

606.

We adopted the standard on

January 1, 2018

using the “modified retrospective method.” Under that method, we will apply the rules to all contracts existing as of

January 1, 2018,

recognizing in the beginning retained earnings an adjustment for the cumulative effect of the change and providing additional disclosure comparing results to previous accounting standards. While we continue to assess all potential impacts of the standard, it is currently anticipated that the standard will

not

have a material impact on our financial statements.

August 2014,

the FASB issued ASU

2014

15,

Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern

. The new standard requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The standard is effective for public entities for annual and interim periods beginning after

December 15, 2016,

with early adoption permitted. We implemented in the

first

quarter of

2017.

July 2015,

the FASB issued ASU

No.

2015

, Inventory (Topic

330

): Simplifying the Measurement of Inventory

, requiring that inventory be measured at the lower of cost and net realizable value. Net realizable value is defined as estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This ASU is effective within annual periods beginning on or after

December

15,

2016,

including interim periods within that reporting period. We implemented in the

first

quarter of

2017.

November 2015,

the FASB issued ASU

2015

17,

“Income Taxes (Topic

740

)”

providing guidance on the balance sheet classification of deferred taxes. The guidance requires that deferred tax assets and liabilities to be classified as noncurrent in the Balance Sheet. The guidance is effective for fiscal years beginning after

December 15, 2016

and for interim periods within those fiscal years, with early adoption permitted. We implemented in the

first

quarter of

2017.

January 2016,

the FASB issued ASU

No.

2016

01,

Financial Instruments-Overall (Subtopic

825

): Recognition and Measurement of Financial Assets and Financial Liabilities

(“ASU

2016

01”

not

result in consolidation and are

not

December 15, 2017,

including interim periods within those fiscal years. The Company does

not

believe that the adoption of this guidance will have a material impact on the Company’s financial statements and disclosures.

February 2016,

the FASB issued ASU

No.

2016

02,

“Leases

(Topic

842”

(“ASU

2016

02”

December 15, 2018.

Early adoption is permitted. We are currently evaluating the timing of our adoption and the impact that the updated standard will have on our financial statements.

March 2016,

the FASB issued ASU

No.

2016

09,

“Compensation (Topic

718

): Improvements to Employee Shares-Based Payment Accounting”

(

“ASU2016

09”

). ASU

2016

simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The standard is effective for fiscal years and interim periods within those fiscal years beginning after

December 15, 2016.

Early adoption is permitted. We implemented in the

first

quarter of

2017.

August 2016,

the FASB issued ASU

No.

2016

15,

Statement of Cash Flows (Topic

230

): Classification of Certain Cash Receipts and Cash Payments,

to address diversity in how certain cash receipts and cash payments are presented and classified in the statements of cash flows. The amendments are effective for public business entities for fiscal years beginning after

December 15, 2017,

and interim periods within those fiscal years. The amendments should be applied using a retrospective transition method to each period presented. If retrospective application is impractical for some of the issues addressed by the update, the amendments for those issues would be applied prospectively as of the earliest date practicable. Early adoption is permitted, including adoption in an interim period. The Company does

not

expect the adoption of ASU

2016

to have a material impact on its financial statements.

December 22, 2017,

the Tax Cuts and Jobs Act of

2017

(Tax Reform Act) was signed into law making significant changes to the Internal Revenue Code. Changes include a reduction in the corporate tax rates, changes to operating loss carry-forwards and carrybacks, and a repeal of the corporate alternative minimum tax. The legislation reduces the U.S. corporate income tax rates from

34%

21%.

As a result of the enacted law, the Company is required to revalue its deferred tax assets and liabilities at the new enacted rate.

We reviewed all other significant newly issued accounting pronouncements and determined they are either

not

applicable to our business or that

material effect is expected on our financial position and results of our operations.

Valuation of Intangible Assets

We review identifiable intangible assets for impairment in accordance with ASC

350

— Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount

may

not

be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount

may

not

be recoverable include, but are

not

limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management’s best estimate of the related risks and return at the time the impairment assessment is made.

Accounting Policies and Estimate

The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Presentation of Taxes Collected from Customers

Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses.

Shipping and Handling

Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations.

Advertising

Advertising costs are expensed as incurred. Advertising expenses were

$37,060

2017,

and

$71,212

2016.

Research and Development

Research and development costs are charged to operations as incurred. Research and development costs were approximately

$289,000

and

$406,000

for

2017

and

2016,

respectively.

Revenue Recognition

The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Revenue Recognition and ASC

606

- Revenue Recognition.

We recognize revenue when the following criteria are met: persuasive evidence of an arrangement exists – we receive both a signed purchase order and contract of terms and conditions confirming the sale from the customer; delivery has occurred – the goods are shipped from our warehouse and delivered and accepted by the customer; the selling price is fixed or determinable – confirmed on the customer purchase order and then invoiced immediately upon shipment of the goods; and collectability is reasonably assured – our customers are long standing hospitals, ambulatory surgical centers and others that pass credit checks. The terms of our agreements with our customers are specified in written agreements. These written agreements, the purchase order and the matching invoice, constitute the persuasive evidence of the arrangements with our customers that are a precondition to the recognition of revenue.

We undertake an evaluation of the creditworthiness of both new and, on a periodic basis, existing customers. Based on these reviews we determine whether collection of our prospective revenue is probable.

We have adopted the provisions of Accounting Standards Update, or “ASU”

2014

09,

Revenue from Contracts with Customers (Accounting Standards Codification, or “ASC”

606

), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. Companies are permitted to adopt ASC

606

using a full retrospective or modified retrospective method. We adopted the standard on

January 1, 2018

using a modified retrospective method.

While we continue to assess all potential impacts of the standard, it is currently anticipated that the standard will

not

have a material impact on our financial statements.

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of

three

months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximate fair value.

Certificates of Deposit

Short-term interest-bearing investments are those with maturities of less than

one

year but greater than

three

months when purchased. Certificates with maturity dates beyond

one

year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value.

Investment Securities

Readily marketable investments in debt and equity services are classified as available-for-sale and are reported at fair value with unrealized gains losses recorded in other comprehensive income. Unrealized gains are charged to earnings when an incline in fair value above the cost basis is determined to be other-than-temporary. Realized gains and losses on dispositions are based on the net proceeds and the adjusted book value of the securities sold, using the specific identification method.

Fair Value Measurements

Under generally accepted accounting principles as outlined in the Financial Accounting Standards Board’s

Accounting Standards Certification

(ASC)

820,

820

establishes a

three

-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level

– Observable inputs such as quoted prices in active markets;

Level

– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level

– Unobservable inputs where there is little or

market data, which requires the reporting entity to develop its own assumptions.

The fair value of the Company’s investment securities were determined based on Level

inputs.

Receivables

Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have

not

been material to the financial statements.

Inventories

Inventories are stated at the lower of cost or market, with cost determined on a

first

-in,

first

-out basis. Inventory balances are as follows:

	December 31, 2017		December 31, 2016

Finished goods	$	62,932	$	38,201
Raw materials		141,028		165,812
Work-In-Process		61,085		68,195
Total	$	265,045	$	272,208

Property and Equipment

	Years
Computers and office equipment	3	-	7
Leasehold improvements		5
Manufacturing Tooling	3	-	7
Demo Equipment		3

The Company’s investment in Fixed Assets consists of the following:

	December 31, 2017		December 31, 2016
Computers and office equipment	$	183,528	$	164,318
Leasehold Improvements		25,635		25,635
Manufacturing Tooling		108,955		103,204
Demo Equipment		43,368		23,236
Total		361,486		316,393
Less: Accumulated Depreciation		273,770		214,897
Total Fixed Assets, Net	$	87,716	$	101,496

Depreciation expense was

$58,872

2017

and

$73,249

2016.

Intangible Assets

Intangible assets consist of trademarks and patent costs. Amortization expense was

$12,689

2017

and

$9,107

2016.

The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.

Income Taxes

The Company accounts for income taxes in accordance with ASC

740

Income Taxes (“ASC

740”

)

. Under ASC

740,

not

that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified

income tax uncertainties.

Tax years subsequent to

2014

remain open to examination by federal and state tax authorities.

Patents and Intellectual Property

January

25th,

2014,

the Company filed a non-provisional PCT Application

No.

PCT/US2014/013081

claiming priority from the U.S. Provisional Patent Application, number

61756763

which was filed

one

year earlier on

January

25th,

2013.

The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the

148

countries of the PCT, including the United States. By filing this single “international” patent application through the PCT, it is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired.

Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is

not

interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid.

The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models:

US7469727,

US8123731

and U.S. Publication

No.

US20090216205

(collectively, the “Patents”). These Patents will begin to expire on

August 8, 2023.

July 2015,

Skyline Medical filed an international (PCT) patent application for its fluid waste collection system and received a favorable determination by the International Searching Authority finding that all of the claims satisfy the requirements for novelty, inventive step and industrial applicability. Skyline anticipates that the favorable International Search Report will result in allowance of its various national applications.

The United States Patent Office has assigned application

#14/763,459

to our previously filed PCT application.

As of

November 22, 2017,

the Company was informed that the European Patent Office has allowed all our claims for application

#14743665.3

1651,

and has sent a Notice of Intent to Grant. Skyline is now in the process of identifying the key European countries that we will validate the patent in.

Credit Risk

one

financial institution. The Company had a credit risk concentration as a result of depositing

$563,000

of funds in excess of insurance limits in a single bank.

Product Warranty Costs

2017

and in

2016,

the Company incurred approximately

$6,209

and

$34,665

in warranty costs.

Segments

The Company operates in

two

segments for the sale of its medical device and consumable products. Substantially all of the Company’s assets, revenues, and expenses for

2017

and

2016

were located at or derived from operations in the United States. There was

$26,662

in revenues from sales outside of the United States during

2017.

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device industry, including, but

not

Note 2 - Equity Method Investment

9 Months Ended

Sep. 30, 2018

Notes to Financial Statements

Equity Method Investments and Joint Ventures Disclosure [Text Block]

NOTE

– EQUITY METHOD INVESTMENT

The Company has an equity method investment in Helomics. The unaudited

nine

-month condensed statement of operations is as follows:

Helomics Holdings Corporation

	For the Nine Months Ended
	September 30, 2018
Revenue	$	623,662

Gross margin	$	441,370


Net loss from continuing operations	$	(6,833,846	)

Net loss to investee	$	(5,227,552	) 1

The loss to investee was calculated at

80%

for the initial period of ownership,

January 11, 2018 –

February 27, 2018,

and then at

75%

for the remainder of the

nine

-month period at the current equity investment percentage owned by the Company.

Helomics’

first

nine

months predominantly included diagnostic revenue only. The contract research organization and D-CHIP Artificial Intelligence products are in the process of launching and have generated approximately

$31,000

of revenue in the

third

quarter.

Note 3 - Revenue Recognition	9 Months Ended
Note 3 - Revenue Recognition	Sep. 30, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	NOTE 3 – REVENUE RECOGNITION Revenue from Product Sales The Company’s revenue consists primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and the Terms and Conditions to be a customer’s contract in all cases. The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected the accounting policy to exclude sales taxes from revenue and expenses. Product sales consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company may, at its discretion, negotiate different shipping terms with customers which may affect the timing of revenue recognition. The Company’s standard payment terms for its customers are generally 30 to 60 days after the Company transfers control of the product to its customer. The Company allows returns of defective disposable merchandise if the customer requests a return merchandise authorization from the Company. Customers may also purchase a maintenance plan from the Company, which requires the Company to service the STREAMWAY System for a period of one year subsequent to the one -year anniversary date of the original STREAMWAY System invoice. The maintenance plan is considered a separate performance obligation from the product sale, is charged separately from the product sale, and is recognized over time (ratably over the one -year period) as maintenance services are provided. A time-elapsed output method is used to measure progress because the Company transfers control evenly by providing a stand-ready service. The Company has determined that this method provides a faithful depiction of the transfer of services to its customers. All amounts billed to a customer in a sales transaction related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not contain any features that create variability in the amount or timing of revenue to be earned. Warranty The Company generally provides one -year warranties against defects in materials and workmanship and will either repair the products or provide replacements at no charge to customers. As they are considered assurance-type warranties, the Company does not account for them as separate performance obligations. Warranty reserve requirements are based on a specific assessment of the products sold with warranties where a customer asserts a claim for warranty or a product defect. Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of September 30, 2018, and December 31, 2017, accounts receivable totaled $238,598 and $137,499, respectively. For the three and nine months ended September 30, 2018, the Company did not incur material impairment losses with respect to its receivables. The Company deferred revenues related primarily to maintenance plans of $15,306 and $6,663 as of September 30, 2018 and December 31, 2017, respectively. Practical Expedients The Company has elected the practical expedient not to determine whether contracts with customers contain significant financing components.

Note 4 - Stockholders' Equity, Stock Options and Warrants

9 Months Ended

12 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

NOTE

– STOCKHOLDERS’ EQUITY, STOCK OPTIONS AND WARRANTS

2018

Firm Commitment Public Offering

January 2018,

the Company completed a firm commitment underwritten public offering of

2,900,000

Units at an offering price of

$0.95

per Unit, with each Unit consisting of

one

share of the Company’s common stock and

0.3

of a Series E Warrant, with each whole Series E Warrant purchasing

one

share of common stock at an exercise price of

$1.00

per whole share. The shares of Common Stock and Series E Warrants were immediately separable and were issued separately. Gross proceeds were approximately

$2,755,000,

before deducting expenses. The Company granted the underwriter a

-day option to purchase an additional (i) up to

290,000

additional shares of Common Stock at the public offering price per Unit less the price of the Series E Warrant included in the Units and less the underwriting discount and/or (ii) additional Series E Warrants to purchase up to

87,000

additional shares of common stock at a purchase price of

$0.001

per Series E Warrant to cover over-allotments, if any. On

February 21, 2018,

the underwriter exercised on

215,247

shares of common stock, par value

$0.01,

$0.9497

per share as described in the Underwriting Agreement. The Company received net proceeds of

$188,066

after deductions of

$16,354

representing the underwriter’s discount of

of the purchase price of the shares.

Share Exchange Agreement With Helomics

January 11, 2018,

the Company entered into a share exchange agreement with Helomics Holding Corporation. Pursuant to the share exchange agreement, Helomics issued

2,500,000

shares of its Series A Preferred Stock in exchange for

1,100,000

shares of common stock. Under the share exchange agreement, in

March 2018

the Company converted

$500,000

in secured notes into another

of Helomics’ outstanding shares, which resulted in the Company owning

25%

of Helomics outstanding stock. The secured notes are related to the Company’s previous loans of

$500,000

to Helomics. The

1,100,000

shares are being held in escrow by Corporate Stock Transfer, Inc. as escrow agent. While the Company’s shares are held in escrow, they will be voted as directed by the Company’s board of directors and management. The Company shares will be released to Helomics following a determination that Helomics’ revenues in any

-month period have been equal or greater than

$8,000,000.

The Helomics Preferred Stock issued to the Company is convertible into an aggregate of

20%

of the outstanding capital stock of Helomics. In addition, the terms of the Helomics Preferred Stock include certain protective provisions that require consent of the Company before Helomics

may

take certain actions, including issuing preferred stock senior to the Helomics Preferred Stock or entering into fundamental corporate transactions. The Company also has certain anti-dilution protections and the right to receive dividends.

Merger Agreement with Helomics

June 28, 2018,

the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Helomics and certain other entities. On

October 26, 2018,

the Merger Agreement was amended and restated – see Note

The Merger Agreement contemplated a reverse triangular merger with Helomics surviving the merger and becoming a wholly-owned operating subsidiary of the Company (the “Merger”). At the time of the Merger, all outstanding shares of Helomics stock

not

already held by the Company were to be converted into the right to receive a proportionate share of

7.5

million shares of newly issued common stock in the Company (“Merger Shares”), in addition to the

1.1

million shares of the Company’s common stock already issued to Helomics for the Company’s initial

20%

ownership in Helomics. Additionally,

860,000

shares of the merger consideration were to be held in escrow for

months to satisfy indemnification claims. Helomics currently has outstanding

$7.6

million in promissory notes and warrants to purchase

18.7

million shares at an exercise price of

$1.00

per share of Helomics common stock held by the investors in the promissory notes. As a result of the Merger, the holders of said promissory notes and warrants would be entitled to additional warrants to purchase up to

5.0

million additional shares of Helomics common stock at an exercise price of

$1.00

per share. Helomics agreed to use commercially reasonable efforts to cause the holder of each such promissory note to enter into an agreement whereby such holder agrees that, effective upon the closing of the Merger, (a) all or a certain portion of the indebtedness evidenced by such promissory note shall be converted into common stock in the Company, (b) all of such holder’s Helomics’ warrants shall be converted into warrants of the Company, and (c) the unconverted portion of said indebtedness shall be converted into a promissory note issued by the Company dated as of the closing of the Merger. The Merger is expressly conditioned on the holders of at least

75%

of the

$7.6

million in outstanding Helomics promissory notes agreeing to such an exchange (and the parties contemplate that each Helomics warrant will be exchanged for a Company warrant at a ratio of

0.6

Precision warrants for each Helomics warrant, with an exercise price of

$1.00

per share. If all holders of such notes agreed to the exchange with respect to the full balance of the notes, such holders would receive an aggregate estimated

23.7

million shares of the Company’s common stock and warrants to purchase an additional

14.2

million shares of the Company’s common stock at

$1.00

per share. In addition, Helomics currently has

995,000

warrants held by other parties at an exercise price of

$0.01

per share of Helomics common stock. It is contemplated that these warrants will be exchanged at the time of the closing of the Merger for warrants to purchase

597,000

shares of Precision common stock at

$0.01

per share.

Under the Merger Agreement, completion of the Merger is subject to customary closing conditions including the approval of the Merger by the stockholders of both companies and other conditions. The Merger Agreement likewise contains customary representations, warranties and covenants, including covenants obligating each of the Company and Helomics to continue to conduct their respective businesses in the ordinary course, and to provide reasonable access to each other’s information. Finally, the Merger Agreement contains certain termination rights in favor of each of the Company and Helomics.

July 10

and

11,

2018,

the Company issued

250,000

shares of common stock, par value

$0.01,

$1.18

per share for consulting fees pursuant to the TumorGenesis license fees contract, and

750,000

shares of common stock, par value

$0.01,

$1.17

per share, in escrow, for TumorGenesis license fees pursuant to the TumorGenesis license fees contract.

Increases in Authorized Shares

At a special meeting of the stockholders on

January 29, 2017,

the stockholders approved a proposal to increase the number of authorized shares of common stock from

8,000,000

shares to

24,000,000

shares of common stock under the Company’s certificate of incorporation.

At the annual meeting on

December 28, 2017,

the stockholders approved a proposal to increase the number of authorized shares of common stock from

24,000,000

50,000,000

shares of common stock,

$0.01

par value. The amendment to the certificate of incorporation to affect this increase was filed on

January 2, 2018.

Equity Incentive Plan

The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to

three

years. Options under this plan have terms ranging from

three

ten

years.

Accounting for share-based payment

The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the expected dividend rate, the risk-free interest rate, and forfeiture taken at occurrence. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future.

Since the Company's common stock has

significant public trading history, and the Company has experienced

significant option exercises in its history, the Company is required to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company compiled historical volatilities over a period of

years of

small-cap medical companies traded on major exchanges and

mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach. In the case of ordinary options to employees the Company determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, the Company estimated the life to be the legal term unless there was a compelling reason to make it shorter.

When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized.

Since the Company has limited trading history in its stock and

first

-hand experience with how its investors and consultants have acted in similar circumstances, the assumptions the Company uses in calculating the fair value of stock-based payment awards represent its best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based consulting and interest expense could be materially different in the future.

Valuation and accounting for options and warrants

The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term.

January 15, 2018,

the Company issued inducement stock options in accordance with NASDAQ listing rule for

50,000

shares of common stock, par value

$0.01

$0.97

per share to the Company’s newly hired International Vice President of Sales. The options will vest in

four

equal increments: on the first, second,

third

and

fourth

quarters of the hiring date anniversary.

March 12, 2018,

the Company issued inducement stock options in accordance with NASDAQ rule for

111,112

shares of common stock, par value

$0.01

$1.35

per share to the Company’s newly hired Vice President of Sales and Marketing. The options will vest in

four

equal increments: on the first, second,

third

and

fourth

quarters of the hiring date anniversary.

For grants of stock option and warrants in

2018

the Company used

2.33%

3.05%

risk free interest rate,

dividend rate,

59%

66%

volatility and estimated terms of

years. Value computed using these assumptions ranged from

$0.4816

$1.0044

per share.

The following summarizes transactions for stock options and warrants for the periods indicated:

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2016		165,643		$	11.22		871,101		$	52.22

Issued		2,612,070			1.45		1,082,946			1.49
Expired		(12,730	)		10.39		(2,790	)		281.46
Exercised		-			-		-			-

Outstanding at December 31, 2017		2,764,983		$	2.00		1,951,257		$	23.74

Issued		836,950			1.12		2,028,776			1.08
Expired		(153,048	)		2.00		(10,706	)		199.55
Exercised		-			-		(650,062	)		1.00

Outstanding at September 30, 2018		3,448,885		$	1.78		3,319,265		$	4.55

September 30, 2018,

2,522,848

stock options are fully vested and currently exercisable with a weighted average exercise price of

$1.93

and a weighted average remaining term of

9.01

years. There are

2,247,489

warrants that are fully vested and exercisable. Stock-based compensation recognized for the

nine

months ended

September 2018

and

September 2017

was

$800,322

and $(

7,908

), respectively. The Company has

$930,349

of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next

months.

The following summarizes the status of options and warrants outstanding at

September 30, 2018:

Range of Prices		Shares		Weighted Remaining Life
Options
$	0.91		10,000		9.55
$	0.965		3,000		9.63
$	0.97		191,753		9.27
$	1.01		149,110		9.38
$	1.06		23,585		10.00
$	1.10		86,958		9.71
$	1.13		195,931		9.80
$	1.15		21,740		9.84
$	1.16		66,451		9.84
$	1.18		30,000		9.86
$	1.20		41,668		9.84
$	1.21		30,000		9.86
$	1.35		111,112		9.45
$	1.454		17,200		9.01
$	1.47		2,347,308		8.73
$	2.10		14,286		8.50
$	2.25		293		7.90
$	2.42		20,640		7.84
$	2.80		57,145		8.26
$	3.75		3,998		5.24
$	4.125		3,636		8.01
$	4.1975		7,147		7.97
$	4.25		3,529		7.50
$	5.125		3,902		7.94
$	65.75		190		7.06
$	73.50		1,157		7.26
$	77.50		2,323		6.75
$	80.25		187		7.01
$	86.25		232		6.50
$	131.25		81		3.94
$	148.125		928		4.47
$	150.00		1,760		3.88

$	162.50	123	6.26
$	206.25	121	6.01
$	248.4375	121	4.79
$	262.50	130	4.79
$	281.25	529	4.30
$	318.75	3	4.60
$	346.875	72	5.50
$	431.25	306	5.44
$	506.25	188	5.25
$	596.25	42	5.00

		3,448,885

Warrants
$	1.00	1,063,935	4.60
$	1.07	697,946	4.10
$	1.155	1,071,776	5.00
$	2.25	385,000	3.32
$	123.75	94,084	1.92
$	243.75	2,529	0.84
$	309.375	2,850	0.86
$	309.50	222	1.10
$	506.25	59	0.38
$	609.375	862	0.34
		3,319,265

At the annual meeting on

December 28, 2017,

the stockholders approved an amendment to the Company’s

2012

Plan to (i) increase the reserve of shares of common stock authorized for issuance thereunder to

5,000,000,

(ii) increase certain threshold limits for grants, and (iii) to re-approve the performance goals thereunder. As described in the Company’s definitive proxy statement filed with the SEC on

December 4, 2017,

amendments to the

2012

Plan were considered at the

2016

annual meeting on

July 28, 2016

but were

not

approved by the required vote. For options to purchase approximately

2.5

million shares granted after the

2016

annual meeting, the grantees agreed

not

to exercise the options prior to further stockholder approval of an increase in the reserve under the

2012

Plan. As a result of the stockholder approval of the amendments at the

2017

annual meeting, these restrictions on exercise were removed on

December 28, 2017.

Due to the removal of this restriction on exercise, the Company recognized a non-cash charge for compensation expense of approximately

$1.9

million in the

fourth

quarter of

2017.

Stock Options and Warrants Granted by the Company

The following table is the listing of stock options and warrants as of

September 30, 2018

by year of grant:

Stock Options:
Year	Shares		Price
2011		173			$281.25
2012		1,841		131.25	–	150.00
2013		1,553		148.13	–	596.25
2014		836		162.50	–	431.25
2015		4,088		65.75	–	86.25
2016		100,292		2.25	–	5.13
2017		2,503,152		1.01	-	2.10
2018		836,950		0.91	-	1.35
Total		3,448,885		$0.91	–	$596.25

Warrants:
Year	Shares		Price
2014		6,455		$243.75	–	$609.38
2015		94,151		0.00	–	243.75
2016		252,333			1.00
2017		1,082,946		1.07	-	2.25
2018		1,883,380		1.00	-	1.155
Total		3,319,265		$0.00	–	$609.38

NOTE

– STOCKHOLDERS’ EQUITY (DEFICIT), STOCK OPTIONS AND WARRANTS

2015

Public Offering of Units

August 31, 2015 (

the “Issuance Date”), the Company completed a public offering (the “Offering”) of

1,666,667

Units (the “Units”) as described below. The public offering price in the Offering was

$9.00

per Unit, and the purchase price for the underwriter of the Offering (the “Underwriter”) was

$8.28

per Unit, resulting in an underwriting discount and commission of

$0.72

(or

8.00%

) per Unit and total net proceeds to the Company before expenses of

$13.8

million. The Company had granted the Underwriter an option for a period of

days to purchase up to an additional

250,000

Units solely to cover over-allotments. The Underwriter chose

not

to purchase any additional Units under the over-allotment option. The Company paid to the Underwriter a non-accountable expense allowance equal to

of the gross proceeds of the Offering and agreed to reimburse expenses incurred by the Underwriter up to

$70,000.

August 31, 2015,

as a result of the communication of the Offering and the issuance of the

228,343

Exchange Units in the Unit Exchange described below, the Company issued a total of

1,895,010

Units, comprised of a total of aggregate of

75,801

shares of Common Stock,

1,895,010

shares of Series B Preferred Stock and

7,580,040

Series A Warrants.

Each Unit consisted of

one

share of common stock, par value

$0.01

per share (the “Common Stock”),

one

share of Series B Convertible Preferred Stock (“Series B Preferred Stock”) and

four

Series A Warrants. The shares of Common Stock, the shares of Series B Preferred Stock and the Series A Warrants that comprise the Units automatically separated on

February

29,

2016.

For a description of the terms of the Series B Convertible Preferred Stock included within the Units, see “Certificate of Designation for Series B Preferred Stock” below. For a description of the terms of the Series A Warrants included within the Units, see “Series A Warrants” below.

Series A Warrants

. The Series A Warrants separated from the Series B Convertible Preferred Stock and the Common Stock included within the Units as described above and are currently exercisable. The Series A Warrants will terminate on

August 31, 2020.

Each Series A Warrant is exercisable into

one

share of Common Stock at an initial cash exercise price of

$123.75

per share. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Common Stock and the exercise price.

Holders

may

exercise Series A Warrants by paying the exercise price in cash or, in lieu of payment of the exercise price in cash, by electing to receive a number of shares of Common Stock equal to the Black Scholes Value (as defined below) based upon the number of shares the holder elects to exercise. The number of shares of Common Stock to be delivered will be determined according to the following formula, referred to as the “Cashless Exercise.”

Total Shares = (A

B) / C

Where:

	☐	Total Shares is the number of shares of Common Stock to be issued upon a Cashless Exercise.

	☐	A is the total number of shares with respect to which the Series A Warrant is then being exercised.

☐

B is the Black Scholes Value (as defined below).

☐

C is the closing bid price of the Common Stock as of

two

trading days prior to the time of such exercise, provided that in

event

may

“C” be less than

$0.43

per share (subject to appropriate adjustment in the event of stock dividends, stock splits or similar events affecting the Common Stock).

The Black Scholes Value (as defined above) as of

September 30, 2016

was

$4.319,

and the closing bid price of Common Stock as of

September 30, 2016,

was

$4.125.

Therefore, an exercise on that date would have resulted in the issuance of

.40

shares of Common Stock for each Series A Warrant. Approximately

6,141,115

Series A Warrants have been exercised in cashless exercises as of

September 30, 2016,

resulting in the issuance of

2,318,663

shares of Common Stock. If all of the remaining

35,084

Series A Warrants that were issued as part of the Units sold in the Offering and part of the Units issued on

August 31, 2015

were exercised pursuant to a cashless exercise and the closing bid price of our common stock as of the

two

trading days prior to the time of such exercise was

$0.43

per share or less and the Black Scholes Value were

$4.319

(the Black Scholes Value as of

September 30, 2016),

then a total of approximately

564

shares of our common stock would be issued to the holders of such Series A Warrants.

The Series A Warrants will

not

be exercisable or exchangeable by the holder of such warrants to the extent (and only to the extent) that the holder or any of its affiliates would beneficially own in excess of

4.99%

of the common stock of the Company, determined in accordance with Section

(d) of the Securities Exchange Act of

1934,

as amended, and the regulations promulgated thereunder.

In addition to (but

not

duplicative of) the adjustments to the exercise price and the number of shares of Common Stock issuable upon exercise of the Series A Warrants in the event of stock dividends, stock splits, reorganizations or similar events, the Series A Warrants provide for certain adjustments if the Company, at any time prior to the

three

year anniversary of the Issuance Date, (

) declares or makes any dividend or other distribution of its assets (or rights to acquire its assets) to all or substantially all of the holders of shares of Common Stock at any time after the Issuance Date, or (

) grants, issues or sells any options, convertible securities or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of shares of Common Stock. Further, if at any time a Series A Warrant is outstanding, the Company consummates any fundamental transaction, as described in the Series A Warrants and generally including any consolidation or merger into another corporation, or the sale of all or substantially all of our assets, or other transaction in which the Common Stock is converted into or exchanged for other securities or other consideration, the holder of any Series A Warrants will thereafter receive, the securities or other consideration to which a holder or the number of shares of Common Stock then deliverable upon the exercise or exchange of such Series A Warrants would have been entitled upon such consolidation or merger or other transaction.

Unit Purchase Option

The Company, in connection with the Offering, entered into a Unit Purchase Option Agreement, dated as of

August 31, 2015 (

the “Unit Purchase Option”), pursuant to which the Company granted the Underwriter the right to purchase from the Company up to a number of Units equal to

of the Units sold in the Offering (or up to

83,333

Units) at an exercise price equal to

125%

of the public offering price of the Units in the Offering, or

$11.25

per Unit. The Unit Purchase Option was terminated in

May 2016

in exchange for

135,995

shares of common stock.

Series B Preferred Stock

Each share of Series B Preferred Stock is convertible into

one

share of Common Stock (subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events) on the

six

-month anniversary of the Issuance Date or on the date of an Early Separation. In addition, the Series B Preferred Stock will automatically convert into shares of common stock upon the occurrence of a fundamental transaction, as described in the certificate of designations for the Series B Preferred Stock but including mergers, sales of the company’s assets, changes in control and similar transactions. The Series B Preferred Stock is

not

convertible by the holder of such preferred stock to the extent (and only to the extent that the holder or any of its affiliates would beneficially own in excess of

4.99%

of the common stock of the Company. The Series B Preferred Stock has

voting rights, except for the right to approve certain amendments to the certificate of designations or similar actions. With respect to payment of dividends and distribution of assets upon liquidation or dissolution or winding up of the Company, the Series B Preferred Stock shall rank equal to the common stock of the Company.

sinking fund has been established for the retirement or redemption of the Series B Preferred Stock.

Unit Exchange

February 4, 2014,

the Company raised

$2,055,000

in gross proceeds from a private placement of

20,550

shares of Series A Convertible Preferred Stock, par value

$0.01,

with a stated value of

$100

per share (the “Series A Preferred Shares”) and warrants to purchase shares of the Company’s common stock. The Series A Preferred Shares and warrants were sold to investors pursuant to a Securities Purchase Agreement, dated as of

February 4, 2014.

August 31, 2015,

the Company issued a total of

228,343

Units (the “Exchange Units”) in exchange for the outstanding Series A Preferred Stock which were then cancelled pursuant to an agreement with the holders of the Series A Preferred Shares. The warrants that were issued in connection with the issuance of the Series A Preferred Shares remained outstanding; however, the warrant amounts were reduced so that the warrants are exercisable into an aggregate of

3,391

shares of the Company’s common stock. The Exchange Units were exempt from registration under Section

(a)(

) of the Securities Act. On

August 31, 2015,

the Company filed a termination certificate with the Delaware Secretary of State. Following that date there were

shares of Series A Preferred Stock outstanding, and the previously authorized shares of Series A Preferred Stock resumed the status of authorized but unissued and undesignated shares of preferred stock of the Company.

Redemption of Convertible Notes

In connection with the closing of the Offering,

$933,074

aggregate principal amount of Convertible Notes plus interest and a

40%

redeemable premium were redeemed for total payments of

$1,548,792.

See Note

Of this amount, approximately

$167,031

was paid to its affiliates in redemption of their Convertible Notes.

Registered Exchange Offer for Warrants

March 25, 2016,

the Company commenced a registered exchange offer (the “Exchange Offer”) to exchange Series B Warrants (the “Series B Warrants”) to purchase shares of our common stock, par value

$0.01

per share (the “Warrant Shares”), for up to an aggregate of

3,157,186

outstanding Series A Warrants (the “Series A Warrants”). On

March 31, 2016,

each Series A Warrant could be exercised on a cashless basis for

10.05

shares of common stock. Each Series B Warrant

may

be exercised on a cashless basis for

one

share of common stock. For each outstanding Series A Warrant tendered by holders, we offered to issue

10.2

Series B Warrants, which are subject to cashless exercise at a fixed rate of

one

share of common stock per Series B Warrant (subject to further adjustment for stock splits, etc.). The Exchange Offer expired at midnight, Eastern time, on

April 21, 2016.

1,770,556

Series A Warrants were tendered by holders. The Company delivered an aggregate of

18,059,671

Series B Warrants pursuant to the terms of the Exchange Offer. In addition, between

March 31, 2016

and

July 6, 2016

1,251,510

Series A Warrants were exercised in cashless exercises, resulting in the issuance of

20,122

shares of common stock.

2016

Registered Direct Offering

November 29, 2016,

the Company closed a registered direct offering for gross proceeds of

$1,983,337.

The offering consisted of

756,999

shares of common stock priced at

$2.62

per share and

five

-year warrants for

756,999

shares of common stock that become exercisable in

six

months, with a strike price of

$4.46

per share. The net proceeds from the sale of the securities, after deducting placement agent fees and related offering expenses, was

$1,739,770.

2017

Firm Commitment Public Offering

January 19, 2017

the Company closed a firm commitment public offering for

1,750,000

Units at

$2.25

per Unit. The Units comprised

one

share of Common Stock and

0.2

Series D Warrants with each whole Series D Warrant purchasing

one

share of our Common Stock at an exercise price of

$2.25

per share. We received gross proceeds of

$3,937,500.

Subsequently the underwriter exercised over-allotment for

175,000

shares of common stock and for Series D warrants to purchase

35,000

shares of common stock at

$0.01

per warrant. The Company received net proceeds from the over-allotment of

$358,312.

2017

Private Placement

November 30, 2017,

the Company closed a private placement of a newly created series of preferred stock designated as “Series C Convertible Preferred Stock” with a New York based Family Office. Pursuant to the Securities Purchase Agreement, the investor purchased

1,213,819

shares of Series C stock at a purchase price of

$1.071

per Series C Share, together with a warrant to purchase up to

606,910

shares of common stock. The warrant has an exercise price of

$1.26

per share, subject to adjustment, has a

five

and

one

-half year term and is exercisable commencing

six

months following the date of issuance. Total gross proceeds to Skyline were

$1,300,000

before deducting expenses and will be used for general working capital. In connection with the Offering and pursuant to a registration rights agreement, the Company has agreed to file a “resale” registration statement covering all of the shares of common stock issuable upon conversion of the warrant. Pursuant to the Securities Purchase agreement, and as of this filing date, all the Preferred Series C shares were converted at a conversion rate of

1.167

to a maximum of

1,250,269

shares of common stock. The remaining

142,466

shares of Preferred Series C stock were cancelled with a redemption payment to the holder for

$189,285.

Equity Incentive Plan

three

years. Options under this plan have terms ranging from

three

ten

years.

Accounting for share-based payment

The Company has adopted ASC

718

Compensation-Stock Compensation

("ASC

718"

). Under ASC

718

stock-based employee compensation cost is recognized using the fair value based method for all new awards granted after

January 1, 2006

and unvested awards outstanding at

January 1, 2006.

Compensation costs for unvested stock options and non-vested awards that were outstanding at

January 1, 2006,

are being recognized over the requisite service period based on the grant-date fair value of those options and awards, using a straight-line method. We elected the modified-prospective method under which prior periods are

not

retroactively restated.

ASC

718

requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means. The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future.

Since the Company's common stock has

significant public trading history, and the Company has experienced

years of

small-cap medical companies traded on major exchanges and

Since the Company has limited trading history in its stock and

first

Valuation and accounting for options and warrants

July 1, 2016,

the Company issued inducement stock options in accordance with NASDAQ listing rule for

40,000

shares of common stock, par value

$0.01

$3.75

per share to the Company’s newly hired Vice President of Sales. The options will vest in

six

equal increments: on the first, second, third, fourth,

fifth

and

sixth

quarters of the hiring date anniversary.

October 4, 2016,

the Company issued

400,000

shares of common stock, par value

$0.01,

to be held in escrow in connection with the Company’s Partnership and Exclusive Reseller Agreement with GLG Pharma, LLC.

For grants of stock options and warrants in

2016

the Company used a

1.46%

2.45%

risk free interest rate,

dividend rate,

59%

66%

volatility and estimated terms of

years. Value computed using these assumptions ranged from

$1.6329

$3.7195

per share.

April 19, 2017,

the Company terminated the Company’s Partnership and Exclusive Reseller Agreement with GLG Pharma, LLC and thereby received

400,000

shares of common stock, par value

$0.01,

from escrow.

For grants of stock options and warrants in

2017

the Company used a

1.92%

2.40%

risk free interest rate,

dividend rate,

59%

66%

volatility and estimated terms of

years. Value computed using these assumptions ranged from

$0.6541

$1.5489

per share.

The following summarizes transactions for stock options and warrants for the periods indicated:

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2015		31,350		$	133.23		323,099		$	128.40

Issued		157,982			3.14		1,487,881			0.71
Expired		(22,377	)		122.13		-			-
Exercised		(1,312	)		65.75		(939,879	)		-

Outstanding at December 31, 2016		165,643		$	11.22		871,101		$	52.22

Issued		2,612,070			1.45		1,082,946			1.49
Expired		(12,730	)		10.39		(2,790	)		281.46
Exercised		-			-		-			-

Outstanding at December 31, 2017		2,764,983		$	2.00		1,951,257		$	23.74

December 31, 2017,

1,728,264

stock options are fully vested and currently exercisable with a weighted average exercise price of

$2.29

and a weighted average remaining term of

9.45

years. There are

1,253,311

warrants that are fully vested and exercisable. Stock-based compensation recognized in

2017

and

2016

was

$1,892,159

and

$165,271,

respectively. The Company has

$1,139,172

of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next

months.

The following summarizes the status of options and warrants outstanding at

December 31, 2017:

Range of Exercise Prices			Shares		Weighted Average Remaining Life
Options:
	$	1.01		124,358	10.00
	$	1.454		17,200	9.75
	$	1.47		2,456,226	9.48
	$	2.10		14,286	9.25
	$	2.25		293	8.65
	$	2.42		24,768	8.38
	$	2.80		57,145	9.01
	$	3.75		44,000	8.50
	$	4.125		3,636	8.75
	$	4.1975		7,147	8.72
	$	4.25		3,529	8.25
	$	5.125		3,902	8.69
	$	65.75		190	7.40
	$	73.50		1,157	8.01
	$	77.50		2,323	7.50
	$	80.25		187	7.75
	$	86.25		232	7.25
	$	131.25		81	4.69
	$	148.125		928	5.21
	$	150.00		1,760	4.63
	$	162.50		123	7.01
	$	206.25		121	6.75
	$	248.4375		121	5.54
	$	262.50		130	5.54
	$	281.25		529	5.04
	$	318.75		3	5.35
	$	346.875		72	6.25
	$	431.25		306	6.19
	$	506.25		188	6.00
	$	596.25		42	5.75
Total				2,764,983

	Warrants
		$	1.07	697,946	4.85
		$	2.25	385,000	4.06
		$	4.46	756,999	3.92
		$	93.75	2,255	0.19
		$	123.75	94,084	2.67
		$	150.00	4,114	0.20
		$	225.00	107	0.07
		$	243.75	2,529	1.59
		$	281.25	3,107	0.14
		$	309.375	2,850	1.61
		$	309.50	222	1.85
		$	337.50	178	0.46
		$	371.25	944	0.41
		$	506.25	59	1.12
		$	609.375	862	1.09
Total				1,951,257

Stock options and warrants expire on various dates from

January 2018

December 2027.

At a special meeting of stockholders held on

September 15, 2016,

the Company’s stockholders (i) approved an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of common stock from

100,000,000

200,000,000

(before the reverse stock split described in the following sentence). (ii) approved an amendment to the Company’s certificate of incorporation to affect a reverse stock split of the outstanding shares of its common stock within certain limits. On

September 16, 2016,

the Company filed a Certificate of Amendment to its Certificate of Incorporation to affect the increase in the authorized capital stock. On

October 26, 2016,

the Company filed a Certificate of Amendment to its Certificate of Incorporation to affect a reverse stock split of the outstanding shares of its common stock at a ratio of

one

-for-

twenty-five

(

1:25

), and a proportionate decrease of the authorized common stock from

200,000,000

shares to

8,000,000

shares. The reverse stock split took effect at

5:00

p.m. New York time on

October 27, 2016,

and the Company’s common stock commenced trading on a post-split basis on

October 28, 2016.

The Company’s board of directors has determined that the Company

may

require additional authorized shares for anticipated equity financings, future equity offerings, strategic acquisition opportunities, and the continued issuance of equity awards under our stock incentive plan to recruit and retain key employees, and for other proper corporate purposes. As a result, the board of directors called another special meeting of the stockholders that took place on

January 29, 2017.

The vote, a proposal to increase the number of authorized shares of common stock from

8,000,000

shares to

24,000,000

shares of common stock under the Company’s certificate of incorporation passed. On

December 28, 2017,

the Company held its annual meeting. Pursuant to the meeting on

January 2, 2018,

the Certificate of Incorporation of the Company was amended to increase the number of authorized shares of common stock from

24,000,000

50,000,000

shares of common stock,

$0.01

par value. Additionally, the stockholders approved an amendment to the Company’s

2012

Plan to (i) increase the reserve of shares of Common Stock authorized for issuance thereunder to

5,000,000,

(ii) to increase certain threshold limits for grants, and (iii) to re-approve the performance goals thereunder. Pursuant to the annual meeting and the aforementioned approvals, and as explained in the Company’s definitive proxy statement filed with the SEC on

December 4, 2017,

amendments to the

2012

Plan were considered at the

2016

annual meeting but were

not

approved by the required vote. For options to purchase approximately

2.5

million shares granted after the

2016

annual meeting, the grantees agreed

not

to exercise the options prior to further stockholder approval of an increase in the reserve under the

2012

Plan. As a result of the stockholder approval of the amendments at the

2017

annual meeting, these restrictions on exercise were removed on

December 28, 2017.

Due to the removal of this restriction on exercise, the Company recognized a non-cash charge for compensation expense of approximately

$1.9

million in the

fourth

quarter of

2017.

Stock Options and Warrants Granted by the Company

The following table is the listing of stock options and warrants as of

December 31, 2017

by year of grant:

Stock Options:
Year	Shares		Price
2011		173			281.25
2012		1,841		131.25	–	150.00
2013		1,553		148.13	–	596.25
2014		835		162.50	–	431.25
2015		4,088		65.75	–	86.25
2016		144,423		2.25	–	5.13
2017		2,612,070		1.01	–	2.10
Total		2,764,983	$	1.01	–	596.25

Warrants:
Year	Shares		Price
2013		10,705		93.75	–	371.25
2014		6,455		243.75	–	609.38
2015		94,152		0.00	–	243.75
2016		756,999			4.46
2017		1,082,946		1.07	–	2.25
Total		1,951,257	$	0.00	–	609.38

Note 5 - Notes Receivable	9 Months Ended	12 Months Ended
Note 5 - Notes Receivable	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 5 – NOTES RECEIVABLE In July 2017, the Company began to advance funds to CytoBioscience for working capital for CytoBioscience’s business. All the notes receivable bear simple interest at 8% and were due in full on December 31, 2017. All the notes are covered by a security interest in all of CytoBioscience’s accounts receivable and related rights in connection with all of the advances. The principal amount of the secured promissory notes receivable from CytoBioscience totaled $1,070,000 as of December 31, 2017. In March 2018, the Company executed a new note replacing all previous CytoBioscience notes for $1,112,524, plus interest paid monthly at the per annum rate of ( 8% ) on the principal amount. The secured note has a term of two years with the unpaid principal and unpaid accrued interest due and payable on February 28, 2020. CytoBioscience was current in its payments to the Company through and including July 2018. The Company has not received the scheduled interest payments from CytoBioscience for the months of August, September and October. On September 27 amd 28, 2018 CytoBioscience, through its parent company (WestMountain) made public filings indicating that their notes payable was in default. In October 2018, CytoBioscience communicated to the Company that CytoBioscience is raising capital that it believes will allow it to resume debt service payments, and that CytoBioscience wishes to negotiate an extension to the note. At this time the Company does not believe a reserve is needed but if CytoBioscience is not successful in its efforts to raise capital, there could be additional reserves or write-offs against this receivable in the future, which could result in a significant loss for the Company. In October 2017, the Company advanced $600,000 for working capital for Helomics’ business. Additionally, in December 2017, the Company advanced $67,512 to De Lage Landen, a vendor of Helomics, as a fifty percent ( 50% ) down payment for a lease to purchase certain equipment. The note is covered by a security interest in certain equipment of Helomics. In March 2018, the Company converted $500,000 of the note receivable into 833,333 shares of common stock for an additional 5% interest in Helomics. The Company now has an equity stake in Helomics totaling 25%. In September 2018, the Company advanced an additional $60,000 for working capital for Helomics’ business. The balance due to the Company is $163,468, plus interest as of September 30, 2018. Subsequently in October 2018, the Company advanced $907,500 for working capital for Helomics’ business. All additional advances are covered by the security interest in certain equipment of Helomics. In addition, Helomics pledged all of its assets as security for the Company’s convertible secured note financing described in Note 9. Upon completion of the merger with Helomics all intercompany notes would be eliminated in their entirety.	NOTE 4– NOTES RECEIVABLE In July 2017, the Company began to advance funds to CytoBioscience for working capital for CytoBioscience’s business. All the notes receivable bear simple interest at 8% and are due in full on December 31, 2017. All the notes are covered by a security interest in all of CytoBioscience’s accounts receivable and related rights in connection with all of the advances. The principal amount of the secured promissory notes receivable from CytoBioscience totaled $1,070,000 as of December 31, 2017. In March 2018, the Company executed a new note replacing all previous CytoBioscience notes for $1,112,524, plus interest paid monthly at the per annum rate of eight percent ( 8% ) on the principal amount. The secured note has a term of two years with the unpaid principal and unpaid accrued interest due and payable on February 28, 2020. The Company advanced $600,000 for working capital for Helomics’ business. The notes receivable bear simple interest at 8% and is due in full on April 30, 2018. Additionally, in December 2017, the Company advanced $67,512.10 to De Lage Landen as fifty percent ( 50% ) down payment for a lease to purchase certain equipment. The note is covered by a security interest in certain equipment of Helomics. In March 2018, the Company converted $500,000 of the note receivable into 833,333 shares of common stock for an additional 5% interest in Helomics Corporation. The Company now has an equity stake in Helomics totaling 25%. The Company is currently negotiating terms for payment on the remaining $167,512.10 plus interest.

Note 6 - Convertible Debt and Derivative Liability	9 Months Ended
Note 6 - Convertible Debt and Derivative Liability	Sep. 30, 2018
Notes to Financial Statements
Convertible Debt and Derivative Liability [Text Block]	NOTE 6 – CONVERTIBLE DEBT AND DERIVATIVE LIABILITY Effective September 28, 2018 ( the “Effective Date”), the Company issued convertible secured promissory notes to two private investors in the original principal amount of an aggregate $2,297,727 (the “bridge loan”). See Note 9 for more information. The closing of the investment took place on October 3, 2018, and therefore, the net cash proceeds to the Company of $1,815,000, representing an aggregate investment of $2,000,000 less commissions, are reflected on the Company’s balance sheet as of September 30, 2018 as Loan Receivable – Bridge Loan. The Company has loaned one -half of the net proceeds to Helomics. The Company and Helomics have granted to each of the investors a security interest in their assets to secure repayment of the notes. The securities purchase agreements with the investors also provide for a second investment of an aggregate of $500,000 by the investors at the consummation of the Merger transaction with Helomics, at which point the aggregate principal amounts of the notes will become $2,865,909.00. As additional consideration for the investment, the Company issued an aggregate 650,000 shares of its common stock (the “Inducement Shares”) to the investors or their affiliates plus warrants to acquire up to an aggregate 1,071,776 shares of the Company’s common stock at an exercise price of $1.155 per share. Upon the closing of the second tranche investment, the warrants will be increased to cover an aggregate total of 1,336,805 shares. Each warrant is exercisable by the investor beginning on the sixth month anniversary of the effective date through the fifth -year anniversary thereof. The notes accrue interest at a rate of 8% per annum (with twelve months of interest guaranteed). The maturity date of the notes is twelve months from the Effective Date. Upon the earlier to occur of an event of default (as defined in the notes) or the filing of certain registration statements, each investor will have the right at any time thereafter to convert all or any part of its Note into shares of the Company’s common stock at a conversion price which is equal to the lesser of: (i) $1.00 and (ii) 70% of the lowest Volume Weighted Average Price (the “VWAP”) of the Company’s common stock during the 20 -trading day period ending on either the last complete trading day prior to the conversion date, or the conversion date (“Conversion Shares”). The number of Conversion Shares that may be issued is subject to an exchange cap such that the sum of (a) the total number of Conversion Shares plus (b) the number of Inducement Shares is limited to an aggregate 2,678,328 shares. Management has concluded the conversion feature is an embedded derivative that is required to be bifurcated and separately presented as a liability on the balance sheet. The embedded derivative’s value was determined using 70% of the VWAP for the 20 trading days preceding the balance sheet date, and assuming conversion on that date as management believed it is probable that the notes will be convertible based on management’s expectation that additional financing will be required. The Company accounted for the warrants by deriving the Black-Scholes value ascertained with a discount rate of 2.94% over five years with a 59% volatility rate pursuant to the Company’s established warrant volatility and a calculated value per warrant of .5361 resulting in a fair value of $574,631. Management concluded that the warrants and Inducement Shares qualify for equity classification. The proceeds from the bridge loan were allocated between the convertible note, warrants, and inducement shares based on the relative fair value of the individual elements. The value of the embedded derivative was based upon level 3 inputs – see the Fair Value Caption in Note 1.

Note 7 - Loss Per Share

9 Months Ended

12 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Notes to Financial Statements

Earnings Per Share [Text Block]

NOTE

- LOSS PER SHARE

The following table presents the shares used in the basic and diluted loss per common share computations:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Numerator
Net loss available in basic and diluted calculation	$	(2,506,869	)	$	(992,095	)	$	(6,640,301	)	$	(4,877,542	)
Comprehensive loss		(2,506,869	)		(992,095	)		(6,640,301	)		(4,877,542	)
Denominator:
Weighted average common shares outstanding-basic		13,252,605			6,232,761			12,178,285			6,283,567

Effect of diluted stock options, warrants and preferred stock (1)		-			-			-			-

Weighted average common shares outstanding-basic		13,252,605			6,262,761			12,178,285			6,283,567

Loss per common share-basic and diluted	$	(0.19	)	$	(0.16	)	$	(0.55	)	$	(0.78	)

(

) The number of shares underlying options and warrants outstanding as of

September 30, 2018

and

September 30, 2017

are

6,768,151

and

3,866,849,

respectively. The number of shares underlying the convertible debt as of

September 30, 2018

5,047,700.

The number of shares underlying the preferred stock as of

September 30, 2018

79,246.

The effect of the shares that would be issued upon exercise of such options, warrants, convertible debt and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

NOTE

- LOSS PER SHARE

The following table presents the shares used in the basic and diluted loss per common share computations:

	Year Ended December 31,
	2017			2016
Numerator:
Net loss available in basic and diluted calculation	$	(7,746,593	)	$	(6,526,014	)
Other comprehensive income:
Unrealized gain (loss) from marketable securities		-			1,501
Comprehensive (loss)		(7,746,593	)		(6,524,513	)
Denominator:
Weighted average common shares outstanding-basic		6,362,989			2,823,345

Effect of dilutive stock options, warrants and preferred stock (1)		-			-

Weighted average common shares outstanding-basic		6,362,989			2,823,345

Loss per common share-basic and diluted	$	(1.22	)	$	(2.31	)

(

) The number of shares underlying options and warrants outstanding as of

December 31, 2017

and

December 31, 2016

are

4,716,240

and

1,036,744,

respectively. The number of shares underlying the preferred stock as of

December 31, 2017

79,246

for Series B Convertible and

647,819

for Series C Convertible. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 8 - Related Party Transactions	9 Months Ended	12 Months Ended
Note 8 - Related Party Transactions	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 8 – RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. In April 2018, one of the Company’s directors, Richard L. Gabriel, executed a six -month consulting contract to help guide operations for the Company’s wholly-owned subsidiary TumorGenesis. Under the terms of the agreement Mr. Gabriel will receive $12,000 monthly cash payment. In addition, Mr. Gabriel will receive a grant of 240,000 performance-based restricted stock units (“RSU’s”) under the Company’s Amended and Restated 2012 Stock Incentive Plan, with the vesting and payment of the RSU’s based on performance milestones as set forth in the agreement. Mr. Gabriel executed another six -month consulting contract for these services in October 2018. The contract has the same terms as the April 2018 contract except for the stock grants and performance milestones, which are covered under the original contract. As of this filing date Mr. Gabriel has not reached any of the prescribed milestones for earning performance based restricted stock units.	NOTE 8 - RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. In September 20, 2016, the Company entered into a partnership and exclusive reseller agreement with GLG. Under the terms of the agreement, GLG would develop rapid diagnostic tests that utilize fluid and tissue collected by the STREAMWAY System during procedures. The Company agreed to issue an aggregate of 400,000 shares of common stock to GLG in four separate tranches of 100,000 shares of common stock in each tranche. The shares reserved in each tranche would be released after the achievement of certain development milestones designated in the agreement. In addition, the Company would pay a royalty to GLG on the sale of individual tests. Also, on November 1, 2016, the Company announced that it agreed to grant GLG exclusive rights to market and distribute the STREAMWAY System in the U.K. On November 2, 2016, the Company announced that it agreed to grant GLG the same rights in Poland and certain other countries in Central Europe. In April 2017, the partnership and exclusive reseller agreement and the distribution agreements between the Company and GLG were terminated.

Note 9 - Subsequent Events	9 Months Ended	12 Months Ended
Note 9 - Subsequent Events	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 9 – SUBSEQUENT EVENTS Private Placement of Convertible Secured Notes Effective as of September 28, 2018 ( the “Effective Date”), the Company issued convertible secured promissory notes two private investors in the original principal amount of an aggregate $2,297,727.50 (the “bridge loans”). The closing of the investment took place on October 3, 2018, and therefore, the net cash proceeds to the Company of $1,815,000, representing an aggregate investment of $2,000,000 less commissions, are reflected on the Company’s balance sheet as of September 30, 2018 as Loan Receivable – Bridge Loan. The Company has loaned one -half of the net proceeds to Helomics. The Company and Helomics have granted to each of the investors a security interest in their assets to secure repayment of the notes. The securities purchase agreements with the investors also provide for a second investment of an aggregate of $500,000 by the investors at the consummation of the merger transaction with Helomics, at which point the aggregate principal amounts of the notes will become $2,865,909.00. As additional consideration for the investment, the Company issued an aggregate 650,000 shares of its common stock (the “Inducement Shares”) to the investors or their affiliates plus warrants to acquire up to an aggregate 1,071,776 shares of the Company’s common stock at an exercise price of $1.155 per share. Upon the closing of the second tranche investment, the warrants will be increased to cover an aggregate total of 1,336,805 shares. Each warrant is exercisable by the investor beginning on the sixth month anniversary of the effective date through the fifth -year anniversary thereof. The notes accrue interest at a rate of 8% per annum (with twelve months of interest guaranteed). The maturity date of the notes is twelve months from the Effective Date. Upon the earlier to occur of an Event of Default (as defined in the Notes) or the filing of certain registration statements, each Investor will have the right at any time thereafter to convert all or any part of its Note into shares of the Company’s common stock at a conversion price which is equal to the lesser of: (i) $1.00 and (ii) 70% of the lowest volume-weighted average price of the Company’s common stock during the 20 -trading day period ending on either the last complete trading day prior to the conversion date, or the conversion date (“Conversion Shares”). The number of Conversion Shares that may be issued is subject to an exchange cap such that the sum of (a) the total number of Conversion Shares plus (b) the number of Inducement Shares is limited to an aggregate 2,678,328 shares. Amended and Restated Merger Agreement On October 26, 2018, the Company entered into an Amended and Restated Agreement and Plan of Merger (the “Amended Merger Agreement”) with Helomics, which restates the Merger Agreement dated June 28, 2018. The Amended Merger Agreement contemplates that the Merger will be a forward triangular merger whereby Helomics will merge with and into Merger Sub. At the time of the Merger, all outstanding shares of Helomics stock not already held by the Company will be converted into the right to receive a proportionate share of 4 million shares of newly issued common stock in the Company and 3.5 million shares of newly issued Series D preferred stock in the Company (rather than a proportionate share of 7.5 million shares of newly issued common stock, as described in Note 4 ), in addition to the 1.1 million shares of the Company’s common stock already issued to Helomics for the Company’s initial 20% ownership in Helomics. The Series D preferred stock does not have voting rights for most purposes and is convertible into common stock after a period of one year. Other economic terms of the Amended Merger Agreement and the exchange offer with holders of Helomics notes and warrants are as described in Note 4.	NOTE 11 – SUBSEQUENT EVENTS In January 2018, the Company completed a firm commitment underwritten public offering of 2,900,000 Units at an offering price of $0.95 per Unit, with each Unit consisting of one share of the Company’s Common Stock and 0.3 of a Series E Warrant, with each whole Series E Warrant purchasing one share of common stock at an exercise price of $1.00 per whole share. The shares of Common Stock and Series E Warrants were immediately separable and were issued separately. Gross proceeds were approximately $2,755,000, before deducting expenses. The Company granted the underwriter a 45 -day option to purchase an additional (i) up to 290,000 additional shares of Common Stock at the public offering price per Unit less the price of the Series E Warrant included in the Units and less the underwriting discount and/or (ii) additional Series E Warrants to purchase up to 87,000 additional shares of common stock at a purchase price of $0.001 per Series E Warrant to cover over-allotments, if any. On February 21, 2018, the underwriter exercised on 215,247 shares of common stock, par value $0.01, at $0.9497 per share as described in the Underwriting Agreement. The Company received net proceeds of $188,066 after deductions of $16,354 representing the Underwriter’s discount of 8% of the purchase price of the shares. On January 11, 2018, the Company entered into a share exchange agreement with Helomics Holding Corporation. Pursuant to the share exchange agreement Helomics issued 2,500,000 shares of its Series A Preferred Stock in exchange for 1,100,000 shares of Skyline’s common stock. Under the share exchange agreement, the Company has the right to convert $500,000 in secured notes into another 5% of Helomics’ outstanding shares, which would result in the Company owning 25% of Helomics outstanding stock. The secured notes are related to the Company’s previous loans of $500,000 to Helomics. The Skyline shares are being held in escrow by Corporate Stock Transfer, Inc. as escrow agent. While the Skyline shares are held in escrow, they will be voted as directed by the Company’s board of directors and management. The Skyline shares will be released to Helomics following a determination that Helomics’ revenues in any 12 -month period have been equal or greater than $8,000,000. The Helomics Preferred Stock issued to the Company is convertible into an aggregate of 20% of the outstanding capital stock of Helomics. In addition, the terms of the Helomics Preferred Stock include certain protective provisions that require consent of the Company before Helomics may take certain actions, including issuing preferred stock senior to the Helomics Preferred Stock or entering into fundamental corporate transactions. The Company also has certain anti-dilution protections and the right to receive dividends. On February 22, 2018, the Company completed a conversion of a portion of the principal amount of Notes owed by Helomics Holding Corporation and received an assignment of intellectual property. Immediately prior to the conversion, Helomics owed the Company $667,512.50. The Company converted $500,000 of the principal amount, including accrued interest thereon, into 833,333 shares of Common Stock of Helomics. Prior to the issuance of the Conversion Shares, the outstanding capital stock of Helomics consists of 2,500,000 shares of Series A Preferred Stock owned by Precision and 10,000,000 shares of Common Stock. After the issuance of the Conversion Shares and upon full conversion of its Series A Preferred Stock, Precision now owns 3,333,333 shares of Helomics Common Stock, which represents 25% of the 13,333,333 now-outstanding shares of Helomics Common Stock. In consideration of the conversion, Helomics assigned to Precision all Helomics’ right, title and interest in the name “Precision Therapeutics”, including any related trademarks, trade names, logos and domain names, as well as all related artwork and other creative content related thereto. There will be a balance of $167,512.50 in Principal Amount remaining outstanding to the Company, which will remain subject to repayment with interest, consistent with the original terms of the Note. The Security Agreement shall remain in full force and effect with respect to the remaining balance of the Principal Amount. On February 27, 2018, the Company formed a wholly owned subsidiary, TumorGenesis Inc., to develop the next generation of patient derived (“PDx”) tumor models for precision cancer therapy and drug development. The Company formed TumorGenesis Inc., to develop a new rapid approach to growing tumors in the laboratory, which essentially “fools” the cancer cells into thinking they are still growing inside the patient. This approach will provide a much more relevant model of the patient tumor that may be used for testing of drugs for personalized therapy or for the development of new drugs. Testing of the TumorGenesis PDx tumors will take place in collaboration with Helomics, in which Precision Therapeutics has a 25% equity stake. The Company is currently in negotiations to license their technology to advance TumorGenesis’s strategic plan. The Company has already executed license agreements with 48Hour Discovery Inc. and SyntArray, Inc.

Note 1 - Summary of Significant Accounting Policies -2

9 Months Ended

12 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Notes to Financial Statements

Significant Accounting Policies [Text Block]

NOTE

— SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations and Continuance of Operations

Precision Therapeutics Inc., (the “Company”) was originally incorporated on

April 23, 2002

in Minnesota as BioDrain Medical, Inc. Effective

August 6, 2013,

the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective

December 16, 2013,

the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware corporation as the surviving corporation of the merger. On

August 31, 2015,

the Company completed a successful offering and concurrent uplisting to the NASDAQ Capital Market. On

February 1, 2018,

February 1, 2018.

Because of this change, the Company’s common stock trades under the new ticker symbol “AIPT,” effective

February 2, 2018.

Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.

As of

September 30, 2018,

the Company had

13,398,339

shares of common stock outstanding, par value

$.01

per share. The Company is a healthcare company that provides personalized medicine solution and medical devices in

two

main areas: (

) precision medicine, which aims to apply artificial intelligence to personalized medicine and drug discovery; and (

April 2009,

the Company received

510

(k) clearance from the Food & Drug Administration (the “FDA”) to authorize the Company to market and sell its STREAMWAY System products.

The Company acquired

25%

of the capital stock of Helomics Holding Corporation (“Helomics”), in transactions in the

first

quarter of

2018,

and in

April 2018

the Company entered into a letter of intent for a proposed merger transaction to acquire the remaining ownership of Helomics. In

June 2018,

the Company and Helomics entered into a definitive merger agreement – see Note

149,000

first

quarter of

2018,

is presented as part of the condensed consolidated financial statements (“financial statements”).

$61,405,345.

The Company does

not

expect to generate sufficient operating revenue to sustain its operations in the near-term. The Company had cash and cash equivalents of

$209,891

as of

September 30, 2018

and needs to raise significant additional capital to meet its operating needs, and therefore there is substantial doubt about the Company’s ability to continue as a going concern for

one

year after the date that the financial statements are issued. The financial statements do

not

include any adjustments that might result from the outcome of this uncertainty. The Company raised

$1,815,000,

net, from a bridge loan executed on

September 28, 2018.

Neither the cash nor the stock transferred until the

first

week in

October 2018

and is reported in the balance sheet as a loan receivable and note payable. Warrants accompanied the agreement with a grant date of

September 28, 2018

and are included in the outstanding stock option and warrant lists.

Since inception to

September 30, 2018,

the Company has raised approximately

$36,490,000

in equity offerings, inclusive of (

)

$2,055,000

from a private placement of Series A Convertible Preferred Stock, (

)

$13,555,003

from the public offering of Units, (

)

$1,739,770

from a registered direct offering, (

)

$3,937,500

plus an overallotment of

$358,312

from a firm commitment underwritten public offering, and (

)

$1,300,000

from a private placement of Series C Convertible Preferred Stock. Also included in the

$36,490,000

aggregate is a total of

$3,405,052

from

2018

including

$2,755,000

from a firm commitment underwritten public offering and

$650,062

from exercising warrants into common stock. In addition, historically there was

$5,685,000

in debt financing.

Interim Financial Statements

-K filed with the SEC on

April 2, 2018.

The nature of the Company’s business is such that the results of any interim period

may

not

be indicative of the results to be expected for the entire year.

Recent Accounting Developments

May 2014,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

No.

2014

09,

Revenue from Contracts with Customers (Topic

606

January 1, 2018

using the modified retrospective method applied to those contracts which were

not

completed as of

December 31, 2017.

Results for reporting periods beginning after

January

2018

are presented under Topic

606,

while prior-period amounts have

not

been retrospectively adjusted and continue to be reported in accordance with Topic

605,

Revenue Recognition

. Based upon the Company’s contracts which were

not

completed as of

December 31, 2017,

the Company was

not

required to make an adjustment to the opening balance of retained earnings as of

January 1, 2018,

and there was

material impact. See Note

for further discussion.

January 2016,

the FASB issued ASU

No.

2016

01,

Financial Instruments-Overall (Subtopic

825

): Recognition and Measurement of Financial Assets and Financial Liabilities

(“ASU

2016

01”

not

result in consolidation and are

not

January 1, 2018.

As of

June 30, 2018,

there is

material impact on the Company’s financial statements and disclosures.

February 2016,

the FASB issued ASU

No.

2016

02,

“

Leases (Topic

842

)

” (“ASU

2016

02”

December 15, 2018.

Early adoption is permitted. The Company believes that upon adoption, ASU

2016

will

not

Valuation of Intangible Assets

The Company reviews identifiable intangible assets for impairment annually, or whenever events or changes in circumstances indicate the carrying amount

may

not

be recoverable. The Company’s intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount

may

not

be recoverable include, but are

not

Accounting Policies and Estimates

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of

three

months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximates fair value.

Certificates of Deposit

Short-term interest-bearing investments are those with maturities of less than

one

year but greater than

three

months when purchased. Certificates with maturity dates beyond

one

year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value.

Fair Value Measurements

Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC)

820,

820

establishes a

three

-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level

– Observable inputs such as quoted prices in active markets;

Level

– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level

– Unobservable inputs where there is little or

market data, which requires the reporting entity to develop its own assumptions.

The fair value of the Company’s investment securities was determined based on Level

inputs.

Inventories

Inventories are stated at the lower of cost and net realizable value, with cost determined on a

first

-in,

first

-out basis. Inventory balances are as follows:

	September 30, 2018		December 31, 2017

Finished goods	$	61,587	$	62,932
Raw materials		157,610		141,028
Work-In-Process		58,958		61,085
Total	$	278,155	$	265,045

Property and Equipment

	Years
Computers and office equipment	3	-	7
Leasehold improvements		3
Manufacturing tooling	3	-	7
Demo equipment		3

The Company’s fixed assets consist of the following:

	September 30, 2018		December 31, 2017
Computers and office equipment	$	204,904	$	183,528
Leasehold improvements		140,114		25,635
Manufacturing tooling		108,955		108,955
Demo equipment		77,496		43,368
Total		531,469		361,486
Less: Accumulated depreciation		333,211		273,770
Total Fixed Assets, Net	$	198,258	$	87,716

Depreciation expense was

$26,120

and

$59,442

in the

three

and

nine

months ended

September 30, 2018

and was

$14,561

and

$44,764

for the

three

and

nine

months ended

September 30, 2017.

Intangible Assets

Intangible assets consist of trademarks, patent costs and license fees. Amortization expense was

$38,387

and

$46,127

in the

three

and

nine

months ended

September 30, 2018

and was

$3,276

and

$9,067

in the

three

and

nine

months ended

September 30, 2017.

The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.

Income Taxes

The Company accounts for income taxes in accordance with ASC

740

Income Taxes

(“ASC

740”

). Under ASC

740,

There is

income tax provision in the accompanying statements of operations due to the cumulative operating losses that indicate a

100%

valuation allowance for the deferred tax assets and state income taxes is appropriate.

not

that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified

income tax uncertainties.

Tax years subsequent to

2014

remain open to examination by federal and state tax authorities.

Offering Costs

Patents and Intellectual Property

January 25, 2014,

the Company filed a non-provisional Patent Cooperation Treaty (“PCT”) Application

No.

PCT/US2014/013081

claiming priority from the U.S. Provisional Patent Application, number

61756763

which was filed

one

year earlier on

January 25, 2013.

The “PCT” allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the

148

not

interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid.

The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models:

US7469727,

US8123731

and U.S. Publication

No.

US20090216205

(collectively, the “Patents”). These Patents will begin to expire on

August 8, 2023.

July 2015,

The United States Patent Office has assigned application

#14/763,459

to the Company’s previously filed PCT application.

As of

November 22, 2017,

the Company was informed that the European Patent Office has allowed all claims for application

#14743665.3

1651

and has sent a Notice of Intent to Grant.

As of

July 11, 2018,

the Company was informed that the European Patent

#EP2948200

was granted and published validating in the following countries: Belgium, Germany, Spain, France, United Kingdom, Ireland, Italy, Netherlands, Norway, Poland and Sweden.

Credit Risk

one

financial institution. The Company has

credit risk concentration because there are

funds in excess of insurance limits in a single bank.

Segments

The Company operates in

two

segments for the sale of its medical device and consumable products. Substantially all the Company’s assets, revenues, and expenses for the

three

and

nine

months ended

September 30, 2018

and

2017

were located at or derived from operations in the United States. There was

$4,195

and

$288

in revenues from sales outside the United States during the

three

-month period of

September 2018

and

2017,

respectively; and

$10,061

and

$25,188

in revenues from sales outside of the United States during the

first

nine

months of

2018

and

2017,

respectively.

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device industry, including, but

not

NOTE

— SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations and Continuance of Operations

The Company was originally incorporated on

April 23, 2002

in Minnesota as BioDrain Medical, Inc. Effective

August 6, 2013,

the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective

December 16, 2013,

the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. On

August 31, 2015,

the Company completed a successful offering and concurrent uplisting to The NASDAQ Capital Market. On

February 1, 2018,

February 1, 2018.

Because of this change, our common stock trades under the new ticker symbol “AIPT,” effective

February 2, 2018.

Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.

As of

December 31, 2017,

the registrant had

6,943,283

shares of common stock, par value

$.01

per share, outstanding, adjusted for a

-for-

reverse stock split effective

October 27, 2016.

April 2009,

the Company received

510

(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY System products.

August 31, 2015

not

include any adjustments that might result from the outcome of this uncertainty.

Since inception to

December 31, 2017,

the Company raised approximately

$29,065,934

in equity, inclusive of

$2,055,000

from a private placement of Series A Convertible Preferred Stock,

$13,555,003

from the public offering of Units,

$1,739,770

from a registered direct offering,

$3,937,500

plus an overallotment of

$358,312

from a firm commitment underwritten public offering,

$1,300,000

from a private placement of Series C Convertible Preferred Stock, and

$5,685,000

in debt financing. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources.”

Recent Accounting Developments

May 2014,

the Financial Accounting Standards Board (“FASB”) issued ASU

2014

09,

Revenue from Contracts with Customers

and created a new topic in the FASB Accounting Standards Codification ("ASC"), Topic

606,

and has since amended the standard with ASU

2015

14,

“Revenue from Contracts with Customers: Deferral of the Effective Date,”

ASU

2016

08,

“Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net),”

ASU

2016

10,

“Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing,”

ASU

2016

12,

“Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients.”

ASU

2017

13.

December 15, 2017,

including interim periods within that reporting period. Early application is

not

permitted. The FASB allows

two

adoption methods under ASC

606.

We adopted the standard on

January 1, 2018

using the “modified retrospective method.” Under that method, we will apply the rules to all contracts existing as of

January 1, 2018,

not

have a material impact on our financial statements.

August 2014,

the FASB issued ASU

2014

15,

Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern

December 15, 2016,

with early adoption permitted. We implemented in the

first

quarter of

2017.

July 2015,

the FASB issued ASU

No.

2015

, Inventory (Topic

330

): Simplifying the Measurement of Inventory

December

15,

2016,

including interim periods within that reporting period. We implemented in the

first

quarter of

2017.

November 2015,

the FASB issued ASU

2015

17,

“Income Taxes (Topic

740

)”

December 15, 2016

and for interim periods within those fiscal years, with early adoption permitted. We implemented in the

first

quarter of

2017.

January 2016,

the FASB issued ASU

No.

2016

01,

Financial Instruments-Overall (Subtopic

825

): Recognition and Measurement of Financial Assets and Financial Liabilities

(“ASU

2016

01”

not

result in consolidation and are

not

December 15, 2017,

including interim periods within those fiscal years. The Company does

not

believe that the adoption of this guidance will have a material impact on the Company’s financial statements and disclosures.

February 2016,

the FASB issued ASU

No.

2016

02,

“Leases

(Topic

842”

(“ASU

2016

02”

December 15, 2018.

Early adoption is permitted. We are currently evaluating the timing of our adoption and the impact that the updated standard will have on our financial statements.

March 2016,

the FASB issued ASU

No.

2016

09,

“Compensation (Topic

718

): Improvements to Employee Shares-Based Payment Accounting”

(

“ASU2016

09”

). ASU

2016

December 15, 2016.

Early adoption is permitted. We implemented in the

first

quarter of

2017.

August 2016,

the FASB issued ASU

No.

2016

15,

Statement of Cash Flows (Topic

230

): Classification of Certain Cash Receipts and Cash Payments,

December 15, 2017,

not

expect the adoption of ASU

2016

to have a material impact on its financial statements.

December 22, 2017,

the Tax Cuts and Jobs Act of

2017

34%

21%.

As a result of the enacted law, the Company is required to revalue its deferred tax assets and liabilities at the new enacted rate.

We reviewed all other significant newly issued accounting pronouncements and determined they are either

not

applicable to our business or that

material effect is expected on our financial position and results of our operations.

Valuation of Intangible Assets

We review identifiable intangible assets for impairment in accordance with ASC

350

— Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount

may

not

be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount

may

not

be recoverable include, but are

not

Accounting Policies and Estimate

Presentation of Taxes Collected from Customers

Shipping and Handling

Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations.

Advertising

Advertising costs are expensed as incurred. Advertising expenses were

$37,060

2017,

and

$71,212

2016.

Research and Development

Research and development costs are charged to operations as incurred. Research and development costs were approximately

$289,000

and

$406,000

for

2017

and

2016,

respectively.

Revenue Recognition

The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Revenue Recognition and ASC

606

- Revenue Recognition.

We have adopted the provisions of Accounting Standards Update, or “ASU”

2014

09,

Revenue from Contracts with Customers (Accounting Standards Codification, or “ASC”

606

), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. Companies are permitted to adopt ASC

606

using a full retrospective or modified retrospective method. We adopted the standard on

January 1, 2018

using a modified retrospective method.

While we continue to assess all potential impacts of the standard, it is currently anticipated that the standard will

not

have a material impact on our financial statements.

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of

three

months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximate fair value.

Certificates of Deposit

Short-term interest-bearing investments are those with maturities of less than

one

year but greater than

three

months when purchased. Certificates with maturity dates beyond

one

year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value.

Investment Securities

Fair Value Measurements

Under generally accepted accounting principles as outlined in the Financial Accounting Standards Board’s

Accounting Standards Certification

(ASC)

820,

820

establishes a

three

-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level

– Observable inputs such as quoted prices in active markets;

Level

– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level

– Unobservable inputs where there is little or

market data, which requires the reporting entity to develop its own assumptions.

The fair value of the Company’s investment securities were determined based on Level

inputs.

Receivables

not

been material to the financial statements.

Inventories

Inventories are stated at the lower of cost or market, with cost determined on a

first

-in,

first

-out basis. Inventory balances are as follows:

	December 31, 2017		December 31, 2016

Finished goods	$	62,932	$	38,201
Raw materials		141,028		165,812
Work-In-Process		61,085		68,195
Total	$	265,045	$	272,208

Property and Equipment

	Years
Computers and office equipment	3	-	7
Leasehold improvements		5
Manufacturing Tooling	3	-	7
Demo Equipment		3

The Company’s investment in Fixed Assets consists of the following:

	December 31, 2017		December 31, 2016
Computers and office equipment	$	183,528	$	164,318
Leasehold Improvements		25,635		25,635
Manufacturing Tooling		108,955		103,204
Demo Equipment		43,368		23,236
Total		361,486		316,393
Less: Accumulated Depreciation		273,770		214,897
Total Fixed Assets, Net	$	87,716	$	101,496

Depreciation expense was

$58,872

2017

and

$73,249

2016.

Intangible Assets

Intangible assets consist of trademarks and patent costs. Amortization expense was

$12,689

2017

and

$9,107

2016.

The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.

Income Taxes

The Company accounts for income taxes in accordance with ASC

740

Income Taxes (“ASC

740”

)

. Under ASC

740,

not

that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified

income tax uncertainties.

Tax years subsequent to

2014

remain open to examination by federal and state tax authorities.

Patents and Intellectual Property

January

25th,

2014,

the Company filed a non-provisional PCT Application

No.

PCT/US2014/013081

claiming priority from the U.S. Provisional Patent Application, number

61756763

which was filed

one

year earlier on

January

25th,

2013.

The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the

148

not

interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid.

The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models:

US7469727,

US8123731

and U.S. Publication

No.

US20090216205

(collectively, the “Patents”). These Patents will begin to expire on

August 8, 2023.

July 2015,

The United States Patent Office has assigned application

#14/763,459

to our previously filed PCT application.

As of

November 22, 2017,

the Company was informed that the European Patent Office has allowed all our claims for application

#14743665.3

1651,

and has sent a Notice of Intent to Grant. Skyline is now in the process of identifying the key European countries that we will validate the patent in.

Credit Risk

one

financial institution. The Company had a credit risk concentration as a result of depositing

$563,000

of funds in excess of insurance limits in a single bank.

Product Warranty Costs

2017

and in

2016,

the Company incurred approximately

$6,209

and

$34,665

in warranty costs.

Segments

The Company operates in

two

segments for the sale of its medical device and consumable products. Substantially all of the Company’s assets, revenues, and expenses for

2017

and

2016

were located at or derived from operations in the United States. There was

$26,662

in revenues from sales outside of the United States during

2017.

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device industry, including, but

not

Note 2 - Development Stage Operations	12 Months Ended
Note 2 - Development Stage Operations	Dec. 31, 2017
Notes to Financial Statements
Development Stage Enterprise Disclosures [Text Block]	NOTE 2 – DEVELOPMENT STAGE OPERATIONS The Company was formed April 23, 2002. Since inception through December 31, 2017, 6,943,283 shares of common stock have been issued between par value and $3,131.25. Operations since incorporation have primarily been devoted to raising capital, obtaining financing, development of the Company’s product, administrative services, customer acceptance and sales and marketing strategies.

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants

9 Months Ended

12 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

NOTE

– STOCKHOLDERS’ EQUITY, STOCK OPTIONS AND WARRANTS

2018

Firm Commitment Public Offering

January 2018,

the Company completed a firm commitment underwritten public offering of

2,900,000

Units at an offering price of

$0.95

per Unit, with each Unit consisting of

one

share of the Company’s common stock and

0.3

of a Series E Warrant, with each whole Series E Warrant purchasing

one

share of common stock at an exercise price of

$1.00

per whole share. The shares of Common Stock and Series E Warrants were immediately separable and were issued separately. Gross proceeds were approximately

$2,755,000,

before deducting expenses. The Company granted the underwriter a

-day option to purchase an additional (i) up to

290,000

87,000

additional shares of common stock at a purchase price of

$0.001

per Series E Warrant to cover over-allotments, if any. On

February 21, 2018,

the underwriter exercised on

215,247

shares of common stock, par value

$0.01,

$0.9497

per share as described in the Underwriting Agreement. The Company received net proceeds of

$188,066

after deductions of

$16,354

representing the underwriter’s discount of

of the purchase price of the shares.

Share Exchange Agreement With Helomics

January 11, 2018,

the Company entered into a share exchange agreement with Helomics Holding Corporation. Pursuant to the share exchange agreement, Helomics issued

2,500,000

shares of its Series A Preferred Stock in exchange for

1,100,000

shares of common stock. Under the share exchange agreement, in

March 2018

the Company converted

$500,000

in secured notes into another

of Helomics’ outstanding shares, which resulted in the Company owning

25%

of Helomics outstanding stock. The secured notes are related to the Company’s previous loans of

$500,000

to Helomics. The

1,100,000

-month period have been equal or greater than

$8,000,000.

The Helomics Preferred Stock issued to the Company is convertible into an aggregate of

20%

of the outstanding capital stock of Helomics. In addition, the terms of the Helomics Preferred Stock include certain protective provisions that require consent of the Company before Helomics

may

Merger Agreement with Helomics

June 28, 2018,

the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Helomics and certain other entities. On

October 26, 2018,

the Merger Agreement was amended and restated – see Note

not

already held by the Company were to be converted into the right to receive a proportionate share of

7.5

million shares of newly issued common stock in the Company (“Merger Shares”), in addition to the

1.1

million shares of the Company’s common stock already issued to Helomics for the Company’s initial

20%

ownership in Helomics. Additionally,

860,000

shares of the merger consideration were to be held in escrow for

months to satisfy indemnification claims. Helomics currently has outstanding

$7.6

million in promissory notes and warrants to purchase

18.7

million shares at an exercise price of

$1.00

5.0

million additional shares of Helomics common stock at an exercise price of

$1.00

75%

of the

$7.6

million in outstanding Helomics promissory notes agreeing to such an exchange (and the parties contemplate that each Helomics warrant will be exchanged for a Company warrant at a ratio of

0.6

Precision warrants for each Helomics warrant, with an exercise price of

$1.00

per share. If all holders of such notes agreed to the exchange with respect to the full balance of the notes, such holders would receive an aggregate estimated

23.7

million shares of the Company’s common stock and warrants to purchase an additional

14.2

million shares of the Company’s common stock at

$1.00

per share. In addition, Helomics currently has

995,000

warrants held by other parties at an exercise price of

$0.01

per share of Helomics common stock. It is contemplated that these warrants will be exchanged at the time of the closing of the Merger for warrants to purchase

597,000

shares of Precision common stock at

$0.01

per share.

July 10

and

11,

2018,

the Company issued

250,000

shares of common stock, par value

$0.01,

$1.18

per share for consulting fees pursuant to the TumorGenesis license fees contract, and

750,000

shares of common stock, par value

$0.01,

$1.17

per share, in escrow, for TumorGenesis license fees pursuant to the TumorGenesis license fees contract.

Increases in Authorized Shares

At a special meeting of the stockholders on

January 29, 2017,

the stockholders approved a proposal to increase the number of authorized shares of common stock from

8,000,000

shares to

24,000,000

shares of common stock under the Company’s certificate of incorporation.

At the annual meeting on

December 28, 2017,

the stockholders approved a proposal to increase the number of authorized shares of common stock from

24,000,000

50,000,000

shares of common stock,

$0.01

par value. The amendment to the certificate of incorporation to affect this increase was filed on

January 2, 2018.

Equity Incentive Plan

three

years. Options under this plan have terms ranging from

three

ten

years.

Accounting for share-based payment

Since the Company's common stock has

significant public trading history, and the Company has experienced

years of

small-cap medical companies traded on major exchanges and

Since the Company has limited trading history in its stock and

first

Valuation and accounting for options and warrants

January 15, 2018,

the Company issued inducement stock options in accordance with NASDAQ listing rule for

50,000

shares of common stock, par value

$0.01

$0.97

per share to the Company’s newly hired International Vice President of Sales. The options will vest in

four

equal increments: on the first, second,

third

and

fourth

quarters of the hiring date anniversary.

March 12, 2018,

the Company issued inducement stock options in accordance with NASDAQ rule for

111,112

shares of common stock, par value

$0.01

$1.35

per share to the Company’s newly hired Vice President of Sales and Marketing. The options will vest in

four

equal increments: on the first, second,

third

and

fourth

quarters of the hiring date anniversary.

For grants of stock option and warrants in

2018

the Company used

2.33%

3.05%

risk free interest rate,

dividend rate,

59%

66%

volatility and estimated terms of

years. Value computed using these assumptions ranged from

$0.4816

$1.0044

per share.

The following summarizes transactions for stock options and warrants for the periods indicated:

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2016		165,643		$	11.22		871,101		$	52.22

Issued		2,612,070			1.45		1,082,946			1.49
Expired		(12,730	)		10.39		(2,790	)		281.46
Exercised		-			-		-			-

Outstanding at December 31, 2017		2,764,983		$	2.00		1,951,257		$	23.74

Issued		836,950			1.12		2,028,776			1.08
Expired		(153,048	)		2.00		(10,706	)		199.55
Exercised		-			-		(650,062	)		1.00

Outstanding at September 30, 2018		3,448,885		$	1.78		3,319,265		$	4.55

September 30, 2018,

2,522,848

stock options are fully vested and currently exercisable with a weighted average exercise price of

$1.93

and a weighted average remaining term of

9.01

years. There are

2,247,489

warrants that are fully vested and exercisable. Stock-based compensation recognized for the

nine

months ended

September 2018

and

September 2017

was

$800,322

and $(

7,908

), respectively. The Company has

$930,349

of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next

months.

The following summarizes the status of options and warrants outstanding at

September 30, 2018:

Range of Prices		Shares		Weighted Remaining Life
Options
$	0.91		10,000		9.55
$	0.965		3,000		9.63
$	0.97		191,753		9.27
$	1.01		149,110		9.38
$	1.06		23,585		10.00
$	1.10		86,958		9.71
$	1.13		195,931		9.80
$	1.15		21,740		9.84
$	1.16		66,451		9.84
$	1.18		30,000		9.86
$	1.20		41,668		9.84
$	1.21		30,000		9.86
$	1.35		111,112		9.45
$	1.454		17,200		9.01
$	1.47		2,347,308		8.73
$	2.10		14,286		8.50
$	2.25		293		7.90
$	2.42		20,640		7.84
$	2.80		57,145		8.26
$	3.75		3,998		5.24
$	4.125		3,636		8.01
$	4.1975		7,147		7.97
$	4.25		3,529		7.50
$	5.125		3,902		7.94
$	65.75		190		7.06
$	73.50		1,157		7.26
$	77.50		2,323		6.75
$	80.25		187		7.01
$	86.25		232		6.50
$	131.25		81		3.94
$	148.125		928		4.47
$	150.00		1,760		3.88

$	162.50	123	6.26
$	206.25	121	6.01
$	248.4375	121	4.79
$	262.50	130	4.79
$	281.25	529	4.30
$	318.75	3	4.60
$	346.875	72	5.50
$	431.25	306	5.44
$	506.25	188	5.25
$	596.25	42	5.00

		3,448,885

Warrants
$	1.00	1,063,935	4.60
$	1.07	697,946	4.10
$	1.155	1,071,776	5.00
$	2.25	385,000	3.32
$	123.75	94,084	1.92
$	243.75	2,529	0.84
$	309.375	2,850	0.86
$	309.50	222	1.10
$	506.25	59	0.38
$	609.375	862	0.34
		3,319,265

At the annual meeting on

December 28, 2017,

the stockholders approved an amendment to the Company’s

2012

Plan to (i) increase the reserve of shares of common stock authorized for issuance thereunder to

5,000,000,

(ii) increase certain threshold limits for grants, and (iii) to re-approve the performance goals thereunder. As described in the Company’s definitive proxy statement filed with the SEC on

December 4, 2017,

amendments to the

2012

Plan were considered at the

2016

annual meeting on

July 28, 2016

but were

not

approved by the required vote. For options to purchase approximately

2.5

million shares granted after the

2016

annual meeting, the grantees agreed

not

to exercise the options prior to further stockholder approval of an increase in the reserve under the

2012

Plan. As a result of the stockholder approval of the amendments at the

2017

annual meeting, these restrictions on exercise were removed on

December 28, 2017.

Due to the removal of this restriction on exercise, the Company recognized a non-cash charge for compensation expense of approximately

$1.9

million in the

fourth

quarter of

2017.

Stock Options and Warrants Granted by the Company

The following table is the listing of stock options and warrants as of

September 30, 2018

by year of grant:

Stock Options:
Year	Shares		Price
2011		173			$281.25
2012		1,841		131.25	–	150.00
2013		1,553		148.13	–	596.25
2014		836		162.50	–	431.25
2015		4,088		65.75	–	86.25
2016		100,292		2.25	–	5.13
2017		2,503,152		1.01	-	2.10
2018		836,950		0.91	-	1.35
Total		3,448,885		$0.91	–	$596.25

Warrants:
Year	Shares		Price
2014		6,455		$243.75	–	$609.38
2015		94,151		0.00	–	243.75
2016		252,333			1.00
2017		1,082,946		1.07	-	2.25
2018		1,883,380		1.00	-	1.155
Total		3,319,265		$0.00	–	$609.38

NOTE

– STOCKHOLDERS’ EQUITY (DEFICIT), STOCK OPTIONS AND WARRANTS

2015

Public Offering of Units

August 31, 2015 (

the “Issuance Date”), the Company completed a public offering (the “Offering”) of

1,666,667

Units (the “Units”) as described below. The public offering price in the Offering was

$9.00

per Unit, and the purchase price for the underwriter of the Offering (the “Underwriter”) was

$8.28

per Unit, resulting in an underwriting discount and commission of

$0.72

(or

8.00%

) per Unit and total net proceeds to the Company before expenses of

$13.8

million. The Company had granted the Underwriter an option for a period of

days to purchase up to an additional

250,000

Units solely to cover over-allotments. The Underwriter chose

not

to purchase any additional Units under the over-allotment option. The Company paid to the Underwriter a non-accountable expense allowance equal to

of the gross proceeds of the Offering and agreed to reimburse expenses incurred by the Underwriter up to

$70,000.

August 31, 2015,

as a result of the communication of the Offering and the issuance of the

228,343

Exchange Units in the Unit Exchange described below, the Company issued a total of

1,895,010

Units, comprised of a total of aggregate of

75,801

shares of Common Stock,

1,895,010

shares of Series B Preferred Stock and

7,580,040

Series A Warrants.

Each Unit consisted of

one

share of common stock, par value

$0.01

per share (the “Common Stock”),

one

share of Series B Convertible Preferred Stock (“Series B Preferred Stock”) and

four

Series A Warrants. The shares of Common Stock, the shares of Series B Preferred Stock and the Series A Warrants that comprise the Units automatically separated on

February

29,

2016.

Series A Warrants

August 31, 2020.

Each Series A Warrant is exercisable into

one

share of Common Stock at an initial cash exercise price of

$123.75

Holders

may

Total Shares = (A

B) / C

Where:

	☐	Total Shares is the number of shares of Common Stock to be issued upon a Cashless Exercise.

	☐	A is the total number of shares with respect to which the Series A Warrant is then being exercised.

☐

B is the Black Scholes Value (as defined below).

☐

C is the closing bid price of the Common Stock as of

two

trading days prior to the time of such exercise, provided that in

event

may

“C” be less than

$0.43

per share (subject to appropriate adjustment in the event of stock dividends, stock splits or similar events affecting the Common Stock).

The Black Scholes Value (as defined above) as of

September 30, 2016

was

$4.319,

and the closing bid price of Common Stock as of

September 30, 2016,

was

$4.125.

Therefore, an exercise on that date would have resulted in the issuance of

.40

shares of Common Stock for each Series A Warrant. Approximately

6,141,115

Series A Warrants have been exercised in cashless exercises as of

September 30, 2016,

resulting in the issuance of

2,318,663

shares of Common Stock. If all of the remaining

35,084

Series A Warrants that were issued as part of the Units sold in the Offering and part of the Units issued on

August 31, 2015

were exercised pursuant to a cashless exercise and the closing bid price of our common stock as of the

two

trading days prior to the time of such exercise was

$0.43

per share or less and the Black Scholes Value were

$4.319

(the Black Scholes Value as of

September 30, 2016),

then a total of approximately

564

shares of our common stock would be issued to the holders of such Series A Warrants.

The Series A Warrants will

not

be exercisable or exchangeable by the holder of such warrants to the extent (and only to the extent) that the holder or any of its affiliates would beneficially own in excess of

4.99%

of the common stock of the Company, determined in accordance with Section

(d) of the Securities Exchange Act of

1934,

as amended, and the regulations promulgated thereunder.

In addition to (but

not

three

year anniversary of the Issuance Date, (

Unit Purchase Option

The Company, in connection with the Offering, entered into a Unit Purchase Option Agreement, dated as of

August 31, 2015 (

the “Unit Purchase Option”), pursuant to which the Company granted the Underwriter the right to purchase from the Company up to a number of Units equal to

of the Units sold in the Offering (or up to

83,333

Units) at an exercise price equal to

125%

of the public offering price of the Units in the Offering, or

$11.25

per Unit. The Unit Purchase Option was terminated in

May 2016

in exchange for

135,995

shares of common stock.

Series B Preferred Stock

Each share of Series B Preferred Stock is convertible into

one

share of Common Stock (subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events) on the

six

not

convertible by the holder of such preferred stock to the extent (and only to the extent that the holder or any of its affiliates would beneficially own in excess of

4.99%

of the common stock of the Company. The Series B Preferred Stock has

sinking fund has been established for the retirement or redemption of the Series B Preferred Stock.

Unit Exchange

February 4, 2014,

the Company raised

$2,055,000

in gross proceeds from a private placement of

20,550

shares of Series A Convertible Preferred Stock, par value

$0.01,

with a stated value of

$100

February 4, 2014.

August 31, 2015,

the Company issued a total of

228,343

3,391

shares of the Company’s common stock. The Exchange Units were exempt from registration under Section

(a)(

) of the Securities Act. On

August 31, 2015,

the Company filed a termination certificate with the Delaware Secretary of State. Following that date there were

Redemption of Convertible Notes

In connection with the closing of the Offering,

$933,074

aggregate principal amount of Convertible Notes plus interest and a

40%

redeemable premium were redeemed for total payments of

$1,548,792.

See Note

Of this amount, approximately

$167,031

was paid to its affiliates in redemption of their Convertible Notes.

Registered Exchange Offer for Warrants

March 25, 2016,

the Company commenced a registered exchange offer (the “Exchange Offer”) to exchange Series B Warrants (the “Series B Warrants”) to purchase shares of our common stock, par value

$0.01

per share (the “Warrant Shares”), for up to an aggregate of

3,157,186

outstanding Series A Warrants (the “Series A Warrants”). On

March 31, 2016,

each Series A Warrant could be exercised on a cashless basis for

10.05

shares of common stock. Each Series B Warrant

may

be exercised on a cashless basis for

one

share of common stock. For each outstanding Series A Warrant tendered by holders, we offered to issue

10.2

Series B Warrants, which are subject to cashless exercise at a fixed rate of

one

share of common stock per Series B Warrant (subject to further adjustment for stock splits, etc.). The Exchange Offer expired at midnight, Eastern time, on

April 21, 2016.

1,770,556

Series A Warrants were tendered by holders. The Company delivered an aggregate of

18,059,671

Series B Warrants pursuant to the terms of the Exchange Offer. In addition, between

March 31, 2016

and

July 6, 2016

1,251,510

Series A Warrants were exercised in cashless exercises, resulting in the issuance of

20,122

shares of common stock.

2016

Registered Direct Offering

November 29, 2016,

the Company closed a registered direct offering for gross proceeds of

$1,983,337.

The offering consisted of

756,999

shares of common stock priced at

$2.62

per share and

five

-year warrants for

756,999

shares of common stock that become exercisable in

six

months, with a strike price of

$4.46

per share. The net proceeds from the sale of the securities, after deducting placement agent fees and related offering expenses, was

$1,739,770.

2017

Firm Commitment Public Offering

January 19, 2017

the Company closed a firm commitment public offering for

1,750,000

Units at

$2.25

per Unit. The Units comprised

one

share of Common Stock and

0.2

Series D Warrants with each whole Series D Warrant purchasing

one

share of our Common Stock at an exercise price of

$2.25

per share. We received gross proceeds of

$3,937,500.

Subsequently the underwriter exercised over-allotment for

175,000

shares of common stock and for Series D warrants to purchase

35,000

shares of common stock at

$0.01

per warrant. The Company received net proceeds from the over-allotment of

$358,312.

2017

Private Placement

November 30, 2017,

1,213,819

shares of Series C stock at a purchase price of

$1.071

per Series C Share, together with a warrant to purchase up to

606,910

shares of common stock. The warrant has an exercise price of

$1.26

per share, subject to adjustment, has a

five

and

one

-half year term and is exercisable commencing

six

months following the date of issuance. Total gross proceeds to Skyline were

$1,300,000

1.167

to a maximum of

1,250,269

shares of common stock. The remaining

142,466

shares of Preferred Series C stock were cancelled with a redemption payment to the holder for

$189,285.

Equity Incentive Plan

three

years. Options under this plan have terms ranging from

three

ten

years.

Accounting for share-based payment

The Company has adopted ASC

718

Compensation-Stock Compensation

("ASC

718"

). Under ASC

718

stock-based employee compensation cost is recognized using the fair value based method for all new awards granted after

January 1, 2006

and unvested awards outstanding at

January 1, 2006.

Compensation costs for unvested stock options and non-vested awards that were outstanding at

January 1, 2006,

not

retroactively restated.

ASC

718

Since the Company's common stock has

significant public trading history, and the Company has experienced

years of

small-cap medical companies traded on major exchanges and

Since the Company has limited trading history in its stock and

first

Valuation and accounting for options and warrants

July 1, 2016,

the Company issued inducement stock options in accordance with NASDAQ listing rule for

40,000

shares of common stock, par value

$0.01

$3.75

per share to the Company’s newly hired Vice President of Sales. The options will vest in

six

equal increments: on the first, second, third, fourth,

fifth

and

sixth

quarters of the hiring date anniversary.

October 4, 2016,

the Company issued

400,000

shares of common stock, par value

$0.01,

to be held in escrow in connection with the Company’s Partnership and Exclusive Reseller Agreement with GLG Pharma, LLC.

For grants of stock options and warrants in

2016

the Company used a

1.46%

2.45%

risk free interest rate,

dividend rate,

59%

66%

volatility and estimated terms of

years. Value computed using these assumptions ranged from

$1.6329

$3.7195

per share.

April 19, 2017,

the Company terminated the Company’s Partnership and Exclusive Reseller Agreement with GLG Pharma, LLC and thereby received

400,000

shares of common stock, par value

$0.01,

from escrow.

For grants of stock options and warrants in

2017

the Company used a

1.92%

2.40%

risk free interest rate,

dividend rate,

59%

66%

volatility and estimated terms of

years. Value computed using these assumptions ranged from

$0.6541

$1.5489

per share.

The following summarizes transactions for stock options and warrants for the periods indicated:

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2015		31,350		$	133.23		323,099		$	128.40

Issued		157,982			3.14		1,487,881			0.71
Expired		(22,377	)		122.13		-			-
Exercised		(1,312	)		65.75		(939,879	)		-

Outstanding at December 31, 2016		165,643		$	11.22		871,101		$	52.22

Issued		2,612,070			1.45		1,082,946			1.49
Expired		(12,730	)		10.39		(2,790	)		281.46
Exercised		-			-		-			-

Outstanding at December 31, 2017		2,764,983		$	2.00		1,951,257		$	23.74

December 31, 2017,

1,728,264

stock options are fully vested and currently exercisable with a weighted average exercise price of

$2.29

and a weighted average remaining term of

9.45

years. There are

1,253,311

warrants that are fully vested and exercisable. Stock-based compensation recognized in

2017

and

2016

was

$1,892,159

and

$165,271,

respectively. The Company has

$1,139,172

of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next

months.

The following summarizes the status of options and warrants outstanding at

December 31, 2017:

Range of Exercise Prices			Shares		Weighted Average Remaining Life
Options:
	$	1.01		124,358	10.00
	$	1.454		17,200	9.75
	$	1.47		2,456,226	9.48
	$	2.10		14,286	9.25
	$	2.25		293	8.65
	$	2.42		24,768	8.38
	$	2.80		57,145	9.01
	$	3.75		44,000	8.50
	$	4.125		3,636	8.75
	$	4.1975		7,147	8.72
	$	4.25		3,529	8.25
	$	5.125		3,902	8.69
	$	65.75		190	7.40
	$	73.50		1,157	8.01
	$	77.50		2,323	7.50
	$	80.25		187	7.75
	$	86.25		232	7.25
	$	131.25		81	4.69
	$	148.125		928	5.21
	$	150.00		1,760	4.63
	$	162.50		123	7.01
	$	206.25		121	6.75
	$	248.4375		121	5.54
	$	262.50		130	5.54
	$	281.25		529	5.04
	$	318.75		3	5.35
	$	346.875		72	6.25
	$	431.25		306	6.19
	$	506.25		188	6.00
	$	596.25		42	5.75
Total				2,764,983

	Warrants
		$	1.07	697,946	4.85
		$	2.25	385,000	4.06
		$	4.46	756,999	3.92
		$	93.75	2,255	0.19
		$	123.75	94,084	2.67
		$	150.00	4,114	0.20
		$	225.00	107	0.07
		$	243.75	2,529	1.59
		$	281.25	3,107	0.14
		$	309.375	2,850	1.61
		$	309.50	222	1.85
		$	337.50	178	0.46
		$	371.25	944	0.41
		$	506.25	59	1.12
		$	609.375	862	1.09
Total				1,951,257

Stock options and warrants expire on various dates from

January 2018

December 2027.

At a special meeting of stockholders held on

September 15, 2016,

the Company’s stockholders (i) approved an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of common stock from

100,000,000

200,000,000

September 16, 2016,

the Company filed a Certificate of Amendment to its Certificate of Incorporation to affect the increase in the authorized capital stock. On

October 26, 2016,

the Company filed a Certificate of Amendment to its Certificate of Incorporation to affect a reverse stock split of the outstanding shares of its common stock at a ratio of

one

-for-

twenty-five

(

1:25

), and a proportionate decrease of the authorized common stock from

200,000,000

shares to

8,000,000

shares. The reverse stock split took effect at

5:00

p.m. New York time on

October 27, 2016,

and the Company’s common stock commenced trading on a post-split basis on

October 28, 2016.

The Company’s board of directors has determined that the Company

may

January 29, 2017.

The vote, a proposal to increase the number of authorized shares of common stock from

8,000,000

shares to

24,000,000

shares of common stock under the Company’s certificate of incorporation passed. On

December 28, 2017,

the Company held its annual meeting. Pursuant to the meeting on

January 2, 2018,

the Certificate of Incorporation of the Company was amended to increase the number of authorized shares of common stock from

24,000,000

50,000,000

shares of common stock,

$0.01

par value. Additionally, the stockholders approved an amendment to the Company’s

2012

Plan to (i) increase the reserve of shares of Common Stock authorized for issuance thereunder to

5,000,000,

December 4, 2017,

amendments to the

2012

Plan were considered at the

2016

annual meeting but were

not

approved by the required vote. For options to purchase approximately

2.5

million shares granted after the

2016

annual meeting, the grantees agreed

not

to exercise the options prior to further stockholder approval of an increase in the reserve under the

2012

Plan. As a result of the stockholder approval of the amendments at the

2017

annual meeting, these restrictions on exercise were removed on

December 28, 2017.

Due to the removal of this restriction on exercise, the Company recognized a non-cash charge for compensation expense of approximately

$1.9

million in the

fourth

quarter of

2017.

Stock Options and Warrants Granted by the Company

The following table is the listing of stock options and warrants as of

December 31, 2017

by year of grant:

Stock Options:
Year	Shares		Price
2011		173			281.25
2012		1,841		131.25	–	150.00
2013		1,553		148.13	–	596.25
2014		835		162.50	–	431.25
2015		4,088		65.75	–	86.25
2016		144,423		2.25	–	5.13
2017		2,612,070		1.01	–	2.10
Total		2,764,983	$	1.01	–	596.25

Warrants:
Year	Shares		Price
2013		10,705		93.75	–	371.25
2014		6,455		243.75	–	609.38
2015		94,152		0.00	–	243.75
2016		756,999			4.46
2017		1,082,946		1.07	–	2.25
Total		1,951,257	$	0.00	–	609.38

Note 4 - Notes Receivable	9 Months Ended	12 Months Ended
Note 4 - Notes Receivable	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 5 – NOTES RECEIVABLE In July 2017, the Company began to advance funds to CytoBioscience for working capital for CytoBioscience’s business. All the notes receivable bear simple interest at 8% and were due in full on December 31, 2017. All the notes are covered by a security interest in all of CytoBioscience’s accounts receivable and related rights in connection with all of the advances. The principal amount of the secured promissory notes receivable from CytoBioscience totaled $1,070,000 as of December 31, 2017. In March 2018, the Company executed a new note replacing all previous CytoBioscience notes for $1,112,524, plus interest paid monthly at the per annum rate of ( 8% ) on the principal amount. The secured note has a term of two years with the unpaid principal and unpaid accrued interest due and payable on February 28, 2020. CytoBioscience was current in its payments to the Company through and including July 2018. The Company has not received the scheduled interest payments from CytoBioscience for the months of August, September and October. On September 27 amd 28, 2018 CytoBioscience, through its parent company (WestMountain) made public filings indicating that their notes payable was in default. In October 2018, CytoBioscience communicated to the Company that CytoBioscience is raising capital that it believes will allow it to resume debt service payments, and that CytoBioscience wishes to negotiate an extension to the note. At this time the Company does not believe a reserve is needed but if CytoBioscience is not successful in its efforts to raise capital, there could be additional reserves or write-offs against this receivable in the future, which could result in a significant loss for the Company. In October 2017, the Company advanced $600,000 for working capital for Helomics’ business. Additionally, in December 2017, the Company advanced $67,512 to De Lage Landen, a vendor of Helomics, as a fifty percent ( 50% ) down payment for a lease to purchase certain equipment. The note is covered by a security interest in certain equipment of Helomics. In March 2018, the Company converted $500,000 of the note receivable into 833,333 shares of common stock for an additional 5% interest in Helomics. The Company now has an equity stake in Helomics totaling 25%. In September 2018, the Company advanced an additional $60,000 for working capital for Helomics’ business. The balance due to the Company is $163,468, plus interest as of September 30, 2018. Subsequently in October 2018, the Company advanced $907,500 for working capital for Helomics’ business. All additional advances are covered by the security interest in certain equipment of Helomics. In addition, Helomics pledged all of its assets as security for the Company’s convertible secured note financing described in Note 9. Upon completion of the merger with Helomics all intercompany notes would be eliminated in their entirety.	NOTE 4– NOTES RECEIVABLE In July 2017, the Company began to advance funds to CytoBioscience for working capital for CytoBioscience’s business. All the notes receivable bear simple interest at 8% and are due in full on December 31, 2017. All the notes are covered by a security interest in all of CytoBioscience’s accounts receivable and related rights in connection with all of the advances. The principal amount of the secured promissory notes receivable from CytoBioscience totaled $1,070,000 as of December 31, 2017. In March 2018, the Company executed a new note replacing all previous CytoBioscience notes for $1,112,524, plus interest paid monthly at the per annum rate of eight percent ( 8% ) on the principal amount. The secured note has a term of two years with the unpaid principal and unpaid accrued interest due and payable on February 28, 2020. The Company advanced $600,000 for working capital for Helomics’ business. The notes receivable bear simple interest at 8% and is due in full on April 30, 2018. Additionally, in December 2017, the Company advanced $67,512.10 to De Lage Landen as fifty percent ( 50% ) down payment for a lease to purchase certain equipment. The note is covered by a security interest in certain equipment of Helomics. In March 2018, the Company converted $500,000 of the note receivable into 833,333 shares of common stock for an additional 5% interest in Helomics Corporation. The Company now has an equity stake in Helomics totaling 25%. The Company is currently negotiating terms for payment on the remaining $167,512.10 plus interest.

Note 5 - Loss Per Share

9 Months Ended

12 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Notes to Financial Statements

Earnings Per Share [Text Block]

NOTE

- LOSS PER SHARE

The following table presents the shares used in the basic and diluted loss per common share computations:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Numerator
Net loss available in basic and diluted calculation	$	(2,506,869	)	$	(992,095	)	$	(6,640,301	)	$	(4,877,542	)
Comprehensive loss		(2,506,869	)		(992,095	)		(6,640,301	)		(4,877,542	)
Denominator:
Weighted average common shares outstanding-basic		13,252,605			6,232,761			12,178,285			6,283,567

Effect of diluted stock options, warrants and preferred stock (1)		-			-			-			-

Weighted average common shares outstanding-basic		13,252,605			6,262,761			12,178,285			6,283,567

Loss per common share-basic and diluted	$	(0.19	)	$	(0.16	)	$	(0.55	)	$	(0.78	)

(

) The number of shares underlying options and warrants outstanding as of

September 30, 2018

and

September 30, 2017

are

6,768,151

and

3,866,849,

respectively. The number of shares underlying the convertible debt as of

September 30, 2018

5,047,700.

The number of shares underlying the preferred stock as of

September 30, 2018

79,246.

NOTE

- LOSS PER SHARE

The following table presents the shares used in the basic and diluted loss per common share computations:

	Year Ended December 31,
	2017			2016
Numerator:
Net loss available in basic and diluted calculation	$	(7,746,593	)	$	(6,526,014	)
Other comprehensive income:
Unrealized gain (loss) from marketable securities		-			1,501
Comprehensive (loss)		(7,746,593	)		(6,524,513	)
Denominator:
Weighted average common shares outstanding-basic		6,362,989			2,823,345

Effect of dilutive stock options, warrants and preferred stock (1)		-			-

Weighted average common shares outstanding-basic		6,362,989			2,823,345

Loss per common share-basic and diluted	$	(1.22	)	$	(2.31	)

(

) The number of shares underlying options and warrants outstanding as of

December 31, 2017

and

December 31, 2016

are

4,716,240

and

1,036,744,

respectively. The number of shares underlying the preferred stock as of

December 31, 2017

79,246

for Series B Convertible and

647,819

Note 6 - Income Taxes

12 Months Ended

Dec. 31, 2017

Notes to Financial Statements

Income Tax Disclosure [Text Block]

NOTE

6–

INCOME TAXES

The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Tax Reform Act was enacted

December 22, 2017.

Effective

January 1, 2018

the Tax Reform Act reduced corporate income tax rates from

34%

21%.

Other changes effect operating loss carry-forwards and carrybacks, as well as a repeal of the corporate alternative minimum tax. As a result of the Tax Reform Act, deferred tax assets and liabilities will be re-measured to account for the lower tax rates.

There was

income tax impact from the re-measurement due to the

100%

valuation allowance on the Company’s deferred tax assets. There is

federal or state income tax provision in the accompanying statements of operations due to the cumulative operating losses incurred and

100%

valuation allowance for the deferred tax assets.

During

September 2013,

the Company experienced an "ownership change" as defined in Section

382

of the Internal Revenue Code which could potentially limit the ability to utilize the Company’s net operating losses (NOLs). The Company

may

have experienced additional “ownership change(s)” since

September 2013,

but a formal study has

not

yet been performed. The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change.

December 31, 2016,

the Company had approximately

$30.9

million of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in

2017,

subject to the Section

382

limitation described above. The federal NOLs will expire beginning in

2022

if unused. The Company also had approximately

$13.0

million of gross NOLs to reduce future state taxable income at

December 31, 2016,

which will expire in years

2022

through

2037

if unused. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At

December 31, 2016,

the federal and state valuation allowances were

$10.7

million and

$0.2

million, respectively.

December 31, 2017,

the Company had approximately

$34.5

million of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in

2018,

subject to the Section

382

limitation described above. The federal NOLs will expire beginning in

2022

if unused. The Company also had approximately

$12.2

million of gross NOLs to reduce future state taxable income at

December 31, 2017,

which will expire in years

2022

through

2037

if unused. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At

December 31, 2017,

the federal and state valuation allowances were

$7.4

million and

$0.2

million, respectively. The reduction in net deferred tax assets and corresponding valuation allowance from the prior period is a result of re measuring the Company’s deferred tax assets and liabilities at the new lower enacted rate.

The valuation allowance has been recorded due to the uncertainty of realization of the benefits associated with the net operating losses. Future events and changes in circumstances could cause this valuation allowance to change.

The components of deferred income taxes at

December 31, 2017

and

December 31, 2016

are as follows:

	December 31, 2017		December 31, 2016

Deferred Tax Asset:
Net Operating Loss	$	7,393,100	$	10,755,000
Other		215,843		189,000
Total Deferred Tax Asset		7,608,943		10,944,000
Less Valuation Allowance		7,608,943		10,944,000
Net Deferred Income Taxes	$	—	$	—

Note 7 - Rent Obligation

12 Months Ended

Dec. 31, 2017

Notes to Financial Statements

Leases of Lessee Disclosure [Text Block]

NOTE

– RENT OBLIGATION

Our corporate offices are located at

2915

Commers Drive, Suite

900,

Eagan, Minnesota

55121.

November 22, 2017,

the Company signed a

second

amendment to our lease last amended on

January 28, 2013.

The lease as amended has a

three

-year term effective

February 1, 2018

ending

January 31, 2021.

We lease

5,773

square feet at this location, of which

2,945

square feet is used for office space and

2,828

is used for manufacturing. Our lease is effective through

January 31, 2021.

We expect that this space will be adequate for our current office and manufacturing needs. Rent expense was

$66,122

and

$66,239

for

2017

and

2016,

respectively.

The Company’s rent obligation for the next

four

years are as follows:

2018	$	39,000
2019	$	40,000
2020	$	42,000
2021	$	3,000

Note 8 - Related Party Transactions	9 Months Ended	12 Months Ended
Note 8 - Related Party Transactions	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 8 – RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. In April 2018, one of the Company’s directors, Richard L. Gabriel, executed a six -month consulting contract to help guide operations for the Company’s wholly-owned subsidiary TumorGenesis. Under the terms of the agreement Mr. Gabriel will receive $12,000 monthly cash payment. In addition, Mr. Gabriel will receive a grant of 240,000 performance-based restricted stock units (“RSU’s”) under the Company’s Amended and Restated 2012 Stock Incentive Plan, with the vesting and payment of the RSU’s based on performance milestones as set forth in the agreement. Mr. Gabriel executed another six -month consulting contract for these services in October 2018. The contract has the same terms as the April 2018 contract except for the stock grants and performance milestones, which are covered under the original contract. As of this filing date Mr. Gabriel has not reached any of the prescribed milestones for earning performance based restricted stock units.	NOTE 8 - RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. In September 20, 2016, the Company entered into a partnership and exclusive reseller agreement with GLG. Under the terms of the agreement, GLG would develop rapid diagnostic tests that utilize fluid and tissue collected by the STREAMWAY System during procedures. The Company agreed to issue an aggregate of 400,000 shares of common stock to GLG in four separate tranches of 100,000 shares of common stock in each tranche. The shares reserved in each tranche would be released after the achievement of certain development milestones designated in the agreement. In addition, the Company would pay a royalty to GLG on the sale of individual tests. Also, on November 1, 2016, the Company announced that it agreed to grant GLG exclusive rights to market and distribute the STREAMWAY System in the U.K. On November 2, 2016, the Company announced that it agreed to grant GLG the same rights in Poland and certain other countries in Central Europe. In April 2017, the partnership and exclusive reseller agreement and the distribution agreements between the Company and GLG were terminated.

Note 9 - Retirement Savings Plans	12 Months Ended
Note 9 - Retirement Savings Plans	Dec. 31, 2017
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE 9 – RETIREMENT SAVINGS PLANS We have a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401 (k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In fiscal 2016, and again in 2017, we matched 100% , of the employee’s contribution up to 4.0% of their earnings. The employer contribution was $29,952 and $33,143 in 2017 and 2016. There were no discretionary contributions to the plan in 2017 and 2016.

Note 10 - Supplemental Cash Flow Data	12 Months Ended
Note 10 - Supplemental Cash Flow Data	Dec. 31, 2017
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	NOTE 10 – SUPPLEMENTAL CASH FLOW DATA Cash payments for interest were $0 and $3 for the fiscal years ended December 31, 2017 and December 31, 2016, respectively.

Note 11 - Subsequent Events	9 Months Ended	12 Months Ended
Note 11 - Subsequent Events	Sep. 30, 2018	Dec. 31, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 9 – SUBSEQUENT EVENTS Private Placement of Convertible Secured Notes Effective as of September 28, 2018 ( the “Effective Date”), the Company issued convertible secured promissory notes two private investors in the original principal amount of an aggregate $2,297,727.50 (the “bridge loans”). The closing of the investment took place on October 3, 2018, and therefore, the net cash proceeds to the Company of $1,815,000, representing an aggregate investment of $2,000,000 less commissions, are reflected on the Company’s balance sheet as of September 30, 2018 as Loan Receivable – Bridge Loan. The Company has loaned one -half of the net proceeds to Helomics. The Company and Helomics have granted to each of the investors a security interest in their assets to secure repayment of the notes. The securities purchase agreements with the investors also provide for a second investment of an aggregate of $500,000 by the investors at the consummation of the merger transaction with Helomics, at which point the aggregate principal amounts of the notes will become $2,865,909.00. As additional consideration for the investment, the Company issued an aggregate 650,000 shares of its common stock (the “Inducement Shares”) to the investors or their affiliates plus warrants to acquire up to an aggregate 1,071,776 shares of the Company’s common stock at an exercise price of $1.155 per share. Upon the closing of the second tranche investment, the warrants will be increased to cover an aggregate total of 1,336,805 shares. Each warrant is exercisable by the investor beginning on the sixth month anniversary of the effective date through the fifth -year anniversary thereof. The notes accrue interest at a rate of 8% per annum (with twelve months of interest guaranteed). The maturity date of the notes is twelve months from the Effective Date. Upon the earlier to occur of an Event of Default (as defined in the Notes) or the filing of certain registration statements, each Investor will have the right at any time thereafter to convert all or any part of its Note into shares of the Company’s common stock at a conversion price which is equal to the lesser of: (i) $1.00 and (ii) 70% of the lowest volume-weighted average price of the Company’s common stock during the 20 -trading day period ending on either the last complete trading day prior to the conversion date, or the conversion date (“Conversion Shares”). The number of Conversion Shares that may be issued is subject to an exchange cap such that the sum of (a) the total number of Conversion Shares plus (b) the number of Inducement Shares is limited to an aggregate 2,678,328 shares. Amended and Restated Merger Agreement On October 26, 2018, the Company entered into an Amended and Restated Agreement and Plan of Merger (the “Amended Merger Agreement”) with Helomics, which restates the Merger Agreement dated June 28, 2018. The Amended Merger Agreement contemplates that the Merger will be a forward triangular merger whereby Helomics will merge with and into Merger Sub. At the time of the Merger, all outstanding shares of Helomics stock not already held by the Company will be converted into the right to receive a proportionate share of 4 million shares of newly issued common stock in the Company and 3.5 million shares of newly issued Series D preferred stock in the Company (rather than a proportionate share of 7.5 million shares of newly issued common stock, as described in Note 4 ), in addition to the 1.1 million shares of the Company’s common stock already issued to Helomics for the Company’s initial 20% ownership in Helomics. The Series D preferred stock does not have voting rights for most purposes and is convertible into common stock after a period of one year. Other economic terms of the Amended Merger Agreement and the exchange offer with holders of Helomics notes and warrants are as described in Note 4.	NOTE 11 – SUBSEQUENT EVENTS In January 2018, the Company completed a firm commitment underwritten public offering of 2,900,000 Units at an offering price of $0.95 per Unit, with each Unit consisting of one share of the Company’s Common Stock and 0.3 of a Series E Warrant, with each whole Series E Warrant purchasing one share of common stock at an exercise price of $1.00 per whole share. The shares of Common Stock and Series E Warrants were immediately separable and were issued separately. Gross proceeds were approximately $2,755,000, before deducting expenses. The Company granted the underwriter a 45 -day option to purchase an additional (i) up to 290,000 additional shares of Common Stock at the public offering price per Unit less the price of the Series E Warrant included in the Units and less the underwriting discount and/or (ii) additional Series E Warrants to purchase up to 87,000 additional shares of common stock at a purchase price of $0.001 per Series E Warrant to cover over-allotments, if any. On February 21, 2018, the underwriter exercised on 215,247 shares of common stock, par value $0.01, at $0.9497 per share as described in the Underwriting Agreement. The Company received net proceeds of $188,066 after deductions of $16,354 representing the Underwriter’s discount of 8% of the purchase price of the shares. On January 11, 2018, the Company entered into a share exchange agreement with Helomics Holding Corporation. Pursuant to the share exchange agreement Helomics issued 2,500,000 shares of its Series A Preferred Stock in exchange for 1,100,000 shares of Skyline’s common stock. Under the share exchange agreement, the Company has the right to convert $500,000 in secured notes into another 5% of Helomics’ outstanding shares, which would result in the Company owning 25% of Helomics outstanding stock. The secured notes are related to the Company’s previous loans of $500,000 to Helomics. The Skyline shares are being held in escrow by Corporate Stock Transfer, Inc. as escrow agent. While the Skyline shares are held in escrow, they will be voted as directed by the Company’s board of directors and management. The Skyline shares will be released to Helomics following a determination that Helomics’ revenues in any 12 -month period have been equal or greater than $8,000,000. The Helomics Preferred Stock issued to the Company is convertible into an aggregate of 20% of the outstanding capital stock of Helomics. In addition, the terms of the Helomics Preferred Stock include certain protective provisions that require consent of the Company before Helomics may take certain actions, including issuing preferred stock senior to the Helomics Preferred Stock or entering into fundamental corporate transactions. The Company also has certain anti-dilution protections and the right to receive dividends. On February 22, 2018, the Company completed a conversion of a portion of the principal amount of Notes owed by Helomics Holding Corporation and received an assignment of intellectual property. Immediately prior to the conversion, Helomics owed the Company $667,512.50. The Company converted $500,000 of the principal amount, including accrued interest thereon, into 833,333 shares of Common Stock of Helomics. Prior to the issuance of the Conversion Shares, the outstanding capital stock of Helomics consists of 2,500,000 shares of Series A Preferred Stock owned by Precision and 10,000,000 shares of Common Stock. After the issuance of the Conversion Shares and upon full conversion of its Series A Preferred Stock, Precision now owns 3,333,333 shares of Helomics Common Stock, which represents 25% of the 13,333,333 now-outstanding shares of Helomics Common Stock. In consideration of the conversion, Helomics assigned to Precision all Helomics’ right, title and interest in the name “Precision Therapeutics”, including any related trademarks, trade names, logos and domain names, as well as all related artwork and other creative content related thereto. There will be a balance of $167,512.50 in Principal Amount remaining outstanding to the Company, which will remain subject to repayment with interest, consistent with the original terms of the Note. The Security Agreement shall remain in full force and effect with respect to the remaining balance of the Principal Amount. On February 27, 2018, the Company formed a wholly owned subsidiary, TumorGenesis Inc., to develop the next generation of patient derived (“PDx”) tumor models for precision cancer therapy and drug development. The Company formed TumorGenesis Inc., to develop a new rapid approach to growing tumors in the laboratory, which essentially “fools” the cancer cells into thinking they are still growing inside the patient. This approach will provide a much more relevant model of the patient tumor that may be used for testing of drugs for personalized therapy or for the development of new drugs. Testing of the TumorGenesis PDx tumors will take place in collaboration with Helomics, in which Precision Therapeutics has a 25% equity stake. The Company is currently in negotiations to license their technology to advance TumorGenesis’s strategic plan. The Company has already executed license agreements with 48Hour Discovery Inc. and SyntArray, Inc.

Note 12 - Investment Securities and Other Comprehensive Income (Loss)

12 Months Ended

Dec. 31, 2017

Notes to Financial Statements

Investment Securities and Other Comprehensive Income/(Loss) [Text Block]

NOTE

– INVESTMENT SECURITIES AND OTHER COMPREHENSIVE INCOME (LOSS)

The cost and fair values of investment securities available-for-sale at

December 31, 2016

were as follows:

	December 31, 2016
Note Description	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value

Mutual Funds	$	282,828	$	1,501	$	-	$	284,329

Significant Accounting Policies (Policies)

9 Months Ended

12 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Nature of Operations and Continuance of Operations

Precision Therapeutics Inc., (the “Company”) was originally incorporated on

April 23, 2002

in Minnesota as BioDrain Medical, Inc. Effective

August 6, 2013,

the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective

December 16, 2013,

the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware corporation as the surviving corporation of the merger. On

August 31, 2015,

the Company completed a successful offering and concurrent uplisting to the NASDAQ Capital Market. On

February 1, 2018,

February 1, 2018.

Because of this change, the Company’s common stock trades under the new ticker symbol “AIPT,” effective

February 2, 2018.

Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.

As of

September 30, 2018,

the Company had

13,398,339

shares of common stock outstanding, par value

$.01

per share. The Company is a healthcare company that provides personalized medicine solution and medical devices in

two

main areas: (

) precision medicine, which aims to apply artificial intelligence to personalized medicine and drug discovery; and (

April 2009,

the Company received

510

(k) clearance from the Food & Drug Administration (the “FDA”) to authorize the Company to market and sell its STREAMWAY System products.

The Company acquired

25%

of the capital stock of Helomics Holding Corporation (“Helomics”), in transactions in the

first

quarter of

2018,

and in

April 2018

the Company entered into a letter of intent for a proposed merger transaction to acquire the remaining ownership of Helomics. In

June 2018,

the Company and Helomics entered into a definitive merger agreement – see Note

149,000

first

quarter of

2018,

is presented as part of the condensed consolidated financial statements (“financial statements”).

$61,405,345.

The Company does

not

expect to generate sufficient operating revenue to sustain its operations in the near-term. The Company had cash and cash equivalents of

$209,891

as of

September 30, 2018

and needs to raise significant additional capital to meet its operating needs, and therefore there is substantial doubt about the Company’s ability to continue as a going concern for

one

year after the date that the financial statements are issued. The financial statements do

not

include any adjustments that might result from the outcome of this uncertainty. The Company raised

$1,815,000,

net, from a bridge loan executed on

September 28, 2018.

Neither the cash nor the stock transferred until the

first

week in

October 2018

and is reported in the balance sheet as a loan receivable and note payable. Warrants accompanied the agreement with a grant date of

September 28, 2018

and are included in the outstanding stock option and warrant lists.

Since inception to

September 30, 2018,

the Company has raised approximately

$36,490,000

in equity offerings, inclusive of (

)

$2,055,000

from a private placement of Series A Convertible Preferred Stock, (

)

$13,555,003

from the public offering of Units, (

)

$1,739,770

from a registered direct offering, (

)

$3,937,500

plus an overallotment of

$358,312

from a firm commitment underwritten public offering, and (

)

$1,300,000

from a private placement of Series C Convertible Preferred Stock. Also included in the

$36,490,000

aggregate is a total of

$3,405,052

from

2018

including

$2,755,000

from a firm commitment underwritten public offering and

$650,062

from exercising warrants into common stock. In addition, historically there was

$5,685,000

in debt financing.

Nature of Operations and Continuance of Operations

The Company was originally incorporated on

April 23, 2002

in Minnesota as BioDrain Medical, Inc. Effective

August 6, 2013,

the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective

December 16, 2013,

the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. On

August 31, 2015,

the Company completed a successful offering and concurrent uplisting to The NASDAQ Capital Market. On

February 1, 2018,

February 1, 2018.

Because of this change, our common stock trades under the new ticker symbol “AIPT,” effective

February 2, 2018.

Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.

As of

December 31, 2017,

the registrant had

6,943,283

shares of common stock, par value

$.01

per share, outstanding, adjusted for a

-for-

reverse stock split effective

October 27, 2016.

April 2009,

the Company received

510

(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY System products.

August 31, 2015

not

include any adjustments that might result from the outcome of this uncertainty.

Since inception to

December 31, 2017,

the Company raised approximately

$29,065,934

in equity, inclusive of

$2,055,000

from a private placement of Series A Convertible Preferred Stock,

$13,555,003

from the public offering of Units,

$1,739,770

from a registered direct offering,

$3,937,500

plus an overallotment of

$358,312

from a firm commitment underwritten public offering,

$1,300,000

from a private placement of Series C Convertible Preferred Stock, and

$5,685,000

in debt financing. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources.”

Interim Financial Statements, Policy [Policy Text Block]

Interim Financial Statements

-K filed with the SEC on

April 2, 2018.

The nature of the Company’s business is such that the results of any interim period

may

not

be indicative of the results to be expected for the entire year.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Developments

May 2014,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

No.

2014

09,

Revenue from Contracts with Customers (Topic

606

January 1, 2018

using the modified retrospective method applied to those contracts which were

not

completed as of

December 31, 2017.

Results for reporting periods beginning after

January

2018

are presented under Topic

606,

while prior-period amounts have

not

been retrospectively adjusted and continue to be reported in accordance with Topic

605,

Revenue Recognition

. Based upon the Company’s contracts which were

not

completed as of

December 31, 2017,

the Company was

not

required to make an adjustment to the opening balance of retained earnings as of

January 1, 2018,

and there was

material impact. See Note

for further discussion.

January 2016,

the FASB issued ASU

No.

2016

01,

Financial Instruments-Overall (Subtopic

825

): Recognition and Measurement of Financial Assets and Financial Liabilities

(“ASU

2016

01”

not

result in consolidation and are

not

January 1, 2018.

As of

June 30, 2018,

there is

material impact on the Company’s financial statements and disclosures.

February 2016,

the FASB issued ASU

No.

2016

02,

“

Leases (Topic

842

)

” (“ASU

2016

02”

December 15, 2018.

Early adoption is permitted. The Company believes that upon adoption, ASU

2016

will

not

Recent Accounting Developments

May 2014,

the Financial Accounting Standards Board (“FASB”) issued ASU

2014

09,

Revenue from Contracts with Customers

and created a new topic in the FASB Accounting Standards Codification ("ASC"), Topic

606,

and has since amended the standard with ASU

2015

14,

“Revenue from Contracts with Customers: Deferral of the Effective Date,”

ASU

2016

08,

“Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net),”

ASU

2016

10,

“Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing,”

ASU

2016

12,

“Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients.”

ASU

2017

13.

December 15, 2017,

including interim periods within that reporting period. Early application is

not

permitted. The FASB allows

two

adoption methods under ASC

606.

We adopted the standard on

January 1, 2018

using the “modified retrospective method.” Under that method, we will apply the rules to all contracts existing as of

January 1, 2018,

not

have a material impact on our financial statements.

August 2014,

the FASB issued ASU

2014

15,

Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern

December 15, 2016,

with early adoption permitted. We implemented in the

first

quarter of

2017.

July 2015,

the FASB issued ASU

No.

2015

, Inventory (Topic

330

): Simplifying the Measurement of Inventory

December

15,

2016,

including interim periods within that reporting period. We implemented in the

first

quarter of

2017.

November 2015,

the FASB issued ASU

2015

17,

“Income Taxes (Topic

740

)”

December 15, 2016

and for interim periods within those fiscal years, with early adoption permitted. We implemented in the

first

quarter of

2017.

January 2016,

the FASB issued ASU

No.

2016

01,

Financial Instruments-Overall (Subtopic

825

): Recognition and Measurement of Financial Assets and Financial Liabilities

(“ASU

2016

01”

not

result in consolidation and are

not

December 15, 2017,

including interim periods within those fiscal years. The Company does

not

believe that the adoption of this guidance will have a material impact on the Company’s financial statements and disclosures.

February 2016,

the FASB issued ASU

No.

2016

02,

“Leases

(Topic

842”

(“ASU

2016

02”

December 15, 2018.

Early adoption is permitted. We are currently evaluating the timing of our adoption and the impact that the updated standard will have on our financial statements.

March 2016,

the FASB issued ASU

No.

2016

09,

“Compensation (Topic

718

): Improvements to Employee Shares-Based Payment Accounting”

(

“ASU2016

09”

). ASU

2016

December 15, 2016.

Early adoption is permitted. We implemented in the

first

quarter of

2017.

August 2016,

the FASB issued ASU

No.

2016

15,

Statement of Cash Flows (Topic

230

): Classification of Certain Cash Receipts and Cash Payments,

December 15, 2017,

not

expect the adoption of ASU

2016

to have a material impact on its financial statements.

December 22, 2017,

the Tax Cuts and Jobs Act of

2017

34%

21%.

As a result of the enacted law, the Company is required to revalue its deferred tax assets and liabilities at the new enacted rate.

We reviewed all other significant newly issued accounting pronouncements and determined they are either

not

applicable to our business or that

material effect is expected on our financial position and results of our operations.

Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]

Valuation of Intangible Assets

The Company reviews identifiable intangible assets for impairment annually, or whenever events or changes in circumstances indicate the carrying amount

may

not

be recoverable. The Company’s intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount

may

not

be recoverable include, but are

not

Valuation of Intangible Assets

We review identifiable intangible assets for impairment in accordance with ASC

350

— Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount

may

not

be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount

may

not

be recoverable include, but are

not

Use of Estimates, Policy [Policy Text Block]

Accounting Policies and Estimates

Accounting Policies and Estimate

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of

three

months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximates fair value.

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of

three

months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximate fair value.

Certificates of Deposit Policy [Policy Text Block]

Certificates of Deposit

Short-term interest-bearing investments are those with maturities of less than

one

year but greater than

three

months when purchased. Certificates with maturity dates beyond

one

year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value.

Certificates of Deposit

Short-term interest-bearing investments are those with maturities of less than

one

year but greater than

three

months when purchased. Certificates with maturity dates beyond

one

year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value.

Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC)

820,

820

establishes a

three

-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level

– Observable inputs such as quoted prices in active markets;

Level

– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level

– Unobservable inputs where there is little or

market data, which requires the reporting entity to develop its own assumptions.

The fair value of the Company’s investment securities was determined based on Level

inputs.

Fair Value Measurements

Under generally accepted accounting principles as outlined in the Financial Accounting Standards Board’s

Accounting Standards Certification

(ASC)

820,

820

establishes a

three

-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level

– Observable inputs such as quoted prices in active markets;

Level

– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level

– Unobservable inputs where there is little or

market data, which requires the reporting entity to develop its own assumptions.

The fair value of the Company’s investment securities were determined based on Level

inputs.

Inventory, Policy [Policy Text Block]

Inventories

Inventories are stated at the lower of cost and net realizable value, with cost determined on a

first

-in,

first

-out basis. Inventory balances are as follows:

	September 30, 2018		December 31, 2017

Finished goods	$	61,587	$	62,932
Raw materials		157,610		141,028
Work-In-Process		58,958		61,085
Total	$	278,155	$	265,045

Inventories

Inventories are stated at the lower of cost or market, with cost determined on a

first

-in,

first

-out basis. Inventory balances are as follows:

	December 31, 2017		December 31, 2016

Finished goods	$	62,932	$	38,201
Raw materials		141,028		165,812
Work-In-Process		61,085		68,195
Total	$	265,045	$	272,208

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

	Years
Computers and office equipment	3	-	7
Leasehold improvements		3
Manufacturing tooling	3	-	7
Demo equipment		3

The Company’s fixed assets consist of the following:

	September 30, 2018		December 31, 2017
Computers and office equipment	$	204,904	$	183,528
Leasehold improvements		140,114		25,635
Manufacturing tooling		108,955		108,955
Demo equipment		77,496		43,368
Total		531,469		361,486
Less: Accumulated depreciation		333,211		273,770
Total Fixed Assets, Net	$	198,258	$	87,716

Depreciation expense was

$26,120

and

$59,442

in the

three

and

nine

months ended

September 30, 2018

and was

$14,561

and

$44,764

for the

three

and

nine

months ended

September 30, 2017.

Property and Equipment

	Years
Computers and office equipment	3	-	7
Leasehold improvements		5
Manufacturing Tooling	3	-	7
Demo Equipment		3

The Company’s investment in Fixed Assets consists of the following:

	December 31, 2017		December 31, 2016
Computers and office equipment	$	183,528	$	164,318
Leasehold Improvements		25,635		25,635
Manufacturing Tooling		108,955		103,204
Demo Equipment		43,368		23,236
Total		361,486		316,393
Less: Accumulated Depreciation		273,770		214,897
Total Fixed Assets, Net	$	87,716	$	101,496

Depreciation expense was

$58,872

2017

and

$73,249

2016.

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Intangible Assets

Intangible assets consist of trademarks, patent costs and license fees. Amortization expense was

$38,387

and

$46,127

in the

three

and

nine

months ended

September 30, 2018

and was

$3,276

and

$9,067

in the

three

and

nine

months ended

September 30, 2017.

The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.

Intangible Assets

Intangible assets consist of trademarks and patent costs. Amortization expense was

$12,689

2017

and

$9,107

2016.

The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.

Income Tax, Policy [Policy Text Block]

Income Taxes

The Company accounts for income taxes in accordance with ASC

740

Income Taxes

(“ASC

740”

). Under ASC

740,

There is

income tax provision in the accompanying statements of operations due to the cumulative operating losses that indicate a

100%

valuation allowance for the deferred tax assets and state income taxes is appropriate.

not

that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified

income tax uncertainties.

Tax years subsequent to

2014

remain open to examination by federal and state tax authorities.

Income Taxes

The Company accounts for income taxes in accordance with ASC

740

Income Taxes (“ASC

740”

)

. Under ASC

740,

not

that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified

income tax uncertainties.

Tax years subsequent to

2014

remain open to examination by federal and state tax authorities.

Offering Costs [Policy Text Block]

Offering Costs

Intangible Assets, Finite-Lived, Policy [Policy Text Block]

Patents and Intellectual Property

January 25, 2014,

the Company filed a non-provisional Patent Cooperation Treaty (“PCT”) Application

No.

PCT/US2014/013081

claiming priority from the U.S. Provisional Patent Application, number

61756763

which was filed

one

year earlier on

January 25, 2013.

The “PCT” allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the

148

not

interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid.

The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models:

US7469727,

US8123731

and U.S. Publication

No.

US20090216205

(collectively, the “Patents”). These Patents will begin to expire on

August 8, 2023.

July 2015,

The United States Patent Office has assigned application

#14/763,459

to the Company’s previously filed PCT application.

As of

November 22, 2017,

the Company was informed that the European Patent Office has allowed all claims for application

#14743665.3

1651

and has sent a Notice of Intent to Grant.

As of

July 11, 2018,

the Company was informed that the European Patent

#EP2948200

was granted and published validating in the following countries: Belgium, Germany, Spain, France, United Kingdom, Ireland, Italy, Netherlands, Norway, Poland and Sweden.

Patents and Intellectual Property

January

25th,

2014,

the Company filed a non-provisional PCT Application

No.

PCT/US2014/013081

claiming priority from the U.S. Provisional Patent Application, number

61756763

which was filed

one

year earlier on

January

25th,

2013.

The Patent Cooperation Treaty (“PCT”) allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the

148

not

interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid.

The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models:

US7469727,

US8123731

and U.S. Publication

No.

US20090216205

(collectively, the “Patents”). These Patents will begin to expire on

August 8, 2023.

July 2015,

The United States Patent Office has assigned application

#14/763,459

to our previously filed PCT application.

As of

November 22, 2017,

the Company was informed that the European Patent Office has allowed all our claims for application

#14743665.3

1651,

and has sent a Notice of Intent to Grant. Skyline is now in the process of identifying the key European countries that we will validate the patent in.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Credit Risk

one

financial institution. The Company has

credit risk concentration because there are

funds in excess of insurance limits in a single bank.

Credit Risk

one

financial institution. The Company had a credit risk concentration as a result of depositing

$563,000

of funds in excess of insurance limits in a single bank.

Segment Reporting, Policy [Policy Text Block]

Segments

The Company operates in

two

segments for the sale of its medical device and consumable products. Substantially all the Company’s assets, revenues, and expenses for the

three

and

nine

months ended

September 30, 2018

and

2017

were located at or derived from operations in the United States. There was

$4,195

and

$288

in revenues from sales outside the United States during the

three

-month period of

September 2018

and

2017,

respectively; and

$10,061

and

$25,188

in revenues from sales outside of the United States during the

first

nine

months of

2018

and

2017,

respectively.

Segments

The Company operates in

two

segments for the sale of its medical device and consumable products. Substantially all of the Company’s assets, revenues, and expenses for

2017

and

2016

were located at or derived from operations in the United States. There was

$26,662

in revenues from sales outside of the United States during

2017.

Risks and Uncertainties Policy [Policy Text Block]

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device industry, including, but

not

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device industry, including, but

not

Presentation of Taxes Collected From Customers, Policy [Policy Text Block]

Presentation of Taxes Collected from Customers

Revenue Recognition, Shipping and Handling Cost, Policy [Policy Text Block]

Shipping and Handling

Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations.

Advertising Costs, Policy [Policy Text Block]

Advertising

Advertising costs are expensed as incurred. Advertising expenses were

$37,060

2017,

and

$71,212

2016.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Research and development costs are charged to operations as incurred. Research and development costs were approximately

$289,000

and

$406,000

for

2017

and

2016,

respectively.

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Revenue Recognition and ASC

606

- Revenue Recognition.

We have adopted the provisions of Accounting Standards Update, or “ASU”

2014

09,

Revenue from Contracts with Customers (Accounting Standards Codification, or “ASC”

606

), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. Companies are permitted to adopt ASC

606

using a full retrospective or modified retrospective method. We adopted the standard on

January 1, 2018

using a modified retrospective method.

While we continue to assess all potential impacts of the standard, it is currently anticipated that the standard will

not

have a material impact on our financial statements.

Marketable Securities, Policy [Policy Text Block]

Investment Securities

Receivables, Policy [Policy Text Block]

Receivables

not

been material to the financial statements.

Standard Product Warranty, Policy [Policy Text Block]

Product Warranty Costs

2017

and in

2016,

the Company incurred approximately

$6,209

and

$34,665

in warranty costs.

Note 1 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	September 30, 2018		December 31, 2017

Finished goods	$	61,587	$	62,932
Raw materials		157,610		141,028
Work-In-Process		58,958		61,085
Total	$	278,155	$	265,045

	December 31, 2017		December 31, 2016

Finished goods	$	62,932	$	38,201
Raw materials		141,028		165,812
Work-In-Process		61,085		68,195
Total	$	265,045	$	272,208

Property Plant and Equipment Useful Life [Table Text Block]

	Years
Computers and office equipment	3	-	7
Leasehold improvements		3
Manufacturing tooling	3	-	7
Demo equipment		3

	Years
Computers and office equipment	3	-	7
Leasehold improvements		5
Manufacturing Tooling	3	-	7
Demo Equipment		3

Property, Plant and Equipment [Table Text Block]

	September 30, 2018		December 31, 2017
Computers and office equipment	$	204,904	$	183,528
Leasehold improvements		140,114		25,635
Manufacturing tooling		108,955		108,955
Demo equipment		77,496		43,368
Total		531,469		361,486
Less: Accumulated depreciation		333,211		273,770
Total Fixed Assets, Net	$	198,258	$	87,716

	December 31, 2017		December 31, 2016
Computers and office equipment	$	183,528	$	164,318
Leasehold Improvements		25,635		25,635
Manufacturing Tooling		108,955		103,204
Demo Equipment		43,368		23,236
Total		361,486		316,393
Less: Accumulated Depreciation		273,770		214,897
Total Fixed Assets, Net	$	87,716	$	101,496

Note 2 - Equity Method Investment (Tables)

9 Months Ended

Sep. 30, 2018

Notes Tables

Equity Method Investments [Table Text Block]

Helomics Holdings Corporation

	For the Nine Months Ended
	September 30, 2018
Revenue	$	623,662

Gross margin	$	441,370


Net loss from continuing operations	$	(6,833,846	)

Net loss to investee	$	(5,227,552	) 1

Note 4 - Stockholders' Equity, Stock Options and Warrants (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Notes Tables

Share-based Compensation, Activity [Table Text Block]

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2016		165,643		$	11.22		871,101		$	52.22

Issued		2,612,070			1.45		1,082,946			1.49
Expired		(12,730	)		10.39		(2,790	)		281.46
Exercised		-			-		-			-

Outstanding at December 31, 2017		2,764,983		$	2.00		1,951,257		$	23.74

Issued		836,950			1.12		2,028,776			1.08
Expired		(153,048	)		2.00		(10,706	)		199.55
Exercised		-			-		(650,062	)		1.00

Outstanding at September 30, 2018		3,448,885		$	1.78		3,319,265		$	4.55

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2015		31,350		$	133.23		323,099		$	128.40

Issued		157,982			3.14		1,487,881			0.71
Expired		(22,377	)		122.13		-			-
Exercised		(1,312	)		65.75		(939,879	)		-

Outstanding at December 31, 2016		165,643		$	11.22		871,101		$	52.22

Issued		2,612,070			1.45		1,082,946			1.49
Expired		(12,730	)		10.39		(2,790	)		281.46
Exercised		-			-		-			-

Outstanding at December 31, 2017		2,764,983		$	2.00		1,951,257		$	23.74

Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]

Range of Prices		Shares		Weighted Remaining Life
Options
$	0.91		10,000		9.55
$	0.965		3,000		9.63
$	0.97		191,753		9.27
$	1.01		149,110		9.38
$	1.06		23,585		10.00
$	1.10		86,958		9.71
$	1.13		195,931		9.80
$	1.15		21,740		9.84
$	1.16		66,451		9.84
$	1.18		30,000		9.86
$	1.20		41,668		9.84
$	1.21		30,000		9.86
$	1.35		111,112		9.45
$	1.454		17,200		9.01
$	1.47		2,347,308		8.73
$	2.10		14,286		8.50
$	2.25		293		7.90
$	2.42		20,640		7.84
$	2.80		57,145		8.26
$	3.75		3,998		5.24
$	4.125		3,636		8.01
$	4.1975		7,147		7.97
$	4.25		3,529		7.50
$	5.125		3,902		7.94
$	65.75		190		7.06
$	73.50		1,157		7.26
$	77.50		2,323		6.75
$	80.25		187		7.01
$	86.25		232		6.50
$	131.25		81		3.94
$	148.125		928		4.47
$	150.00		1,760		3.88

$	162.50	123	6.26
$	206.25	121	6.01
$	248.4375	121	4.79
$	262.50	130	4.79
$	281.25	529	4.30
$	318.75	3	4.60
$	346.875	72	5.50
$	431.25	306	5.44
$	506.25	188	5.25
$	596.25	42	5.00

		3,448,885

Warrants
$	1.00	1,063,935	4.60
$	1.07	697,946	4.10
$	1.155	1,071,776	5.00
$	2.25	385,000	3.32
$	123.75	94,084	1.92
$	243.75	2,529	0.84
$	309.375	2,850	0.86
$	309.50	222	1.10
$	506.25	59	0.38
$	609.375	862	0.34
		3,319,265

Range of Exercise Prices			Shares		Weighted Average Remaining Life
Options:
	$	1.01		124,358	10.00
	$	1.454		17,200	9.75
	$	1.47		2,456,226	9.48
	$	2.10		14,286	9.25
	$	2.25		293	8.65
	$	2.42		24,768	8.38
	$	2.80		57,145	9.01
	$	3.75		44,000	8.50
	$	4.125		3,636	8.75
	$	4.1975		7,147	8.72
	$	4.25		3,529	8.25
	$	5.125		3,902	8.69
	$	65.75		190	7.40
	$	73.50		1,157	8.01
	$	77.50		2,323	7.50
	$	80.25		187	7.75
	$	86.25		232	7.25
	$	131.25		81	4.69
	$	148.125		928	5.21
	$	150.00		1,760	4.63
	$	162.50		123	7.01
	$	206.25		121	6.75
	$	248.4375		121	5.54
	$	262.50		130	5.54
	$	281.25		529	5.04
	$	318.75		3	5.35
	$	346.875		72	6.25
	$	431.25		306	6.19
	$	506.25		188	6.00
	$	596.25		42	5.75
Total				2,764,983

	Warrants
		$	1.07	697,946	4.85
		$	2.25	385,000	4.06
		$	4.46	756,999	3.92
		$	93.75	2,255	0.19
		$	123.75	94,084	2.67
		$	150.00	4,114	0.20
		$	225.00	107	0.07
		$	243.75	2,529	1.59
		$	281.25	3,107	0.14
		$	309.375	2,850	1.61
		$	309.50	222	1.85
		$	337.50	178	0.46
		$	371.25	944	0.41
		$	506.25	59	1.12
		$	609.375	862	1.09
Total				1,951,257

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

Stock Options:
Year	Shares		Price
2011		173			$281.25
2012		1,841		131.25	–	150.00
2013		1,553		148.13	–	596.25
2014		836		162.50	–	431.25
2015		4,088		65.75	–	86.25
2016		100,292		2.25	–	5.13
2017		2,503,152		1.01	-	2.10
2018		836,950		0.91	-	1.35
Total		3,448,885		$0.91	–	$596.25

Warrants:
Year	Shares		Price
2014		6,455		$243.75	–	$609.38
2015		94,151		0.00	–	243.75
2016		252,333			1.00
2017		1,082,946		1.07	-	2.25
2018		1,883,380		1.00	-	1.155
Total		3,319,265		$0.00	–	$609.38

Stock Options:
Year	Shares		Price
2011		173			281.25
2012		1,841		131.25	–	150.00
2013		1,553		148.13	–	596.25
2014		835		162.50	–	431.25
2015		4,088		65.75	–	86.25
2016		144,423		2.25	–	5.13
2017		2,612,070		1.01	–	2.10
Total		2,764,983	$	1.01	–	596.25

Warrants:
Year	Shares		Price
2013		10,705		93.75	–	371.25
2014		6,455		243.75	–	609.38
2015		94,152		0.00	–	243.75
2016		756,999			4.46
2017		1,082,946		1.07	–	2.25
Total		1,951,257	$	0.00	–	609.38

Note 7 - Loss Per Share (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Numerator
Net loss available in basic and diluted calculation	$	(2,506,869	)	$	(992,095	)	$	(6,640,301	)	$	(4,877,542	)
Comprehensive loss		(2,506,869	)		(992,095	)		(6,640,301	)		(4,877,542	)
Denominator:
Weighted average common shares outstanding-basic		13,252,605			6,232,761			12,178,285			6,283,567

Effect of diluted stock options, warrants and preferred stock (1)		-			-			-			-

Weighted average common shares outstanding-basic		13,252,605			6,262,761			12,178,285			6,283,567

Loss per common share-basic and diluted	$	(0.19	)	$	(0.16	)	$	(0.55	)	$	(0.78	)

	Year Ended December 31,
	2017			2016
Numerator:
Net loss available in basic and diluted calculation	$	(7,746,593	)	$	(6,526,014	)
Other comprehensive income:
Unrealized gain (loss) from marketable securities		-			1,501
Comprehensive (loss)		(7,746,593	)		(6,524,513	)
Denominator:
Weighted average common shares outstanding-basic		6,362,989			2,823,345

Effect of dilutive stock options, warrants and preferred stock (1)		-			-

Weighted average common shares outstanding-basic		6,362,989			2,823,345

Loss per common share-basic and diluted	$	(1.22	)	$	(2.31	)

Note 1 - Summary of Significant Accounting Policies -2 (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	September 30, 2018		December 31, 2017

Finished goods	$	61,587	$	62,932
Raw materials		157,610		141,028
Work-In-Process		58,958		61,085
Total	$	278,155	$	265,045

	December 31, 2017		December 31, 2016

Finished goods	$	62,932	$	38,201
Raw materials		141,028		165,812
Work-In-Process		61,085		68,195
Total	$	265,045	$	272,208

Property Plant and Equipment Useful Life [Table Text Block]

	Years
Computers and office equipment	3	-	7
Leasehold improvements		3
Manufacturing tooling	3	-	7
Demo equipment		3

	Years
Computers and office equipment	3	-	7
Leasehold improvements		5
Manufacturing Tooling	3	-	7
Demo Equipment		3

Property, Plant and Equipment [Table Text Block]

	September 30, 2018		December 31, 2017
Computers and office equipment	$	204,904	$	183,528
Leasehold improvements		140,114		25,635
Manufacturing tooling		108,955		108,955
Demo equipment		77,496		43,368
Total		531,469		361,486
Less: Accumulated depreciation		333,211		273,770
Total Fixed Assets, Net	$	198,258	$	87,716

	December 31, 2017		December 31, 2016
Computers and office equipment	$	183,528	$	164,318
Leasehold Improvements		25,635		25,635
Manufacturing Tooling		108,955		103,204
Demo Equipment		43,368		23,236
Total		361,486		316,393
Less: Accumulated Depreciation		273,770		214,897
Total Fixed Assets, Net	$	87,716	$	101,496

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Notes Tables

Share-based Compensation, Activity [Table Text Block]

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2016		165,643		$	11.22		871,101		$	52.22

Issued		2,612,070			1.45		1,082,946			1.49
Expired		(12,730	)		10.39		(2,790	)		281.46
Exercised		-			-		-			-

Outstanding at December 31, 2017		2,764,983		$	2.00		1,951,257		$	23.74

Issued		836,950			1.12		2,028,776			1.08
Expired		(153,048	)		2.00		(10,706	)		199.55
Exercised		-			-		(650,062	)		1.00

Outstanding at September 30, 2018		3,448,885		$	1.78		3,319,265		$	4.55

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2015		31,350		$	133.23		323,099		$	128.40

Issued		157,982			3.14		1,487,881			0.71
Expired		(22,377	)		122.13		-			-
Exercised		(1,312	)		65.75		(939,879	)		-

Outstanding at December 31, 2016		165,643		$	11.22		871,101		$	52.22

Issued		2,612,070			1.45		1,082,946			1.49
Expired		(12,730	)		10.39		(2,790	)		281.46
Exercised		-			-		-			-

Outstanding at December 31, 2017		2,764,983		$	2.00		1,951,257		$	23.74

Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]

Range of Prices		Shares		Weighted Remaining Life
Options
$	0.91		10,000		9.55
$	0.965		3,000		9.63
$	0.97		191,753		9.27
$	1.01		149,110		9.38
$	1.06		23,585		10.00
$	1.10		86,958		9.71
$	1.13		195,931		9.80
$	1.15		21,740		9.84
$	1.16		66,451		9.84
$	1.18		30,000		9.86
$	1.20		41,668		9.84
$	1.21		30,000		9.86
$	1.35		111,112		9.45
$	1.454		17,200		9.01
$	1.47		2,347,308		8.73
$	2.10		14,286		8.50
$	2.25		293		7.90
$	2.42		20,640		7.84
$	2.80		57,145		8.26
$	3.75		3,998		5.24
$	4.125		3,636		8.01
$	4.1975		7,147		7.97
$	4.25		3,529		7.50
$	5.125		3,902		7.94
$	65.75		190		7.06
$	73.50		1,157		7.26
$	77.50		2,323		6.75
$	80.25		187		7.01
$	86.25		232		6.50
$	131.25		81		3.94
$	148.125		928		4.47
$	150.00		1,760		3.88

$	162.50	123	6.26
$	206.25	121	6.01
$	248.4375	121	4.79
$	262.50	130	4.79
$	281.25	529	4.30
$	318.75	3	4.60
$	346.875	72	5.50
$	431.25	306	5.44
$	506.25	188	5.25
$	596.25	42	5.00

		3,448,885

Warrants
$	1.00	1,063,935	4.60
$	1.07	697,946	4.10
$	1.155	1,071,776	5.00
$	2.25	385,000	3.32
$	123.75	94,084	1.92
$	243.75	2,529	0.84
$	309.375	2,850	0.86
$	309.50	222	1.10
$	506.25	59	0.38
$	609.375	862	0.34
		3,319,265

Range of Exercise Prices			Shares		Weighted Average Remaining Life
Options:
	$	1.01		124,358	10.00
	$	1.454		17,200	9.75
	$	1.47		2,456,226	9.48
	$	2.10		14,286	9.25
	$	2.25		293	8.65
	$	2.42		24,768	8.38
	$	2.80		57,145	9.01
	$	3.75		44,000	8.50
	$	4.125		3,636	8.75
	$	4.1975		7,147	8.72
	$	4.25		3,529	8.25
	$	5.125		3,902	8.69
	$	65.75		190	7.40
	$	73.50		1,157	8.01
	$	77.50		2,323	7.50
	$	80.25		187	7.75
	$	86.25		232	7.25
	$	131.25		81	4.69
	$	148.125		928	5.21
	$	150.00		1,760	4.63
	$	162.50		123	7.01
	$	206.25		121	6.75
	$	248.4375		121	5.54
	$	262.50		130	5.54
	$	281.25		529	5.04
	$	318.75		3	5.35
	$	346.875		72	6.25
	$	431.25		306	6.19
	$	506.25		188	6.00
	$	596.25		42	5.75
Total				2,764,983

	Warrants
		$	1.07	697,946	4.85
		$	2.25	385,000	4.06
		$	4.46	756,999	3.92
		$	93.75	2,255	0.19
		$	123.75	94,084	2.67
		$	150.00	4,114	0.20
		$	225.00	107	0.07
		$	243.75	2,529	1.59
		$	281.25	3,107	0.14
		$	309.375	2,850	1.61
		$	309.50	222	1.85
		$	337.50	178	0.46
		$	371.25	944	0.41
		$	506.25	59	1.12
		$	609.375	862	1.09
Total				1,951,257

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

Stock Options:
Year	Shares		Price
2011		173			$281.25
2012		1,841		131.25	–	150.00
2013		1,553		148.13	–	596.25
2014		836		162.50	–	431.25
2015		4,088		65.75	–	86.25
2016		100,292		2.25	–	5.13
2017		2,503,152		1.01	-	2.10
2018		836,950		0.91	-	1.35
Total		3,448,885		$0.91	–	$596.25

Warrants:
Year	Shares		Price
2014		6,455		$243.75	–	$609.38
2015		94,151		0.00	–	243.75
2016		252,333			1.00
2017		1,082,946		1.07	-	2.25
2018		1,883,380		1.00	-	1.155
Total		3,319,265		$0.00	–	$609.38

Stock Options:
Year	Shares		Price
2011		173			281.25
2012		1,841		131.25	–	150.00
2013		1,553		148.13	–	596.25
2014		835		162.50	–	431.25
2015		4,088		65.75	–	86.25
2016		144,423		2.25	–	5.13
2017		2,612,070		1.01	–	2.10
Total		2,764,983	$	1.01	–	596.25

Warrants:
Year	Shares		Price
2013		10,705		93.75	–	371.25
2014		6,455		243.75	–	609.38
2015		94,152		0.00	–	243.75
2016		756,999			4.46
2017		1,082,946		1.07	–	2.25
Total		1,951,257	$	0.00	–	609.38

Note 5 - Loss Per Share (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Numerator
Net loss available in basic and diluted calculation	$	(2,506,869	)	$	(992,095	)	$	(6,640,301	)	$	(4,877,542	)
Comprehensive loss		(2,506,869	)		(992,095	)		(6,640,301	)		(4,877,542	)
Denominator:
Weighted average common shares outstanding-basic		13,252,605			6,232,761			12,178,285			6,283,567

Effect of diluted stock options, warrants and preferred stock (1)		-			-			-			-

Weighted average common shares outstanding-basic		13,252,605			6,262,761			12,178,285			6,283,567

Loss per common share-basic and diluted	$	(0.19	)	$	(0.16	)	$	(0.55	)	$	(0.78	)

	Year Ended December 31,
	2017			2016
Numerator:
Net loss available in basic and diluted calculation	$	(7,746,593	)	$	(6,526,014	)
Other comprehensive income:
Unrealized gain (loss) from marketable securities		-			1,501
Comprehensive (loss)		(7,746,593	)		(6,524,513	)
Denominator:
Weighted average common shares outstanding-basic		6,362,989			2,823,345

Effect of dilutive stock options, warrants and preferred stock (1)		-			-

Weighted average common shares outstanding-basic		6,362,989			2,823,345

Loss per common share-basic and diluted	$	(1.22	)	$	(2.31	)

Note 6 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Notes Tables

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	December 31, 2017		December 31, 2016

Deferred Tax Asset:
Net Operating Loss	$	7,393,100	$	10,755,000
Other		215,843		189,000
Total Deferred Tax Asset		7,608,943		10,944,000
Less Valuation Allowance		7,608,943		10,944,000
Net Deferred Income Taxes	$	—	$	—

Note 7 - Rent Obligation (Tables)

12 Months Ended

Dec. 31, 2017

Notes Tables

Schedule of Rent Expense [Table Text Block]

2018	$	39,000
2019	$	40,000
2020	$	42,000
2021	$	3,000

Note 12 - Investment Securities and Other Comprehensive Income (Loss) (Tables)

12 Months Ended

Dec. 31, 2017

Notes Tables

Schedule of Available-for-sale Securities Reconciliation [Table Text Block]

	December 31, 2016
Note Description	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value

Mutual Funds	$	282,828	$	1,501	$	-	$	284,329

Note 1 - Summary of Significant Accounting Policies (Details Textual)				1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended		190 Months Ended	199 Months Ended
	Feb. 22, 2017 USD ($)	Nov. 29, 2016 USD ($)	Aug. 31, 2015 USD ($)	Oct. 31, 2018 USD ($)	Jan. 31, 2018 USD ($)	Sep. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2017 USD ($)	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Sep. 30, 2018 USD ($) $ / shares shares	Jul. 11, 2018 $ / shares	Jul. 10, 2018 $ / shares	Mar. 31, 2018	Feb. 21, 2018 $ / shares	Jan. 11, 2018	Jan. 02, 2018 $ / shares	Dec. 28, 2017 $ / shares	Apr. 19, 2017 $ / shares	Oct. 04, 2016 $ / shares	Dec. 31, 2015 USD ($)
Common Stock, Shares, Outstanding, Ending Balance \| shares						13,398,339		13,398,339		6,943,283	4,564,428	6,943,283	13,398,339
Common Stock, Par or Stated Value Per Share \| $ / shares						$ 0.01		$ 0.01		$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01		$ 0.01			$ 0.01	$ 0.01	$ 0.01
Retained Earnings (Accumulated Deficit), Ending Balance						$ (61,405,345)		$ (61,405,345)		$ (54,765,045)	$ (47,018,451)	$ (54,765,045)	$ (61,405,345)
Cash and Cash Equivalents, at Carrying Value, Ending Balance						209,891	$ 765,704	209,891	$ 765,704	766,189	1,764,090	766,189	209,891										$ 4,856,232
Stockholders' Equity, Period Increase (Decrease), Total												29,065,934	36,490,000
Stock Issued During Period, Value, New Issues								2,755,087	3,421,188	3,421,188
Proceeds from Issuance or Sale of Equity, Total			$ 13,800,000					3,405,052
Proceeds from Warrant Exercises								650,062					650,062
Debt Instrument, Increase (Decrease), Net, Total												$ 5,685,000	$ 5,685,000
Depreciation, Total						26,120	14,561	59,442	44,764	58,872	73,249
Amortization of Intangible Assets, Total						$ 38,387	3,276	46,127	9,067	12,689	9,107
Income Tax Expense (Benefit), Total								$ 0	0	$ 0
Valuation Allowance Percentage						100.00%		100.00%		100.00%		100.00%	100.00%
Unrecognized Tax Benefits, Ending Balance						$ 0		$ 0		$ 0		$ 0	$ 0
Cash, Uninsured Amount						0		$ 0		$ 563,000		563,000	0
Number of Operating Segments								2		2
Non-US [Member]
Revenues, Total						$ 4,195	$ 288	$ 10,061	25,188	$ 26,662
Earliest Tax Year [Member]
Open Tax Year								2014
Private Placement [Member]
Stock Issued During Period, Value, New Issues										1,213,819
IPO [Member]
Stock Issued During Period, Value, New Issues												13,555,003	13,555,003
Proceeds from Issuance or Sale of Equity, Total												3,937,500	3,937,500
The 2016 Registered Direct Offering [Member]
Stock Issued During Period, Value, New Issues											$ 1,625,905
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs		$ 1,739,770										1,739,770	1,739,770
Proceeds from Issuance or Sale of Equity, Total		$ 1,983,337
Over-Allotment Option [Member]
Stock Issued During Period, Value, New Issues								$ 204,422	$ 393,750	$ 393,750
Proceeds from Issuance or Sale of Equity, Total	$ 358,312											358,312	358,312
The 2018 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total					$ 2,755,000								2,755,000
Series A Convertible Preferred Stock [Member] \| Private Placement [Member]
Stock Issued During Period, Value, New Issues												2,055,000	2,055,000
Series C Convertible Preferred Stock [Member] \| Private Placement [Member]
Stock Issued During Period, Value, New Issues												$ 1,300,000	$ 1,300,000
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares																	$ 0.01		$ 0.01
Subsequent Event [Member] \| The 2018 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total					$ 2,755,000
Subsequent Event [Member] \| Convertible Promissory Note [Member] \| Securities Purchase Agreements [Member]
Proceeds from Convertible Debt				$ 1,815,000
Helomics Holding Corp. [Member]
Share Exchange Agreement, Potential Interest																25.00%
Helomics Holding Corp. [Member] \| Subsequent Event [Member]
Share Exchange Agreement, Potential Interest																		25.00%

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Finished goods	$ 61,587	$ 62,932	$ 38,201
Raw materials	157,610	141,028	165,812
Work-In-Process	58,958	61,085	68,195
Total	$ 278,155	$ 265,045	$ 272,208

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	3 years	5 years
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years	3 years
Minimum [Member] \| Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years	3 years
Minimum [Member] \| Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years	3 years
Maximum [Member] \| Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years	7 years
Maximum [Member] \| Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years	7 years

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Property, Plant, and Equipment Gross	$ 531,469	$ 361,486	$ 316,393
Less: Accumulated depreciation	333,211	273,770	214,897
Total Fixed Assets, Net	198,258	87,716	101,496
Office Equipment [Member]
Property, Plant, and Equipment Gross	204,904	183,528	164,318
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	140,114	25,635	25,635
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,955	108,955	103,204
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 77,496	$ 43,368	$ 23,236

Note 2 - Equity Method Investment (Details Textual) - Helomics Holding Corp. [Member] - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Feb. 27, 2018
Equity Method Investment, Ownership Percentage	75.00%	75.00%	80.00%
Equity Method Investment, Summarized Financial Information, Revenue		$ 623,662
Contract Research Organization and D-CHIP Artificial Intelligence Products [Member]
Equity Method Investment, Summarized Financial Information, Revenue	$ 31,000

Note 2 - Equity Method Investment - Summary of Equity Method Investments (Details) - Helomics Holding Corp. [Member]

9 Months Ended

Sep. 30, 2018

USD ($)

Revenue

$ 623,662

Gross margin

441,370

Net loss from continuing operations

(6,833,846)

Net loss to investee

$ (5,227,552)

^[1]

[1]	The loss to investee was calculated at 80% for the initial period of ownership, January 11, 2018 - February 27, 2018, and then at 75% for the remainder of the nine-month period at the current equity investment percentage owned by the Company.

Note 3 - Revenue Recognition (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice	1 year
Standard Product Warranty, Term	1 year
Accounts Receivable, Net, Current, Total	$ 238,598	$ 137,499	$ 38,919
Contract with Customer, Liability, Current	$ 15,306	$ 6,663	$ 7,998
Minimum [Member]
Standard Payment Term for Customers	30 days
Maximum [Member]
Standard Payment Term for Customers	60 days

Note 4 - Stockholders' Equity, Stock Options and Warrants (Details Textual)														1 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended		190 Months Ended	199 Months Ended
	Oct. 26, 2018 USD ($) $ / shares shares	Jul. 11, 2018 $ / shares shares	Jul. 10, 2018 $ / shares shares	Jun. 28, 2018 shares	Mar. 12, 2018 $ / shares shares	Feb. 21, 2018 USD ($) $ / shares shares	Jan. 15, 2018 $ / shares shares	Jan. 11, 2018 USD ($) shares	Feb. 22, 2017 USD ($)	Jan. 19, 2017 $ / shares shares	Oct. 04, 2016 $ / shares shares	Jul. 01, 2016 $ / shares shares	Aug. 31, 2015 USD ($) $ / shares	Jan. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Sep. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2017 USD ($)	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Sep. 30, 2018 USD ($) $ / shares shares	Mar. 31, 2018 USD ($) shares	Jan. 02, 2018 $ / shares shares	Dec. 28, 2017 $ / shares shares	Apr. 19, 2017 $ / shares	Jan. 29, 2017 shares	Oct. 27, 2016 shares	Sep. 30, 2016 $ / shares	Sep. 15, 2016 shares	Sep. 14, 2016 shares
Stock Issued During Period, Shares, New Issues											400,000
Share Price \| $ / shares																												$ 4.125
Proceeds from Issuance or Sale of Equity, Total \| $													$ 13,800,000			$ 3,405,052
Common Stock, Par or Stated Value Per Share \| $ / shares		$ 0.01	$ 0.01			$ 0.01					$ 0.01				$ 0.01	$ 0.01		$ 0.01	$ 0.01	$ 0.01	$ 0.01			$ 0.01	$ 0.01
Shares Issued, Price Per Share \| $ / shares		$ 1.17	$ 1.18										$ 9
Stock Issued During Period, Shares, Issued for Services			250,000
Stock Issued During Period, Share, Issued in Escrow		750,000
Common Stock, Shares Authorized															50,000,000	50,000,000		50,000,000	50,000,000	50,000,000	50,000,000			50,000,000		24,000,000	8,000,000		200,000,000	100,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																0.00%		0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number															1,728,264	2,522,848		1,728,264		1,728,264	2,522,848
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares															$ 2.29	$ 1.93		$ 2.29		$ 2.29	$ 1.93
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term																9 years 3 days		9 years 164 days
Class of Warrant or Right Number of Warrants Vested and Exercisable															1,253,311	2,247,489		1,253,311		1,253,311	2,247,489
Allocated Share-based Compensation Expense, Total \| $																$ 800,322	$ 7,908	$ 1,892,159	$ 165,271
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options \| $															$ 1,139,172	$ 930,349		$ 1,139,172		$ 1,139,172	$ 930,349
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost \| $															$ 1,900,000
Vice President of Sales [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares							$ 0.01					$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							50,000					40,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares							$ 0.97					$ 3.75
Number of Equal Installments Options are Expected to Vest							4					6
Vice President of Sales and Marketing [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares					$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					111,112
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares					$ 1.35
Number of Equal Installments Options are Expected to Vest					4
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares															$ 609.38	$ 609.38		$ 609.38		$ 609.38	$ 609.38
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares																$ 596.25		$ 596.25
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																3.05%		2.40%	2.45%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate																66.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																10 years		10 years	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares																$ 1.0044		$ 1.5489	$ 3.7195
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares															$ 0	0		0		$ 0	$ 0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares																$ 0.91		$ 1.01
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																2.33%		1.92%	1.46%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate																59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																5 years		5 years	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares																$ 0.4816		$ 0.6541	$ 1.6329
Equity Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																3 years		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																10 years		10 years
Equity Incentive Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																3 years		3 years
Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																		2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																								5,000,000
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares						$ 0.01																	$ 0.01
Common Stock, Shares Authorized																							50,000,000
Subsequent Event [Member] \| Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																							5,000,000
Helomics Holding Corp. [Member]
Convertible Preferred Stock Held, Conversion Feature, Percent				20.00%
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares				1,100,000
Helomics Holding Corp. [Member] \| Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares				7,500,000
Helomics Holding Corp. [Member] \| Subsequent Event [Member]
Convertible Preferred Stock Held, Conversion Feature, Percent	20.00%
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	1,100,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow	860,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow, Period	1 year 180 days
Notes Payable, Total \| $	$ 7,600,000
Percentage of Holders of Acquiree's Promissory Note Agreeing to Merger	75.00%
Business Acquisition, Warrant Exchange Ratio	0.6
Helomics Holding Corp. [Member] \| Subsequent Event [Member] \| Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	7,500,000
Helomics Holding Corp. [Member]
Stock Issued During Period, Shares, New Issues								1,100,000
Share Exchange Agreement, Shares Received								2,500,000
Share Exchange Agreement, Convertible Notes Receivable \| $																						$ 500,000
Share Exchange Agreement, Convertible Notes, Percent of Stock																						5.00%
Share Exchange Agreement, Potential Interest																						25.00%
Share Exchange Agreement, Number of Shares Held in Escrow																						1,100,000
Share Exchange Agreement, Contingent Revenue, Minimum \| $								$ 8,000,000
Convertible Preferred Stock Held, Conversion Feature, Percent								20.00%
Helomics Holding Corp. [Member] \| Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues								1,100,000
Share Exchange Agreement, Shares Received								2,500,000
Share Exchange Agreement, Convertible Notes Receivable \| $								$ 500,000
Share Exchange Agreement, Convertible Notes, Percent of Stock								5.00%														5.00%
Share Exchange Agreement, Potential Interest								25.00%
Share Exchange Agreement, Contingent Revenue, Minimum \| $								$ 8,000,000
Convertible Preferred Stock Held, Conversion Feature, Percent								20.00%
Helomics Warrants Held by Investors [Member] \| Subsequent Event [Member] \| Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	18,700,000
Helomics Warrants Held by Investors [Member] \| Helomics Holding Corp. [Member] \| Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,000,000
Precision Warrants [Member] \| Helomics Holding Corp. [Member] \| Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1
Business Acquisition, Warrant Issued or Issuable, Exercise Price \| $ / shares	$ 1
Business Acquisition, Equity Interest Issued or Issuable from Exchange of Warrants	23,700,000
Class of Warrant or Right, Additional Number of Securities Called by Warrants or Rights	14,200,000
Helomics Warrants Held by Other Parties [Member] \| Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	597,000
Helomics Warrants Held by Other Parties [Member] \| Subsequent Event [Member] \| Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	995,000
The 2018 Public Offering [Member]
Stock Issued During Period, Shares, New Issues														2,900,000
Share Price \| $ / shares														$ 0.95
Proceeds from Issuance or Sale of Equity, Total \| $														$ 2,755,000							$ 2,755,000
The 2018 Public Offering [Member] \| Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues														2,900,000
Share Price \| $ / shares														$ 0.95
Proceeds from Issuance or Sale of Equity, Total \| $														$ 2,755,000
The 2018 Public Offering [Member] \| Series E Warrants [Member]
Class of Warrant or Right, Issued per Unit														0.3
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right														1
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares														$ 1
The 2018 Public Offering [Member] \| Series E Warrants [Member] \| Subsequent Event [Member]
Class of Warrant or Right, Issued per Unit														0.3
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right														1
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares														$ 1
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues						215,247
Proceeds from Issuance or Sale of Equity, Total \| $									$ 358,312											$ 358,312	$ 358,312
Sale of Stock, Underwriter Option Term														45 days
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase										175,000				290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase										35,000				87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase \| $ / shares										$ 0.01				$ 0.001
Shares Issued, Price Per Share \| $ / shares						$ 0.9497
Proceeds from Underwriter Shares Exercised, Net \| $						$ 188,066
Stock Issued During Period, Underwriter Discount \| $						$ 16,354
Underwriter Discount Percentage						8.00%
Over-Allotment Option [Member] \| Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues						215,247
Share Price \| $ / shares						$ 0.9497
Sale of Stock, Underwriter Option Term														45 days
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase														290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase														87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase \| $ / shares														$ 0.001
Proceeds from Underwriter Shares Exercised, Net \| $						$ 188,066
Stock Issued During Period, Underwriter Discount \| $						$ 16,354
Underwriter Discount Percentage						8.00%

Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Shares Outstanding (in shares)	2,764,983
Average Exercise Price Exercised (in dollars per share)			$ 65.75
Number of Shares Outstanding (in shares)	3,448,885	2,764,983
Warrant [Member]
Number of Shares Outstanding (in shares)	1,951,257	871,101	323,099
Average Exercise Price Outstanding (in dollars per share)	$ 23.74	$ 52.22	$ 128.40
Number of Shares Issued (in shares)	2,028,776	1,082,946	1,487,881
Average Exercise Price Issued (in dollars per share)	$ 1.08	$ 1.49	$ 0.71
Number of Shares Expired (in shares)	(10,706)	(2,790)
Average Exercise Price Expired (in dollars per share)	$ 199.55	$ 281.46
Number of Shares Exercised (in shares)	(650,062)		(939,879)
Average Exercise Price Exercised (in dollars per share)	$ 1
Number of Shares Outstanding (in shares)	3,319,265	1,951,257	871,101
Average Exercise Price Outstanding (in dollars per share)	$ 4.55	$ 23.74	$ 52.22
Employee Stock Option [Member]
Number of Shares Outstanding (in shares)	2,764,983	165,643	31,350
Average Exercise Price Outstanding (in dollars per share)	$ 2	$ 11.22	$ 133.23
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	836,950	2,612,070	157,982
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 1.12	$ 1.45	$ 3.14
Number of Shares Expired (in shares)	(153,048)	(12,730)	(22,377)
Average Exercise Price Expired (in dollars per share)	$ 2	$ 10.39	$ 122.13
Number of Shares Exercised (in shares)			(1,312)
Average Exercise Price Exercised (in dollars per share)			$ 65.75
Number of Shares Outstanding (in shares)	3,448,885	2,764,983	165,643
Average Exercise Price Outstanding (in dollars per share)	$ 1.78	$ 2	$ 11.22

Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Shares, options (in shares)	3,448,885	2,764,983
Shares, warrants (in shares)	3,319,265	1,951,257
Warrant One [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1	$ 1.07
Shares, warrants (in shares)	1,063,935	697,946
Weighted average remaining life, warrants (Year)	4 years 219 days	4 years 310 days
Warrant Two [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.07	$ 2.25
Shares, warrants (in shares)	697,946	385,000
Weighted average remaining life, warrants (Year)	4 years 36 days	4 years 21 days
Warrant Three [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.155	$ 4.46
Shares, warrants (in shares)	1,071,776	756,999
Weighted average remaining life, warrants (Year)	5 years	3 years 335 days
Warrant Four [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 2.25	$ 93.75
Shares, warrants (in shares)	385,000	2,255
Weighted average remaining life, warrants (Year)	3 years 116 days	69 days
Warrant Five [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 123.75	$ 123.75
Shares, warrants (in shares)	94,084	94,084
Weighted average remaining life, warrants (Year)	1 year 335 days	2 years 244 days
Warrant Six [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75	$ 150
Shares, warrants (in shares)	2,529	4,114
Weighted average remaining life, warrants (Year)	306 days	73 days
Warrant Seven [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 309.375	$ 225
Shares, warrants (in shares)	2,850	107
Weighted average remaining life, warrants (Year)	313 days	25 days
Warrant Eight [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 309.50	$ 243.75
Shares, warrants (in shares)	222	2,529
Weighted average remaining life, warrants (Year)	1 year 36 days	1 year 215 days
Warrant Nine [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 506.25	$ 281.25
Shares, warrants (in shares)	59	3,107
Weighted average remaining life, warrants (Year)	138 days	51 days
Warrant Ten [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 609.375	$ 309.375
Shares, warrants (in shares)	862	2,850
Weighted average remaining life, warrants (Year)	124 days	1 year 222 days
Stock Options One [Member]
Range of exercise prices, options (in dollars per share)	$ 0.91	$ 1.01
Shares, options (in shares)	10,000	124,358
Weighted average remaining life, options (Year)	9 years 200 days	10 years
Stock Options Thirty-Three [Member]
Range of exercise prices, options (in dollars per share)	$ 162.50
Shares, options (in shares)	123
Weighted average remaining life, options (Year)	6 years 94 days
Stock Options Two [Member]
Range of exercise prices, options (in dollars per share)	$ 0.965	$ 1.454
Shares, options (in shares)	3,000	17,200
Weighted average remaining life, options (Year)	9 years 229 days	9 years 273 days
Stock Options Thirty-Four [Member]
Range of exercise prices, options (in dollars per share)	$ 206.25
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	6 years 3 days
Stock Options Three [Member]
Range of exercise prices, options (in dollars per share)	$ 0.97	$ 1.47
Shares, options (in shares)	191,753	2,456,226
Weighted average remaining life, options (Year)	9 years 98 days	9 years 175 days
Stock Options Thirty-Five [Member]
Range of exercise prices, options (in dollars per share)	$ 248.4375
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	4 years 288 days
Stock Options Four [Member]
Range of exercise prices, options (in dollars per share)	$ 1.01	$ 2.10
Shares, options (in shares)	149,110	14,286
Weighted average remaining life, options (Year)	9 years 138 days	9 years 91 days
Stock Options Thirty-Six [Member]
Range of exercise prices, options (in dollars per share)	$ 262.50
Shares, options (in shares)	130
Weighted average remaining life, options (Year)	4 years 288 days
Stock Options Five [Member]
Range of exercise prices, options (in dollars per share)	$ 1.06	$ 2.25
Shares, options (in shares)	23,585	293
Weighted average remaining life, options (Year)	10 years	8 years 237 days
Stock Options Thirty-Seven [Member]
Range of exercise prices, options (in dollars per share)	$ 281.25
Shares, options (in shares)	529
Weighted average remaining life, options (Year)	4 years 109 days
Stock Options Six [Member]
Range of exercise prices, options (in dollars per share)	$ 1.10	$ 2.42
Shares, options (in shares)	86,958	24,768
Weighted average remaining life, options (Year)	9 years 259 days	8 years 138 days
Stock Options Thirty-Eight [Member]
Range of exercise prices, options (in dollars per share)	$ 318.75
Shares, options (in shares)	3
Weighted average remaining life, options (Year)	4 years 219 days
Stock Options Seven [Member]
Range of exercise prices, options (in dollars per share)	$ 1.13	$ 2.80
Shares, options (in shares)	195,931	57,145
Weighted average remaining life, options (Year)	9 years 292 days	9 years 3 days
Stock Options Thirty-Nine [Member]
Range of exercise prices, options (in dollars per share)	$ 346.875
Shares, options (in shares)	72
Weighted average remaining life, options (Year)	5 years 182 days
Stock Options Eight [Member]
Range of exercise prices, options (in dollars per share)	$ 1.15	$ 3.75
Shares, options (in shares)	21,740	44,000
Weighted average remaining life, options (Year)	9 years 306 days	8 years 182 days
Stock Options Forty [Member]
Range of exercise prices, options (in dollars per share)	$ 431.25
Shares, options (in shares)	306
Weighted average remaining life, options (Year)	5 years 160 days
Stock Options Nine [Member]
Range of exercise prices, options (in dollars per share)	$ 1.16	$ 4.125
Shares, options (in shares)	66,451	3,636
Weighted average remaining life, options (Year)	9 years 306 days	8 years 273 days
Stock Options Forty-One [Member]
Range of exercise prices, options (in dollars per share)	$ 506.25
Shares, options (in shares)	188
Weighted average remaining life, options (Year)	5 years 91 days
Stock Options Ten [Member]
Range of exercise prices, options (in dollars per share)	$ 1.18	$ 4.1975
Shares, options (in shares)	30,000	7,147
Weighted average remaining life, options (Year)	9 years 313 days	8 years 262 days
Stock Options Forty-Two [Member]
Range of exercise prices, options (in dollars per share)	$ 596.25
Shares, options (in shares)	42
Weighted average remaining life, options (Year)	5 years
Stock Options Eleven [Member]
Range of exercise prices, options (in dollars per share)	$ 1.20	$ 4.25
Shares, options (in shares)	41,668	3,529
Weighted average remaining life, options (Year)	9 years 306 days	8 years 91 days
Stock Options Twelve [Member]
Range of exercise prices, options (in dollars per share)	$ 1.21	$ 5.125
Shares, options (in shares)	30,000	3,902
Weighted average remaining life, options (Year)	9 years 313 days	8 years 251 days
Stock Options Thirteen [Member]
Range of exercise prices, options (in dollars per share)	$ 1.35	$ 65.75
Shares, options (in shares)	111,112	190
Weighted average remaining life, options (Year)	9 years 164 days	7 years 146 days
Stock Options Fourteen [Member]
Range of exercise prices, options (in dollars per share)	$ 1.454	$ 73.50
Shares, options (in shares)	17,200	1,157
Weighted average remaining life, options (Year)	9 years 3 days	8 years 3 days
Stock Options Fifteen [Member]
Range of exercise prices, options (in dollars per share)	$ 1.47	$ 77.50
Shares, options (in shares)	2,347,308	2,323
Weighted average remaining life, options (Year)	8 years 266 days	7 years 182 days
Stock Options Sixteen [Member]
Range of exercise prices, options (in dollars per share)	$ 2.10	$ 80.25
Shares, options (in shares)	14,286	187
Weighted average remaining life, options (Year)	8 years 182 days	7 years 273 days
Stock Options Seventeen [Member]
Range of exercise prices, options (in dollars per share)	$ 2.25	$ 86.25
Shares, options (in shares)	293	232
Weighted average remaining life, options (Year)	7 years 328 days	7 years 91 days
Stock Options Eighteen [Member]
Range of exercise prices, options (in dollars per share)	$ 2.42	$ 131.25
Shares, options (in shares)	20,640	81
Weighted average remaining life, options (Year)	7 years 306 days	4 years 251 days
Stock Options Nineteen [Member]
Range of exercise prices, options (in dollars per share)	$ 2.80	$ 148.125
Shares, options (in shares)	57,145	928
Weighted average remaining life, options (Year)	8 years 94 days	5 years 76 days
Stock Options Twenty [Member]
Range of exercise prices, options (in dollars per share)	$ 3.75	$ 150
Shares, options (in shares)	3,998	1,760
Weighted average remaining life, options (Year)	5 years 87 days	4 years 229 days
Stock Options Twenty One [Member]
Range of exercise prices, options (in dollars per share)	$ 4.125	$ 162.50
Shares, options (in shares)	3,636	123
Weighted average remaining life, options (Year)	8 years 3 days	7 years 3 days
Stock Options Twenty Two [Member]
Range of exercise prices, options (in dollars per share)	$ 4.1975	$ 206.25
Shares, options (in shares)	7,147	121
Weighted average remaining life, options (Year)	7 years 354 days	6 years 273 days
Stock Options Twenty Three [Member]
Range of exercise prices, options (in dollars per share)	$ 4.25	$ 248.4375
Shares, options (in shares)	3,529	121
Weighted average remaining life, options (Year)	7 years 182 days	5 years 197 days
Stock Options Twenty Four [Member]
Range of exercise prices, options (in dollars per share)	$ 5.125	$ 262.50
Shares, options (in shares)	3,902	130
Weighted average remaining life, options (Year)	7 years 343 days	5 years 197 days
Stock Options Twenty Five [Member]
Range of exercise prices, options (in dollars per share)	$ 65.75	$ 281.25
Shares, options (in shares)	190	529
Weighted average remaining life, options (Year)	7 years 21 days	5 years 14 days
Stock Options Twenty Six [Member]
Range of exercise prices, options (in dollars per share)	$ 73.50	$ 318.75
Shares, options (in shares)	1,157	3
Weighted average remaining life, options (Year)	7 years 94 days	5 years 127 days
Stock Options Twenty Seven [Member]
Range of exercise prices, options (in dollars per share)	$ 77.50	$ 346.875
Shares, options (in shares)	2,323	72
Weighted average remaining life, options (Year)	6 years 273 days	6 years 91 days
Stock Options Twenty Eight [Member]
Range of exercise prices, options (in dollars per share)	$ 80.25	$ 431.25
Shares, options (in shares)	187	306
Weighted average remaining life, options (Year)	7 years 3 days	6 years 69 days
Stock Options Twenty Nine [Member]
Range of exercise prices, options (in dollars per share)	$ 86.25	$ 506.25
Shares, options (in shares)	232	188
Weighted average remaining life, options (Year)	6 years 182 days	6 years
Stock Options Thirty [Member]
Range of exercise prices, options (in dollars per share)	$ 131.25	$ 596.25
Shares, options (in shares)	81	42
Weighted average remaining life, options (Year)	3 years 343 days	5 years 273 days
Stock Options Thirty-One [Member]
Range of exercise prices, options (in dollars per share)	$ 148.125
Shares, options (in shares)	928
Weighted average remaining life, options (Year)	4 years 171 days
Stock Options Thirty-Two [Member]
Range of exercise prices, options (in dollars per share)	$ 150
Shares, options (in shares)	1,760
Weighted average remaining life, options (Year)	3 years 321 days

Note 4 - Stockholders' Equity, Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Shares, options (in shares)	3,448,885	2,764,983
Shares, warrants (in shares)	3,319,265	1,951,257
Minimum [Member]
Price, options (in dollars per share)	$ 0.91	$ 1.01
Warrant exercises, exercise price per share (in dollars per share)	0	0
Maximum [Member]
Price, options (in dollars per share)	596.25	596.25
Warrant exercises, exercise price per share (in dollars per share)	$ 609.38	$ 609.38
Warrants 2014 [Member]
Shares, warrants (in shares)	6,455	6,455
Warrants 2014 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75	$ 243.75
Warrants 2014 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 609.38	$ 609.38
Warrants 2015 [Member]
Shares, warrants (in shares)	94,151	94,152
Warrants 2015 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 0	$ 0
Warrants 2015 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75	$ 243.75
Warrants 2016 [Member]
Shares, warrants (in shares)	252,333	756,999
Warrant exercises, exercise price per share (in dollars per share)	$ 1	$ 4.46
Warrants 2017 [Member]
Shares, warrants (in shares)	1,082,946	1,082,946
Warrants 2017 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.07	$ 1.07
Warrants 2017 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 2.25	$ 2.25
Warrants 2018 [Member]
Shares, warrants (in shares)	1,883,380
Warrants 2018 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1
Warrants 2018 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.155
Stock Options 2011 [Member]
Shares, options (in shares)	173	173
Price, options (in dollars per share)	$ 281.25	$ 281.25
Stock Options 2012 [Member]
Shares, options (in shares)	1,841	1,841
Stock Options 2012 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 131.25	$ 131.25
Stock Options 2012 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 150	$ 150
Stock Options 2013 [Member]
Shares, options (in shares)	1,553	1,553
Stock Options 2013 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 148.13	$ 148.13
Stock Options 2013 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 596.25	$ 596.25
Stock Options 2014 [Member]
Shares, options (in shares)	836	835
Stock Options 2014 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 162.50	$ 162.50
Stock Options 2014 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 431.25	$ 431.25
Stock Options 2015 [Member]
Shares, options (in shares)	4,088	4,088
Stock Options 2015 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 65.75	$ 65.75
Stock Options 2015 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 86.25	$ 86.25
Stock Options 2016 [Member]
Shares, options (in shares)	100,292	144,423
Stock Options 2016 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 2.25	$ 2.25
Stock Options 2016 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 5.13	$ 5.13
Stock Options 2017 [Member]
Shares, options (in shares)	2,503,152	2,612,070
Stock Options 2017 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 1.01	$ 1.01
Stock Options 2017 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 2.10	$ 2.10
Stock Options 2018 [Member]
Shares, options (in shares)	836,950
Stock Options 2018 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 0.91
Stock Options 2018 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 1.35

Note 5 - Notes Receivable (Details Textual) - USD ($)		1 Months Ended
Note 5 - Notes Receivable (Details Textual) - USD ($)	Feb. 22, 2018	Oct. 31, 2018	Sep. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Nov. 30, 2017	Oct. 31, 2017	Feb. 21, 2018	Jan. 11, 2018	Jul. 31, 2017
Advance to Helomics [Member]
Notes Receivable, Interest Rate, Stated Percentage						8.00%
Payments to Acquire Notes Receivable						$ 600,000	$ 600,000
Advances to De Lage Landen [Member]
Payments to Acquire Notes Receivable			$ 60,000		$ 67,512.10
Lease to Purchase Equipment, Down Payment, Percentage					50.00%
Advances to De Lage Landen [Member] \| Subsequent Event [Member]
Payments to Acquire Notes Receivable		$ 907,500
CytoBioscience [Member] \| Promissory Notes Receivable [Member]
Notes Receivable, Interest Rate, Stated Percentage				8.00%						8.00%
Financing Receivable, Net, Total				$ 1,112,524	$ 1,070,000
Notes Receivable, Term				2 years
CytoBioscience [Member] \| Promissory Notes Receivable [Member] \| Subsequent Event [Member]
Notes Receivable, Interest Rate, Stated Percentage				8.00%
Financing Receivable, Net, Total				$ 1,112,524
Notes Receivable, Term				2 years
Helomics Holding Corp. [Member]
Financing Receivable, Net, Total			$ 163,468
Share Exchange Agreement, Outstanding Receivables, Amount Converted				$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables				833,333
Share Exchange Agreement, Convertible Notes, Percent of Stock				5.00%
Investment, Ownership Percent				25.00%
Helomics Holding Corp. [Member] \| Subsequent Event [Member]
Financing Receivable, Net, Total	$ 167,512.50			$ 167,512.10				$ 667,512.50
Share Exchange Agreement, Outstanding Receivables, Amount Converted	$ 500,000			$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables	833,333			833,333
Share Exchange Agreement, Convertible Notes, Percent of Stock				5.00%					5.00%
Investment, Ownership Percent	25.00%			25.00%

Note 6 - Convertible Debt and Derivative Liability (Details Textual)	Oct. 26, 2018 USD ($) shares	Oct. 03, 2018 USD ($) $ / shares shares	Oct. 04, 2016 shares	Sep. 30, 2018 USD ($) yr $ / shares	Sep. 28, 2018 USD ($)	Dec. 31, 2017 $ / shares
Stock Issued During Period, Shares, New Issues \| shares			400,000
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 609.38		$ 609.38
Warrants in Connection with Convertible Promissory Note [Member]
Class of Warrant or Right, Fair Value per Warrant \| $ / shares				$ 0.5361
Warrants and Rights Outstanding				$ 574,631
Warrants in Connection with Convertible Promissory Note [Member] \| Measurement Input, Discount Rate [Member]
Warrants and Rights Outstanding, Measurement Input				0.0294
Warrants in Connection with Convertible Promissory Note [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input \| yr				5
Warrants in Connection with Convertible Promissory Note [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input				0.59
Subsequent Event [Member] \| Warrants in Connection with Convertible Promissory Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares	1,336,805	1,071,776
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares		$ 1.155
Warrants and Rights Outstanding, Term		5 years
Subsequent Event [Member] \| Inducement Common Stock Issued in Connection with Convertible Promissory Notes [Member]
Stock Issued During Period, Shares, New Issues \| shares		650,000
Securities Purchase Agreements [Member] \| Convertible Promissory Note [Member]
Debt Instrument, Face Amount					$ 2,297,727.50
Securities Purchase Agreements [Member] \| Convertible Promissory Note [Member] \| Subsequent Event [Member]
Debt Instrument, Face Amount	$ 2,865,909
Proceeds from Notes Payable, Net		$ 1,815,000
Proceeds from Notes Payable, Total	$ 500,000	$ 2,000,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Debt Instrument, Term		1 year
Debt Instrument, Convertible, Conversion Price, Percentage of Lowers Volume-weighted Average Price of Common Stock		70.00%
Conversion Shares, Sum of Number of Conversion Shares Plus Inducement Shares \| shares		2,678,328
Securities Purchase Agreements [Member] \| Convertible Promissory Note [Member] \| Subsequent Event [Member] \| Maximum [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares		$ 1

Note 7 - Loss Per Share (Details Textual) - shares	9 Months Ended		12 Months Ended
Note 7 - Loss Per Share (Details Textual) - shares	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,768,151	3,866,849	4,716,240	1,036,744
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,047,700
Preferred Stock 1 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	79,246

Note 7 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Dec. 31, 2017

Dec. 31, 2016

Net loss available in basic and diluted calculation

$ (2,506,869)

$ (992,095)

$ (6,640,301)

$ (4,877,542)

$ (7,746,593)

$ (6,526,014)

Comprehensive loss

$ (2,506,869)

$ (992,095)

$ (6,640,301)

$ (4,877,542)

$ (7,746,593)

$ (6,524,513)

Weighted average common shares outstanding-basic (in shares)

13,252,605

6,232,761

12,178,285

6,283,567

6,362,989

2,823,345

Effect of diluted stock options, warrants and preferred stock (1) (in shares)

^[1]

^[2]

Weighted average common shares outstanding-basic (in shares)

13,252,605

6,262,761

12,178,285

6,283,567

Loss per common share - basic and diluted (in dollars per share)

$ (0.19)

$ (0.16)

$ (0.55)

$ (0.78)

$ (1.22)

$ (2.31)

[1]

The number of shares underlying options and warrants outstanding as of September 30, 2018 and September 30, 2017 are 6,768,151 and 3,866,849, respectively. The number of shares underlying the convertible debt as of September 30, 2018 is 5,047,700. The number of shares underlying the preferred stock as of September 30, 2018 is 79,246. The effect of the shares that would be issued upon exercise of such options, warrants, convertible debt and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

[2]

The number of shares underlying options and warrants outstanding as of December 31, 2017 and December 31, 2016 are 4,716,240 and 1,036,744, respectively. The number of shares underlying the preferred stock as of December 31, 2017 is 79,246 for Series B Convertible and 647,819 for Series C Convertible. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 8 - Related Party Transactions (Details Textual) - Director [Member]	1 Months Ended
	Apr. 30, 2018 USD ($) shares
Related Party Transaction, Monthly Cash Payment \| $	$ 12,000
Restricted Stock Units (RSUs) [Member] \| Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period \| shares	240,000

Note 9 - Subsequent Events (Details Textual) - USD ($)	Oct. 26, 2018	Oct. 03, 2018	Jun. 28, 2018	Oct. 04, 2016	Sep. 30, 2018	Sep. 28, 2018	Dec. 31, 2017
Stock Issued During Period, Shares, New Issues				400,000
Helomics Holding Corp. [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares			1,100,000
Convertible Preferred Stock Held, Conversion Feature, Percent			20.00%
Helomics Holding Corp. [Member] \| Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares			7,500,000
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 609.38		$ 609.38
Subsequent Event [Member] \| Helomics Holding Corp. [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	1,100,000
Convertible Preferred Stock Held, Conversion Feature, Percent	20.00%
Subsequent Event [Member] \| Helomics Holding Corp. [Member] \| Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	7,500,000
Subsequent Event [Member] \| Helomics Holding Corp. [Member] \| Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	4,000,000
Subsequent Event [Member] \| Helomics Holding Corp. [Member] \| Series D Preferred Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	3,500,000
Subsequent Event [Member] \| Warrants in Connection with Convertible Promissory Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,336,805	1,071,776
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.155
Warrants and Rights Outstanding, Term		5 years
Subsequent Event [Member] \| Inducement Common Stock Issued in Connection with Convertible Promissory Notes [Member]
Stock Issued During Period, Shares, New Issues		650,000
Securities Purchase Agreements [Member] \| Convertible Promissory Note [Member]
Debt Instrument, Face Amount						$ 2,297,727.50
Securities Purchase Agreements [Member] \| Convertible Promissory Note [Member] \| Subsequent Event [Member]
Debt Instrument, Face Amount	$ 2,865,909
Proceeds from Notes Payable, Net		$ 1,815,000
Proceeds from Notes Payable, Total	$ 500,000	$ 2,000,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Debt Instrument, Term		1 year
Debt Instrument, Convertible, Conversion Price, Percentage of Lowers Volume-weighted Average Price of Common Stock		70.00%
Conversion Shares, Sum of Number of Conversion Shares Plus Inducement Shares		2,678,328
Securities Purchase Agreements [Member] \| Convertible Promissory Note [Member] \| Subsequent Event [Member] \| Maximum [Member]
Debt Instrument, Convertible, Conversion Price		$ 1

Note 1 - Summary of Significant Accounting Policies -2 (Details Textual)					3 Months Ended		9 Months Ended		12 Months Ended			190 Months Ended	199 Months Ended
	Feb. 22, 2017 USD ($)	Nov. 29, 2016 USD ($)	Oct. 27, 2016	Aug. 31, 2015 USD ($)	Sep. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2017 USD ($)	Dec. 31, 2018	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Sep. 30, 2018 USD ($) $ / shares shares	Jul. 11, 2018 $ / shares	Jul. 10, 2018 $ / shares	Feb. 21, 2018 $ / shares	Dec. 28, 2017 $ / shares	Apr. 19, 2017 $ / shares	Oct. 04, 2016 $ / shares
Common Stock, Shares, Outstanding, Ending Balance \| shares					13,398,339		13,398,339			6,943,283	4,564,428	6,943,283	13,398,339
Common Stock, Par or Stated Value Per Share \| $ / shares					$ 0.01		$ 0.01			$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Stockholders' Equity, Period Increase (Decrease), Total												$ 29,065,934	$ 36,490,000
Stock Issued During Period, Value, New Issues							$ 2,755,087	$ 3,421,188		$ 3,421,188
Proceeds from Issuance or Sale of Equity, Total				$ 13,800,000			3,405,052
Debt Instrument, Increase (Decrease), Net, Total												5,685,000	5,685,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent										34.00%
Advertising Expense										$ 37,060	$ 71,212
Research and Development Expense, Total										289,000	406,000
Depreciation, Total					$ 26,120	$ 14,561	59,442	44,764		58,872	73,249
Amortization of Intangible Assets, Total					38,387	3,276	46,127	9,067		12,689	9,107
Unrecognized Tax Benefits, Ending Balance					0		0			0		0	0
Cash, Uninsured Amount					0		$ 0			563,000		563,000	0
Product Warranty Expense										$ 6,209	34,665
Number of Operating Segments							2			2
Non-US [Member]
Revenues, Total					$ 4,195	$ 288	$ 10,061	25,188		$ 26,662
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent									21.00%
Private Placement [Member]
Stock Issued During Period, Value, New Issues										1,213,819
IPO [Member]
Stock Issued During Period, Value, New Issues												13,555,003	13,555,003
Proceeds from Issuance or Sale of Equity, Total												3,937,500	3,937,500
The 2016 Registered Direct Offering [Member]
Stock Issued During Period, Value, New Issues											$ 1,625,905
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs		$ 1,739,770										1,739,770	1,739,770
Proceeds from Issuance or Sale of Equity, Total		$ 1,983,337
Over-Allotment Option [Member]
Stock Issued During Period, Value, New Issues							$ 204,422	$ 393,750		$ 393,750
Proceeds from Issuance or Sale of Equity, Total	$ 358,312											358,312	358,312
Series A Convertible Preferred Stock [Member] \| Private Placement [Member]
Stock Issued During Period, Value, New Issues												2,055,000	2,055,000
Series C Convertible Preferred Stock [Member] \| Private Placement [Member]
Stock Issued During Period, Value, New Issues												$ 1,300,000	$ 1,300,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio			25

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventories (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Finished goods	$ 61,587	$ 62,932	$ 38,201
Raw materials	157,610	141,028	165,812
Work-In-Process	58,958	61,085	68,195
Total	$ 278,155	$ 265,045	$ 272,208

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Lives (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	3 years	5 years
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years	3 years
Minimum [Member] \| Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years	3 years
Minimum [Member] \| Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years	3 years
Maximum [Member] \| Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years	7 years
Maximum [Member] \| Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years	7 years

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Net (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Property, Plant, and Equipment Gross	$ 531,469	$ 361,486	$ 316,393
Less: Accumulated depreciation	333,211	273,770	214,897
Total Fixed Assets, Net	198,258	87,716	101,496
Office Equipment [Member]
Property, Plant, and Equipment Gross	204,904	183,528	164,318
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	140,114	25,635	25,635
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,955	108,955	103,204
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 77,496	$ 43,368	$ 23,236

Note 2 - Development Stage Operations (Details Textual) - $ / shares	Dec. 31, 2017	Sep. 30, 2016
Common Stock, Shares, Issued, Total	6,943,283
Share Price		$ 4.125
Common Stock [Member] \| Maximum [Member]
Share Price	$ 3,131.25

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants (Details Textual)														1 Months Ended		3 Months Ended		6 Months Ended	9 Months Ended			12 Months Ended		190 Months Ended	199 Months Ended
	Feb. 21, 2018 $ / shares shares	Jan. 15, 2018 $ / shares shares	Nov. 30, 2017 USD ($) $ / shares shares	Apr. 19, 2017 $ / shares shares	Feb. 22, 2017 USD ($)	Jan. 19, 2017 USD ($) $ / shares shares	Nov. 29, 2016 USD ($) $ / shares shares	Oct. 27, 2016 shares	Oct. 04, 2016 $ / shares shares	Jul. 01, 2016 $ / shares shares	Mar. 31, 2016 shares	Aug. 31, 2015 USD ($) $ / shares shares	Feb. 04, 2014 USD ($) $ / shares shares	Jan. 31, 2018 $ / shares shares	May 31, 2016 shares	Dec. 31, 2017 USD ($) $ / shares shares	Jul. 06, 2016 shares	Jun. 30, 2018 USD ($) shares	Sep. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2017 USD ($) shares	Sep. 30, 2016 $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Sep. 30, 2018 USD ($) $ / shares shares	Jul. 11, 2018 $ / shares	Jul. 10, 2018 $ / shares	Jan. 02, 2018 $ / shares shares	Dec. 28, 2017 $ / shares shares	Jan. 29, 2017 shares	Sep. 15, 2016 shares	Sep. 14, 2016 shares	Apr. 21, 2016 shares	Mar. 25, 2016 $ / shares shares
Shares Issued, Price Per Share \| $ / shares												$ 9														$ 1.17	$ 1.18
Underwriter Price \| $ / shares												8.28
Underwriting Discount \| $ / shares												$ 0.72
Underwriting Commission												8.00%
Proceeds from Issuance or Sale of Equity, Total \| $												$ 13,800,000							$ 3,405,052
Option Granted to Underwriter to Purchase Additional Units Period												45 days
Option Granted to Underwriter to Purchase Additional Units Number of Units Granted												250,000
Underwriting Agreement Non-accountable Expense Allowance Percentage												1.00%
Common Stock, Par or Stated Value Per Share \| $ / shares	$ 0.01			$ 0.01					$ 0.01							$ 0.01			$ 0.01			$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01		$ 0.01
Share Price \| $ / shares																					$ 4.125
Class of Warrant or Right, Outstanding																1,951,257			3,319,265			1,951,257		1,951,257	3,319,265
Stock Issued During Period, Value, New Issues \| $																			$ 2,755,087	$ 3,421,188		$ 3,421,188
Stock Issued During Period, Shares, New Issues									400,000
Proceeds from Issuance of Convertible Preferred Stock \| $																						$ 1,300,001
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																			0.00%			0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum																						59.00%	59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum																						66.00%	66.00%
Reverse Shares Issued for Escrow Pursuant to Termination of Agreement, Shares				400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number																1,728,264			2,522,848			1,728,264		1,728,264	2,522,848
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares																$ 2.29			$ 1.93			$ 2.29		$ 2.29	$ 1.93
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term																			9 years 3 days			9 years 164 days
Class of Warrant or Right Number of Warrants Vested and Exercisable																1,253,311			2,247,489			1,253,311		1,253,311	2,247,489
Allocated Share-based Compensation Expense, Total \| $																			$ 800,322	7,908		$ 1,892,159	$ 165,271
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options \| $																$ 1,139,172			$ 930,349			$ 1,139,172		$ 1,139,172	$ 930,349
Common Stock, Shares Authorized								8,000,000								50,000,000			50,000,000			50,000,000	50,000,000	50,000,000	50,000,000				50,000,000	24,000,000	200,000,000	100,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost \| $																$ 1,900,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio								25
Vice President of Sales [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares		$ 0.01								$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		50,000								40,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares		$ 0.97								$ 3.75
Number of Equal Installments Options are Expected to Vest		4								6
Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																						2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																													5,000,000
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares	0.01																											$ 0.01
Common Stock, Shares Authorized																												50,000,000
Subsequent Event [Member] \| Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																												5,000,000
The 2016 Registered Direct Offering [Member]
Proceeds from Issuance or Sale of Equity, Total \| $							$ 1,983,337
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares							$ 4.46
Share Price \| $ / shares							$ 2.62
Stock Issued During Period, Value, New Issues \| $																							$ 1,625,905
Stock Issued During Period, Shares, New Issues							756,999
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							756,999
Class of Warrant or Right Term							5 years
Class of Warrant or Right, Vesting Period							180 days
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs \| $							$ 1,739,770																	$ 1,739,770	$ 1,739,770
The 2017 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total \| $						$ 3,937,500
Share Price \| $ / shares						$ 2.25
Stock Issued During Period, Shares, New Issues						1,750,000
Share Per Each Unit						1
Over-Allotment Option [Member]
Shares Issued, Price Per Share \| $ / shares	$ 0.9497
Proceeds from Issuance or Sale of Equity, Total \| $					$ 358,312																			$ 358,312	$ 358,312
Stock Issued During Period, Value, New Issues \| $																			$ 204,422	393,750		$ 393,750
Stock Issued During Period, Shares, New Issues	215,247
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase						175,000								290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase						35,000								87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase \| $ / shares						$ 0.01								$ 0.001
Over-Allotment Option [Member] \| Subsequent Event [Member]
Share Price \| $ / shares	$ 0.9497
Stock Issued During Period, Shares, New Issues	215,247
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase														290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase														87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase \| $ / shares														$ 0.001
Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 1.26
Stock Issued During Period, Value, New Issues \| $																						$ 1,213,819
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			606,910
Class of Warrant or Right Term			5 years 182 days
Class of Warrant or Right, Vesting Period			180 days
Proceeds from Issuance of Convertible Preferred Stock \| $			$ 1,300,000
Conversion from Series C Convertible Preferred Stock to Common Stock [Member] \| Subsequent Event [Member]
Convertible Preferred Stock, Shares Issued upon Conversion																		1.167
Conversion of Stock, Shares Issued																		1,250,269
The Convertible Notes [Member]
Debt Instrument Redemption Principal Amount \| $												$ 933,074
Debt Instrument Redemption Premium Percentage												40.00%
Debt Instrument Redemption Price \| $												$ 1,548,792
Debt Instrument Redemption Amount Paid to Affiliates \| $												$ 167,031
Series B Convertible Preferred Stock [Member]
Beneficial Ownership Limitation Percentage																						4.99%
Stock Issued During Period, Value, New Issues \| $													$ 2,055,000
Stock Issued During Period, Shares, New Issues													20,550
Preferred Stock Par Value \| $ / shares													$ 0.01
Preferred Stock Stated Value \| $ / shares													$ 100
Preferred Stock, Shares Outstanding, Ending Balance																79,246			79,246			79,246	79,246	79,246	79,246
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance												0
Series C Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance																647,819			0			647,819	0	647,819	0
Series A Warrants [Member] \| Exchange Offer [Member]
Stock to be Issued for Exchange Offer, Shares, Maximum																																		3,157,186
Cashless Exercise of Common Stock Warrants, Total											10.05
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																																	1,770,556
Exchange from Series B Warrants to Warrant Shares [Member] \| Exchange Offer [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares																																		$ 0.01
Series B Warrants [Member] \| Exchange Offer [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right											1
Class of Warrant or Right Exercised During Period																	1,251,510
Stock Issued During Period, Shares, Warrants Exercised																	20,122
Cashless Exercise of Common Stock Warrants, Total											10.2
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																																	18,059,671
Series D Warrants [Member] \| The 2017 Public Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares						$ 2.25
Class of Warrant or Right, Issued per Unit						0.2
Common Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities																			589,747			660,522
Stock Issued During Period, Value, New Issues \| $																			$ 29,000	$ 17,500		$ 17,500
Stock Issued During Period, Shares, New Issues																			2,900,000	1,750,000		1,750,000
Reverse Shares Issued for Escrow Pursuant to Termination of Agreement, Shares																				400,000		400,000
Common Stock [Member] \| The 2016 Registered Direct Offering [Member]
Stock Issued During Period, Value, New Issues \| $																							$ 7,570
Stock Issued During Period, Shares, New Issues																							756,999
Common Stock [Member] \| Over-Allotment Option [Member]
Shares Issued, Price Per Share \| $ / shares																			$ 0.9497						$ 0.9497
Stock Issued During Period, Value, New Issues \| $																			$ 2,153	$ 1,750		$ 1,750
Stock Issued During Period, Shares, New Issues																			215,247	175,000		175,000
Common Stock [Member] \| Series A Warrants [Member]
Stock Issued During Period, Shares, Warrants Exercised																							2,318,663
Common Stock [Member] \| Series B Warrants [Member]
Stock Issued During Period, Shares, Warrants Exercised																							628,237
Preferred Stock [Member]
Stock Issued During Period, Value, New Issues \| $
Preferred Stock [Member] \| Over-Allotment Option [Member]
Stock Issued During Period, Value, New Issues \| $
Preferred Stock [Member] \| Private Placement [Member]
Stock Issued During Period, Value, New Issues \| $																						$ 12,138
Preferred Stock [Member] \| Series C Convertible Preferred Stock [Member] \| Subsequent Event [Member]
Stock Redeemed or Called During Period, Shares																		142,466
Payments for Repurchase of Convertible Preferred Stock \| $																		$ 189,285
Preferred Stock [Member] \| Series C Convertible Preferred Stock [Member] \| Private Placement [Member]
Shares Issued, Price Per Share \| $ / shares			$ 1.071
Stock Issued During Period, Shares, New Issues			1,213,819
Corporate Stock Transfer Inc. [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit												1
Common Stock, Par or Stated Value Per Share \| $ / shares												$ 0.01
Corporate Stock Transfer Inc. [Member] \| Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right																					0.4
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares																$ 123.75						$ 123.75		$ 123.75
Cash Less Exercise Formula Definition of Letter C in the Formula Closing Bid Price Number of Trading Days Prior to the Time of Exercise																						2 days
Cash Less Exercise Formula Closing Bid Price Per Share Minimum to Be Used in the Formula \| $ / shares																$ 0.43						$ 0.43		$ 0.43
Warrants Option to Settle in Cash Fair Value Disclosure \| $ / shares																					$ 4.319
Class of Warrant or Right Exercised During Period																					6,141,115
Stock Issued During Period, Shares, Warrants Exercised																					2,318,663
Class of Warrant or Right, Outstanding																35,084						35,084		35,084
Class of Warrant or Right Cash less Exercise Common Stock Price That Would Result in a Dilutive Exercise \| $ / shares																$ 0.43						$ 0.43		$ 0.43
Beneficial Ownership Limitation Percentage																						4.99%
Corporate Stock Transfer Inc. [Member] \| Series A Warrants [Member] \| Scenario, All Outstanding Warrants Exercised at Minimum Bid Price [Member]
Stock Issued During Period, Shares, Warrants Exercised																					564
Corporate Stock Transfer Inc. [Member] \| Series B Convertible Preferred Stock [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit												1
Corporate Stock Transfer Inc. [Member] \| Series A Convertible Preferred Stock [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit												4
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right												1
Maximum [Member]
Underwriting Agreement Expenses Agreed to Reimburse the Underwriter \| $												$ 70,000
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares																609.38			$ 609.38			$ 609.38		609.38	609.38
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares																			$ 596.25			$ 596.25
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																			3.05%			2.40%	2.45%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																			10 years			10 years	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares																			$ 1.0044			$ 1.5489	$ 3.7195
Maximum [Member] \| Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																			3 years			3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																			10 years			10 years
Maximum [Member] \| Common Stock [Member]
Share Price \| $ / shares																3,131.25						$ 3,131.25		3,131.25
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares																$ 0			$ 0			0		$ 0	$ 0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares																			$ 0.91			$ 1.01
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																			2.33%			1.92%	1.46%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																			5 years			5 years	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares																			$ 0.4816			$ 0.6541	$ 1.6329
Minimum [Member] \| Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																			3 years			3 years
Exchange Units [Member]
Unit Purchase Option Units Sold												1,666,667
Stock Issued During Period, Shares, Conversion of Convertible Securities												1,895,010
Exchange Units [Member] \| Series A Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities												3,391
Exchange Units [Member] \| Series A Warrants [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities												7,580,040
Exchange Units [Member] \| Common Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities												75,801
Exchange Units [Member] \| Series B Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities												1,895,010
Exchange Units [Member] \| Corporate Stock Transfer Inc. [Member]
Unit Purchase Option Units Issued												228,343
Stock Issued During Period, Shares, Conversion of Convertible Securities															135,995
Unit Purchase Option Number of Units Available for Underwriter to Purchase, Percentage												5.00%
Unit Purchase Option Number of Units Available For Underwriter to Purchase												83,333
Unit Purchase Option Exercise Price, Percentage												125.00%
Unit Purchase Option Exercise Price \| $ / shares												$ 11.25
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																			836,950			2,612,070	157,982
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares																			$ 1.12			$ 1.45	$ 3.14
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition																						2 years

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Shares Outstanding (in shares)	2,764,983
Options exercise price (in dollars per share)			$ 65.75
Number of Shares Outstanding (in shares)	3,448,885	2,764,983
Warrant [Member]
Number of Shares Outstanding (in shares)	1,951,257	871,101	323,099
Average Exercise Price Outstanding (in dollars per share)	$ 23.74	$ 52.22	$ 128.40
Number of Shares Issued (in shares)	2,028,776	1,082,946	1,487,881
Average Exercise Price Issued (in dollars per share)	$ 1.08	$ 1.49	$ 0.71
Number of Shares Expired (in shares)	(10,706)	(2,790)
Average Exercise Price Expired (in dollars per share)	$ 199.55	$ 281.46
Number of Shares Exercised (in shares)	(650,062)		(939,879)
Average Exercise Price Exercised (in dollars per share)	$ 1
Number of Shares Outstanding (in shares)	3,319,265	1,951,257	871,101
Average Exercise Price Outstanding (in dollars per share)	$ 4.55	$ 23.74	$ 52.22
Employee Stock Option [Member]
Number of Shares Outstanding (in shares)	2,764,983	165,643	31,350
Average Exercise Price Outstanding (in dollars per share)	$ 2	$ 11.22	$ 133.23
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	836,950	2,612,070	157,982
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 1.12	$ 1.45	$ 3.14
Number of Shares Expired (in shares)	(153,048)	(12,730)	(22,377)
Average Exercise Price Expired (in dollars per share)	$ 2	$ 10.39	$ 122.13
Number of Shares Exercised (in shares)			(1,312)
Options exercise price (in dollars per share)			$ 65.75
Number of Shares Outstanding (in shares)	3,448,885	2,764,983	165,643
Average Exercise Price Outstanding (in dollars per share)	$ 1.78	$ 2	$ 11.22

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Shares, options (in shares)	3,448,885	2,764,983
Shares, warrants (in shares)	3,319,265	1,951,257
Warrant One [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1	$ 1.07
Shares, warrants (in shares)	1,063,935	697,946
Weighted average remaining life, warrants (Year)	4 years 219 days	4 years 310 days
Warrant Two [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.07	$ 2.25
Shares, warrants (in shares)	697,946	385,000
Weighted average remaining life, warrants (Year)	4 years 36 days	4 years 21 days
Warrant Three [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.155	$ 4.46
Shares, warrants (in shares)	1,071,776	756,999
Weighted average remaining life, warrants (Year)	5 years	3 years 335 days
Warrant Four [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 2.25	$ 93.75
Shares, warrants (in shares)	385,000	2,255
Weighted average remaining life, warrants (Year)	3 years 116 days	69 days
Warrant Five [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 123.75	$ 123.75
Shares, warrants (in shares)	94,084	94,084
Weighted average remaining life, warrants (Year)	1 year 335 days	2 years 244 days
Warrant Six [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75	$ 150
Shares, warrants (in shares)	2,529	4,114
Weighted average remaining life, warrants (Year)	306 days	73 days
Warrant Seven [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 309.375	$ 225
Shares, warrants (in shares)	2,850	107
Weighted average remaining life, warrants (Year)	313 days	25 days
Warrant Eight [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 309.50	$ 243.75
Shares, warrants (in shares)	222	2,529
Weighted average remaining life, warrants (Year)	1 year 36 days	1 year 215 days
Warrant Nine [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 506.25	$ 281.25
Shares, warrants (in shares)	59	3,107
Weighted average remaining life, warrants (Year)	138 days	51 days
Warrant Ten [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 609.375	$ 309.375
Shares, warrants (in shares)	862	2,850
Weighted average remaining life, warrants (Year)	124 days	1 year 222 days
Warrant Eleven [Member]
Warrant exercises, exercise price per share (in dollars per share)		$ 309.50
Shares, warrants (in shares)		222
Weighted average remaining life, warrants (Year)		1 year 310 days
Warrant Twelve [Member]
Warrant exercises, exercise price per share (in dollars per share)		$ 337.50
Shares, warrants (in shares)		178
Weighted average remaining life, warrants (Year)		167 days
Warrant Thirteen [Member]
Warrant exercises, exercise price per share (in dollars per share)		$ 371.25
Shares, warrants (in shares)		944
Weighted average remaining life, warrants (Year)		149 days
Warrant Fourteen [Member]
Warrant exercises, exercise price per share (in dollars per share)		$ 506.25
Shares, warrants (in shares)		59
Weighted average remaining life, warrants (Year)		1 year 43 days
Warrant Fifteen [Member]
Warrant exercises, exercise price per share (in dollars per share)		$ 609.375
Shares, warrants (in shares)		862
Weighted average remaining life, warrants (Year)		1 year 32 days
Stock Options One [Member]
Range of exercise prices, options (in dollars per share)	$ 0.91	$ 1.01
Shares, options (in shares)	10,000	124,358
Weighted average remaining life, options (Year)	9 years 200 days	10 years
Stock Options Two [Member]
Range of exercise prices, options (in dollars per share)	$ 0.965	$ 1.454
Shares, options (in shares)	3,000	17,200
Weighted average remaining life, options (Year)	9 years 229 days	9 years 273 days
Stock Options Three [Member]
Range of exercise prices, options (in dollars per share)	$ 0.97	$ 1.47
Shares, options (in shares)	191,753	2,456,226
Weighted average remaining life, options (Year)	9 years 98 days	9 years 175 days
Stock Options Four [Member]
Range of exercise prices, options (in dollars per share)	$ 1.01	$ 2.10
Shares, options (in shares)	149,110	14,286
Weighted average remaining life, options (Year)	9 years 138 days	9 years 91 days
Stock Options Five [Member]
Range of exercise prices, options (in dollars per share)	$ 1.06	$ 2.25
Shares, options (in shares)	23,585	293
Weighted average remaining life, options (Year)	10 years	8 years 237 days
Stock Options Six [Member]
Range of exercise prices, options (in dollars per share)	$ 1.10	$ 2.42
Shares, options (in shares)	86,958	24,768
Weighted average remaining life, options (Year)	9 years 259 days	8 years 138 days
Stock Options Seven [Member]
Range of exercise prices, options (in dollars per share)	$ 1.13	$ 2.80
Shares, options (in shares)	195,931	57,145
Weighted average remaining life, options (Year)	9 years 292 days	9 years 3 days
Stock Options Eight [Member]
Range of exercise prices, options (in dollars per share)	$ 1.15	$ 3.75
Shares, options (in shares)	21,740	44,000
Weighted average remaining life, options (Year)	9 years 306 days	8 years 182 days
Stock Options Nine [Member]
Range of exercise prices, options (in dollars per share)	$ 1.16	$ 4.125
Shares, options (in shares)	66,451	3,636
Weighted average remaining life, options (Year)	9 years 306 days	8 years 273 days
Stock Options Ten [Member]
Range of exercise prices, options (in dollars per share)	$ 1.18	$ 4.1975
Shares, options (in shares)	30,000	7,147
Weighted average remaining life, options (Year)	9 years 313 days	8 years 262 days
Stock Options Eleven [Member]
Range of exercise prices, options (in dollars per share)	$ 1.20	$ 4.25
Shares, options (in shares)	41,668	3,529
Weighted average remaining life, options (Year)	9 years 306 days	8 years 91 days
Stock Options Twelve [Member]
Range of exercise prices, options (in dollars per share)	$ 1.21	$ 5.125
Shares, options (in shares)	30,000	3,902
Weighted average remaining life, options (Year)	9 years 313 days	8 years 251 days
Stock Options Thirteen [Member]
Range of exercise prices, options (in dollars per share)	$ 1.35	$ 65.75
Shares, options (in shares)	111,112	190
Weighted average remaining life, options (Year)	9 years 164 days	7 years 146 days
Stock Options Fourteen [Member]
Range of exercise prices, options (in dollars per share)	$ 1.454	$ 73.50
Shares, options (in shares)	17,200	1,157
Weighted average remaining life, options (Year)	9 years 3 days	8 years 3 days
Stock Options Fifteen [Member]
Range of exercise prices, options (in dollars per share)	$ 1.47	$ 77.50
Shares, options (in shares)	2,347,308	2,323
Weighted average remaining life, options (Year)	8 years 266 days	7 years 182 days
Stock Options Sixteen [Member]
Range of exercise prices, options (in dollars per share)	$ 2.10	$ 80.25
Shares, options (in shares)	14,286	187
Weighted average remaining life, options (Year)	8 years 182 days	7 years 273 days
Stock Options Seventeen [Member]
Range of exercise prices, options (in dollars per share)	$ 2.25	$ 86.25
Shares, options (in shares)	293	232
Weighted average remaining life, options (Year)	7 years 328 days	7 years 91 days
Stock Options Eighteen [Member]
Range of exercise prices, options (in dollars per share)	$ 2.42	$ 131.25
Shares, options (in shares)	20,640	81
Weighted average remaining life, options (Year)	7 years 306 days	4 years 251 days
Stock Options Nineteen [Member]
Range of exercise prices, options (in dollars per share)	$ 2.80	$ 148.125
Shares, options (in shares)	57,145	928
Weighted average remaining life, options (Year)	8 years 94 days	5 years 76 days
Stock Options Twenty [Member]
Range of exercise prices, options (in dollars per share)	$ 3.75	$ 150
Shares, options (in shares)	3,998	1,760
Weighted average remaining life, options (Year)	5 years 87 days	4 years 229 days
Stock Options Twenty One [Member]
Range of exercise prices, options (in dollars per share)	$ 4.125	$ 162.50
Shares, options (in shares)	3,636	123
Weighted average remaining life, options (Year)	8 years 3 days	7 years 3 days
Stock Options Twenty Two [Member]
Range of exercise prices, options (in dollars per share)	$ 4.1975	$ 206.25
Shares, options (in shares)	7,147	121
Weighted average remaining life, options (Year)	7 years 354 days	6 years 273 days
Stock Options Twenty Three [Member]
Range of exercise prices, options (in dollars per share)	$ 4.25	$ 248.4375
Shares, options (in shares)	3,529	121
Weighted average remaining life, options (Year)	7 years 182 days	5 years 197 days
Stock Options Twenty Four [Member]
Range of exercise prices, options (in dollars per share)	$ 5.125	$ 262.50
Shares, options (in shares)	3,902	130
Weighted average remaining life, options (Year)	7 years 343 days	5 years 197 days
Stock Options Twenty Five [Member]
Range of exercise prices, options (in dollars per share)	$ 65.75	$ 281.25
Shares, options (in shares)	190	529
Weighted average remaining life, options (Year)	7 years 21 days	5 years 14 days
Stock Options Twenty Six [Member]
Range of exercise prices, options (in dollars per share)	$ 73.50	$ 318.75
Shares, options (in shares)	1,157	3
Weighted average remaining life, options (Year)	7 years 94 days	5 years 127 days
Stock Options Twenty Seven [Member]
Range of exercise prices, options (in dollars per share)	$ 77.50	$ 346.875
Shares, options (in shares)	2,323	72
Weighted average remaining life, options (Year)	6 years 273 days	6 years 91 days
Stock Options Twenty Eight [Member]
Range of exercise prices, options (in dollars per share)	$ 80.25	$ 431.25
Shares, options (in shares)	187	306
Weighted average remaining life, options (Year)	7 years 3 days	6 years 69 days
Stock Options Twenty Nine [Member]
Range of exercise prices, options (in dollars per share)	$ 86.25	$ 506.25
Shares, options (in shares)	232	188
Weighted average remaining life, options (Year)	6 years 182 days	6 years
Stock Options Thirty [Member]
Range of exercise prices, options (in dollars per share)	$ 131.25	$ 596.25
Shares, options (in shares)	81	42
Weighted average remaining life, options (Year)	3 years 343 days	5 years 273 days

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Shares, options (in shares)	3,448,885	2,764,983
Shares, warrants (in shares)	3,319,265	1,951,257
Minimum [Member]
Price, options (in dollars per share)	$ 0.91	$ 1.01
Warrant exercises, exercise price per share (in dollars per share)	0	0
Maximum [Member]
Price, options (in dollars per share)	596.25	596.25
Warrant exercises, exercise price per share (in dollars per share)	$ 609.38	$ 609.38
Warrants 2013 [Member]
Shares, warrants (in shares)		10,705
Warrants 2013 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)		$ 93.75
Warrants 2013 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)		$ 371.25
Warrants 2014 [Member]
Shares, warrants (in shares)	6,455	6,455
Warrants 2014 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75	$ 243.75
Warrants 2014 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 609.38	$ 609.38
Warrants 2015 [Member]
Shares, warrants (in shares)	94,151	94,152
Warrants 2015 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 0	$ 0
Warrants 2015 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75	$ 243.75
Warrants 2016 [Member]
Shares, warrants (in shares)	252,333	756,999
Warrant exercises, exercise price per share (in dollars per share)	$ 1	$ 4.46
Warrants 2017 [Member]
Shares, warrants (in shares)	1,082,946	1,082,946
Warrants 2017 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.07	$ 1.07
Warrants 2017 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 2.25	$ 2.25
Stock Options 2011 [Member]
Shares, options (in shares)	173	173
Price, options (in dollars per share)	$ 281.25	$ 281.25
Stock Options 2012 [Member]
Shares, options (in shares)	1,841	1,841
Stock Options 2012 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 131.25	$ 131.25
Stock Options 2012 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 150	$ 150
Stock Options 2013 [Member]
Shares, options (in shares)	1,553	1,553
Stock Options 2013 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 148.13	$ 148.13
Stock Options 2013 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 596.25	$ 596.25
Stock Options 2014 [Member]
Shares, options (in shares)	836	835
Stock Options 2014 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 162.50	$ 162.50
Stock Options 2014 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 431.25	$ 431.25
Stock Options 2015 [Member]
Shares, options (in shares)	4,088	4,088
Stock Options 2015 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 65.75	$ 65.75
Stock Options 2015 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 86.25	$ 86.25
Stock Options 2016 [Member]
Shares, options (in shares)	100,292	144,423
Stock Options 2016 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 2.25	$ 2.25
Stock Options 2016 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 5.13	$ 5.13
Stock Options 2017 [Member]
Shares, options (in shares)	2,503,152	2,612,070
Stock Options 2017 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 1.01	$ 1.01
Stock Options 2017 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 2.10	$ 2.10

Note 4 - Notes Receivable (Details Textual) - USD ($)		1 Months Ended
Note 4 - Notes Receivable (Details Textual) - USD ($)	Feb. 22, 2018	Oct. 31, 2018	Sep. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Nov. 30, 2017	Oct. 31, 2017	Feb. 21, 2018	Jan. 11, 2018	Jul. 31, 2017
Advance to Helomics [Member]
Notes Receivable, Interest Rate, Stated Percentage						8.00%
Payments to Acquire Notes Receivable						$ 600,000	$ 600,000
Advances to De Lage Landen [Member]
Payments to Acquire Notes Receivable			$ 60,000		$ 67,512.10
Lease to Purchase Equipment, Down Payment, Percentage					50.00%
Advances to De Lage Landen [Member] \| Subsequent Event [Member]
Payments to Acquire Notes Receivable		$ 907,500
CytoBioscience [Member] \| Promissory Notes Receivable [Member]
Notes Receivable, Interest Rate, Stated Percentage				8.00%						8.00%
Financing Receivable, Net, Total				$ 1,112,524	$ 1,070,000
Notes Receivable, Term				2 years
CytoBioscience [Member] \| Promissory Notes Receivable [Member] \| Subsequent Event [Member]
Notes Receivable, Interest Rate, Stated Percentage				8.00%
Financing Receivable, Net, Total				$ 1,112,524
Notes Receivable, Term				2 years
Helomics Holding Corp. [Member]
Financing Receivable, Net, Total			$ 163,468
Share Exchange Agreement, Outstanding Receivables, Amount Converted				$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables				833,333
Share Exchange Agreement, Convertible Notes, Percent of Stock				5.00%
Investment, Ownership Percent				25.00%
Helomics Holding Corp. [Member] \| Subsequent Event [Member]
Financing Receivable, Net, Total	$ 167,512.50			$ 167,512.10				$ 667,512.50
Share Exchange Agreement, Outstanding Receivables, Amount Converted	$ 500,000			$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables	833,333			833,333
Share Exchange Agreement, Convertible Notes, Percent of Stock				5.00%					5.00%
Investment, Ownership Percent	25.00%			25.00%

Note 5 - Loss Per Share (Details Textual) - shares	9 Months Ended		12 Months Ended
Note 5 - Loss Per Share (Details Textual) - shares	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,768,151	3,866,849	4,716,240	1,036,744
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			79,246
Series C Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			647,819

Note 5 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Dec. 31, 2017

Dec. 31, 2016

Net loss available in basic and diluted calculation

$ (2,506,869)

$ (992,095)

$ (6,640,301)

$ (4,877,542)

$ (7,746,593)

$ (6,526,014)

Unrealized gain (loss) from marketable securities

(1,501)

1,501

Comprehensive loss

$ (2,506,869)

$ (992,095)

$ (6,640,301)

$ (4,877,542)

$ (7,746,593)

$ (6,524,513)

Weighted average common shares outstanding-basic (in shares)

13,252,605

6,232,761

12,178,285

6,283,567

6,362,989

2,823,345

Effect of diluted stock options, warrants and preferred stock (1) (in shares)

^[1]

^[2]

Loss per common share - basic and diluted (in dollars per share)

$ (0.19)

$ (0.16)

$ (0.55)

$ (0.78)

$ (1.22)

$ (2.31)

[1]

[2]

Note 6 - Income Taxes (Details Textual) - USD ($)	9 Months Ended		12 Months Ended
Note 6 - Income Taxes (Details Textual) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent				34.00%
Income Tax Expense (Benefit), Total	$ 0	$ 0		$ 0
Valuation Allowance Percentage	100.00%			100.00%
Federal Income Tax Expense (Benefit), Continuing Operations, Total				$ 0
State and Local Income Tax Expense (Benefit), Continuing Operations, Total				0
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total				34,500,000	$ 30,900,000
Operating Loss Carryforwards, Valuation Allowance, Total				7,400,000	10,700,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total				12,200,000	13,000,000
Operating Loss Carryforwards, Valuation Allowance, Total				$ 200,000	$ 200,000
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%

Note 6 - Income Taxes - Components of Deferred Income Taxes (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Net Operating Loss	$ 7,393,100	$ 10,755,000
Other	215,843	189,000
Total Deferred Tax Asset	7,608,943	10,944,000
Less Valuation Allowance	7,608,943	10,944,000
Net Deferred Income Taxes	$ 0	$ 0

Note 7 - Rent Obligation (Details Textual)	12 Months Ended
Note 7 - Rent Obligation (Details Textual)	Dec. 31, 2017 USD ($) ft²	Dec. 31, 2016 USD ($)
Operating Leases, Rent Expense, Total \| $	$ 66,122	$ 66,239
Corporate Office, Minnesota [Member]
Lessee Leasing Arrangements Operating Leases Terms of Contract Cancellation	3 years
Area of Real Estate Property	5,773
Corporate Office, Minnesota [Member] \| Office Space [Member]
Area of Real Estate Property	2,945
Corporate Office, Minnesota [Member] \| Manufacturing Facility [Member]
Area of Real Estate Property	2,828

Note 7 - Rent Obligation - Rent Obligation (Details)	Dec. 31, 2017 USD ($)
2018	$ 39,000
2019	40,000
2020	42,000
2021	$ 3,000

Note 8 - Related Party Transactions (Details Textual) - GLG Pharma, LLC. [Member]	Sep. 20, 2016 shares
Stock Expected to be Issued Upon Agreement, Shares	400,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche One	100,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche Two	100,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche Three	100,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche Four	100,000

Note 9 - Retirement Savings Plans (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%	100.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	4.00%	4.00%
Defined Contribution Plan, Employer Contribution Amount	$ 29,952	$ 33,143
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0

Note 10 - Supplemental Cash Flow Data (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Interest Paid, Excluding Capitalized Interest, Operating Activities	$ 0	$ 3

Note 11 - Subsequent Events (Details Textual) - USD ($)								1 Months Ended		9 Months Ended	190 Months Ended	199 Months Ended
Note 11 - Subsequent Events (Details Textual) - USD ($)	Feb. 22, 2018	Feb. 21, 2018	Jan. 11, 2018	Feb. 22, 2017	Jan. 19, 2017	Oct. 04, 2016	Aug. 31, 2015	Mar. 31, 2018	Jan. 31, 2018	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2018	Jul. 11, 2018	Jul. 10, 2018	Jan. 02, 2018	Dec. 28, 2017	Apr. 19, 2017	Dec. 31, 2016	Sep. 30, 2016
Stock Issued During Period, Shares, New Issues						400,000
Share Price																			$ 4.125
Proceeds from Issuance or Sale of Equity, Total							$ 13,800,000			$ 3,405,052
Common Stock, Par or Stated Value Per Share		$ 0.01				$ 0.01				$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01		$ 0.01	$ 0.01	$ 0.01
Loans Receivable, Net, Total										$ 1,815,000		$ 1,815,000
Common Stock, Shares, Outstanding, Ending Balance										13,398,339	6,943,283	13,398,339						4,564,428
Helomics Holding Corp. [Member]
Stock Issued During Period, Shares, New Issues			1,100,000
Share Exchange Agreement, Shares Received			2,500,000
Share Exchange Agreement, Convertible Notes Receivable								$ 500,000
Share Exchange Agreement, Convertible Notes, Percent of Stock								5.00%
Share Exchange Agreement, Potential Interest								25.00%
Loans Receivable, Net, Total											$ 500,000
Share Exchange Agreement, Contingent Revenue, Minimum			$ 8,000,000
Convertible Preferred Stock Held, Conversion Feature, Percent			20.00%
Financing Receivable, Net, Total										$ 163,468		$ 163,468
Share Exchange Agreement, Outstanding Receivables, Amount Converted								$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables								833,333
Investment, Ownership Percent								25.00%
The 2018 Public Offering [Member]
Stock Issued During Period, Shares, New Issues									2,900,000
Share Price									$ 0.95
Proceeds from Issuance or Sale of Equity, Total									$ 2,755,000			2,755,000
The 2018 Public Offering [Member] \| Series E Warrants [Member]
Class of Warrant or Right, Issued per Unit									0.3
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right									1
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 1
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues		215,247
Proceeds from Issuance or Sale of Equity, Total				$ 358,312							$ 358,312	$ 358,312
Sale of Stock, Underwriter Option Term									45 days
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase					175,000				290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase					35,000				87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase					$ 0.01				$ 0.001
Proceeds from Underwriter Shares Exercised, Net		$ 188,066
Stock Issued During Period, Underwriter Discount		$ 16,354
Underwriter Discount Percentage		8.00%
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share		$ 0.01													$ 0.01
Subsequent Event [Member] \| Helomics Holding Corp. [Member]
Common Stock, Shares, Outstanding, Ending Balance	13,333,333	10,000,000
Subsequent Event [Member] \| Helomics Holding Corp. [Member]
Stock Issued During Period, Shares, New Issues			1,100,000
Share Exchange Agreement, Shares Received			2,500,000
Share Exchange Agreement, Convertible Notes Receivable			$ 500,000
Share Exchange Agreement, Convertible Notes, Percent of Stock			5.00%					5.00%
Share Exchange Agreement, Potential Interest			25.00%
Share Exchange Agreement, Contingent Revenue, Minimum			$ 8,000,000
Convertible Preferred Stock Held, Conversion Feature, Percent			20.00%
Financing Receivable, Net, Total	$ 167,512.50	$ 667,512.50						$ 167,512.10
Share Exchange Agreement, Outstanding Receivables, Amount Converted	$ 500,000							$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables	833,333							833,333
Holding Interest, Preferred Stock		2,500,000
Holding Interest, Common Stock	3,333,333
Investment, Ownership Percent	25.00%							25.00%
Subsequent Event [Member] \| The 2018 Public Offering [Member]
Stock Issued During Period, Shares, New Issues									2,900,000
Share Price									$ 0.95
Proceeds from Issuance or Sale of Equity, Total									$ 2,755,000
Subsequent Event [Member] \| The 2018 Public Offering [Member] \| Series E Warrants [Member]
Class of Warrant or Right, Issued per Unit									0.3
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right									1
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 1
Subsequent Event [Member] \| Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues		215,247
Share Price		$ 0.9497
Sale of Stock, Underwriter Option Term									45 days
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase									290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase									87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase									$ 0.001
Proceeds from Underwriter Shares Exercised, Net		$ 188,066
Stock Issued During Period, Underwriter Discount		$ 16,354
Underwriter Discount Percentage		8.00%

Note 12 - Investment Securities and Other Comprehensive Income (Loss) - Cost and Fair Values of Investment Securities Available-for-sale (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Fair Value		$ 284,329
Mutual Fund [Member]
Cost		282,828
Gross Unrealized Gains		1,501
Gross Unrealized Losses
Fair Value		$ 284,329